<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002757</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>147</s160></s100><s200><s210>1</s210><s211>120</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 1Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ala Val Ser Ser Ile Asn            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Thr Pro Glu Lys Val Arg Lys Leu Val        35                  40                  45Ala Thr Met Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Tyr Ala Lys Asn Thr Val Ala Leu65                  70                  75                  80Gln Met Asn Asn Leu Ile Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala                85                  90                  95Ala Asp Lys Phe Gly Ala Asp Ile His Glu Val Asp Tyr Trp Gly Lys            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>2</s210><s211>118</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 2Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Ile Ser Ile Arg Arg Ile Asn            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Val Ile Ser Ser Pro Asn Lys Thr Leu Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Lys Asp Asn Tyr Thr Asn Thr Leu Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ser                85                  90                  95Ala Trp Arg Ile Gly Val Asp Thr Thr Asp Tyr Tyr Gly Gln Gly Thr            100                 105                 110Gln Val Thr Val Ser Ser        115</s400><s200><s210>3</s210><s211>126</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 3Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Leu Asp Tyr Tyr            20                  25                  30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val        35                  40                  45Ser Cys Ile Ser Ser Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Met Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Asp Ile His Cys Ser Gly Tyr Val Leu Phe Ser Pro Ser Asp            100                 105                 110Phe Gly Asn Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>4</s210><s211>120</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 4Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Val Pro Ser Gly Ser Ile Ser Ser Ile Tyr            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ala Leu Gly Pro Glu Arg Glu Leu Val        35                  40                  45Ala Ala Gln Thr Leu Gly Gly Gly Thr Tyr Tyr Ala Asn Pro Val Lys    50                  55                  60Gly Arg Phe Thr Ile Tyr Arg Asp Asn Asp Lys Asn Thr Leu Tyr Leu65                  70                  75                  80Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala                85                  90                  95Thr Pro Gly Glu His Trp Gly Ser Ser Asp Val Thr Asn Trp Gly Gln            100                 105                 110Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>5</s210><s211>119</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 5Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Ile Ser Gly Asp Asp            20                  25                  30His Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Ala Gly Gln Glu Arg        35                  40                  45Asp Leu Val Ala Ala Phe Ser Asn Val Gly Lys Ala Tyr Tyr Ala Asp    50                  55                  60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn His Asn Asn Thr65                  70                  75                  80Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Asp Asp Thr Ala Met Tyr                85                  90                  95Tyr Cys Ala Ala Trp Ser Pro Arg His Pro Thr Tyr Tyr Gly Gln Gly            100                 105                 110Thr Gln Val Thr Val Ser Ser        115</s400><s200><s210>6</s210><s211>122</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 6Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ala Asp Ser Ile Pro            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Tyr Leu        35                  40                  45Ala Ala Ile Ser Ser Gly Thr Asn Thr Tyr Tyr Ala Ser Ser Ala Lys    50                  55                  60Gly Arg Phe Ala Ile Ser Arg Asn Asn Ala Asn Asn Thr Leu Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala                85                  90                  95Thr Cys Ser Ser Tyr Tyr Tyr Cys Ser Gly Pro Tyr Val Arg Ser Trp            100                 105                 110Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>7</s210><s211>121</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 7Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr            20                  25                  30Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val        35                  40                  45Ser Ile Ile Ser Thr Gly Gly Ala Ser Thr Val Tyr Thr Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ala Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys                85                  90                  95Val Arg Gly Asn Ser Arg Ser Gly Leu Ile Pro Arg Ala Tyr Trp Gly            100                 105                 110Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>8</s210><s211>115</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 8Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Val Phe Arg Leu Asn            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Leu Val        35                  40                  45Ala Thr Ile Ala Ser Gly Gly Trp Ala Tyr Tyr Gly Asp Thr Met Ser    50                  55                  60Gly Arg Val Thr Ile Ser Arg Asp Asn Asp Lys Asn Thr Leu Tyr Leu65                  70                  75                  80Glu Met Asn Ser Leu Lys Pro Glu Asp Ser Ala Met Tyr Tyr Cys Ser                85                  90                  95Ala Gly Gly Ala Arg Pro His Ser Trp Gly Gln Gly Thr Gln Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>9</s210><s211>115</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 9Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Val Ala            20                  25                  30Ala Met Arg Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Trp Val        35                  40                  45Ala Ser Ala Phe Ser Asp Gly Asn Leu His Tyr Glu Asp Phe Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Thr Leu Tyr Leu65                  70                  75                  80Gln Met Asp Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Ala Gly Thr Pro Ser Arg Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>10</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 10Gln Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Ile Phe Ser Ile Asn            20                  25                  30Ala Met Gly Trp Tyr Arg Arg Ala Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Ser Ile Ser Ser Asp Gly Ser Ile Tyr Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Asp Cys Ala                85                  90                  95Ala Leu Gly Val Val Asn Val Gly Val Arg Pro Thr Leu Glu Tyr Ile            100                 105                 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>11</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 11Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Phe Gly Asn Thr Gly Ala Ile His            20                  25                  30Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Glu Val        35                  40                  45Ala Arg Ile Ser Phe Gly Asp Gly Arg Thr Val Tyr Gly Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Gly Asp Asp Ala Lys Asn Thr Met Tyr65                  70                  75                  80Leu Gln Met Asn Ile Leu Lys Ala Glu Asp Thr Ala Glu Tyr Tyr Cys                85                  90                  95Asn Ala Val Phe Leu Gly Ile Gly Pro Thr Gly Arg Phe Glu Tyr Glu            100                 105                 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>12</s210><s211>120</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 12Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ala Val Ser Ser Ile Asn            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Thr Pro Glu Lys Val Arg Lys Leu Val        35                  40                  45Ala Thr Met Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Tyr Ala Lys Asn Thr Val Ala Leu65                  70                  75                  80Gln Met Asn Asn Leu Ile Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala                85                  90                  95Ala Asp Lys Phe Gly Ala Asp Ile His Glu Val Asp Tyr Trp Gly Lys            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>13</s210><s211>123</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 13Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Phe            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Ile Ser Trp Ser Gly Gly Gln Thr Tyr Asn Val Glu Ser Ala    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Lys Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Ser Thr Met Val Val Thr Thr Val Ala Ala Asp Tyr Lys Tyr            100                 105                 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>14</s210><s211>129</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 14Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Lys Thr Gly Asp1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Ile Ser Gly Tyr            20                  25                  30Glu Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Gly Ile Ser Arg Asn Gly Arg Ser Thr Gly Tyr Ser Asp Ser Ala    50                  55                  60Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Gly Leu Lys Ala Asp Tyr Gly Asp Ser Tyr Val Asp Thr Ser            100                 105                 110Thr Arg Asn Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser        115                 120                 125Ser</s400><s200><s210>15</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 15Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Ser Arg Cys            20                  25                  30Thr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Ile Ser Trp Gly Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val    50                  55                  60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asp Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Asp Tyr Asn Arg Leu Gln Ile Gly Gln Arg Ser Arg Asp Tyr            100                 105                 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>16</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 16Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Ser Arg Thr            20                  25                  30Thr Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Ile Ser Trp Ala Gly Ser Ser Thr Val Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Tyr Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Gly Arg Pro Phe Gly Leu Gln Leu Asp Thr His Gln Ala Asp Tyr            100                 105                 110Asn Ile Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>17</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 17Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Ala Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Arg Pro Phe Ser Ile Tyr            20                  25                  30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val        35                  40                  45Ala Val Ile Asn Leu Ser Arg Gly Asn Thr Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Leu Asp Ser Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Ser Cys                85                  90                  95Gly Val Asp Arg Arg Gln Tyr Gly Leu Gly Ile Pro Pro Leu Ala Asp            100                 105                 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>18</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 18Arg Gly Ala Gly Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Tyr            20                  25                  30Ala Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Gly Ile Asn Trp Lys Gly Asp Arg Thr Tyr Tyr Thr Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Thr Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Val Ala Asp Tyr Arg Val Trp Gly Thr Arg Ile Ala Gly Thr Lys Tyr            100                 105                 110Asp Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>19</s210><s211>128</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 19Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Asn Ser Tyr            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Ile Ser Gln Asn Gly Gly Ser Gln Gly Tyr Ala Glu Ala Val    50                  55                  60Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Thr Asn Lys Val Val Ala65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ala Tyr Tyr Cys                85                  90                  95Ala Ala Asp Gly Asp Ala Ser Asp Arg Ser Tyr Ala Pro Pro Arg Asp            100                 105                 110Tyr Lys Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>20</s210><s211>123</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 20Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Arg Thr Phe Ser Asn Tyr            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ser Val Thr Trp Gly Gly Ser Gly Thr Phe Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ile Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Asp Asn Val Gly Asp Ser Trp Tyr Ser Asp Asp Tyr Lys Tyr            100                 105                 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>21</s210><s211>126</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 21Glu Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser Gly Tyr            20                  25                  30Ala Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Val Asn Trp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asp Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Asn Ala Arg Pro Thr Phe Gly Ala Tyr Tyr Ser Asp Tyr Lys Ser Gly            100                 105                 110Val Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>22</s210><s211>119</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 22Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ala1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Ser Ile Tyr            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Tyr Ile Thr Ser Gly Gly Ser Thr Thr Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Arg Gly Asn Tyr Tyr Arg Asp Tyr Lys Pro Glu Phe Trp Gly Gln Gly            100                 105                 110Thr Gln Val Thr Val Ser Ser        115</s400><s200><s210>23</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 23Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp His Tyr            20                  25                  30Asp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ala Val        35                  40                  45Ser Cys Ile Ser Ser Ser Asp Gly Arg Thr Tyr Tyr Glu Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Leu Tyr Arg Cys                85                  90                  95Thr Thr Glu Val Ala Cys Tyr Ser Asp Tyr Lys Ser Thr Gln Ile Ser            100                 105                 110Arg Ile Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>24</s210><s211>122</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 24Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Arg Gly Phe Ser Glu His            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ser Pro Gly Lys Gln Arg Glu Phe Val        35                  40                  45Ala Gly Val Thr Ser Tyr Gly Gly Thr Asn Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Gly Asn Thr Val Phe Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Tyr Lys Arg Gly His Tyr Pro Asp Gly Val Ser Thr Tyr Glu Tyr Trp            100                 105                 110Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>25</s210><s211>122</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 25Glu Val Gln Val Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Gly Phe Thr Glu His            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ser Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Gly Ile Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Val Ser Arg Asp Ser Ala Gly Asn Thr Val Ala Leu65                  70                  75                  80Gln Met Asp Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ser                85                  90                  95Tyr Lys Arg Gly Arg Tyr Pro Asp Gly Val Ser Thr Leu Glu Tyr Trp            100                 105                 110Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>26</s210><s211>121</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 26Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr            20                  25                  30Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ser Ala Ile Asp Thr Thr Gly Gly Ser Thr Ala Tyr Thr His Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Asn Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Asn Ser Thr Tyr Phe Asn Asp Asp Pro Glu Tyr Asp Arg Trp Gly            100                 105                 110Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>27</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 27Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr            20                  25                  30Ala Met Thr Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Ala Ile Ser Ser Ala Gly Tyr Thr Thr Thr Tyr Ala Gly Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Asn Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Asn Ala Gly Arg Leu Ser Tyr Gly Gly Ser Tyr Tyr Pro Asn Asp Asp            100                 105                 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>28</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 28Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Arg Thr Phe Ser Ser Tyr            20                  25                  30Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Asp Phe Val        35                  40                  45Ala Ala Ile Ser Arg Ser Gly Gly Arg Thr Trp Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Phe Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ser Tyr Tyr Cys                85                  90                  95Asn Thr Asp Tyr Thr Phe Ala Lys Leu Thr Ala Pro Asp Arg Arg Asn            100                 105                 110Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>29</s210><s211>118</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 29Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asp Thr Ile Phe Ile Ser            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Ala Ile Thr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Ala Asp Thr Ile Ala Thr Met Thr Asp Asp Tyr Trp Gly Gln Gly Thr            100                 105                 110Gln Val Thr Val Ser Ser        115</s400><s200><s210>30</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 30Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Ser Ser Phe Ser Ser Tyr            20                  25                  30Ala Met Ser Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Ala Met Thr Ala Pro Gly Gly Asp Ile Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ala Val Tyr65                  70                  75                  80Leu Arg Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys                85                  90                  95Asn Ala Thr Arg Pro Arg Asp Asp Tyr Tyr Tyr Thr Gly Gly Phe Leu            100                 105                 110Tyr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>31</s210><s211>123</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 31Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr            20                  25                  30Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Val Asn Trp Ser Asn Ser Ser Ala Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Asp Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Ser Thr Ile Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Arg Pro Tyr Ser Asp Tyr Val Thr Tyr Asp Pro Asp Asp Tyr Asp Tyr            100                 105                 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>32</s210><s211>123</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 32Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Asn Phe Ser Ser Tyr            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Val Phe Val        35                  40                  45Ala Thr Ile Asn Trp Lys Gly Val Ser Thr Tyr Tyr Ala Pro Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Asn Thr Asp Pro Asp Tyr Ser Asp Tyr Asp Asp Met Tyr Val Arg Ser            100                 105                 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>33</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 33Arg Gly Ala Gly Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Tyr            20                  25                  30Ala Thr Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Val Val        35                  40                  45Ala Ala Ile Ser Trp Asn Gly Gly Asn Thr Tyr Tyr Ala Ala Ser Gly    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Thr Asn Ser Asn Thr Asp Trp Arg Thr Tyr Thr Glu Tyr Asn            100                 105                 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>34</s210><s211>126</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 34Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Asp Phe Val        35                  40                  45Ala Gly Ile Ser Gly Ser Gly Gly Asn Thr Pro Tyr Ala Glu Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Ala65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Lys Phe Thr Ser Ser Ser Phe Tyr Tyr Arg Ser Pro Arg Glu            100                 105                 110Tyr Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>35</s210><s211>127</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 35Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr            20                  25                  30Val Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ser Ala Ile Asn Ser Gly Gly Ser Ser Ser Ser Tyr Pro Glu Ser Val    50                  55                  60Lys Asp Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Ala Lys Asn Val Pro Gly Phe Tyr Tyr Ser Asp Tyr Ala Asn His            100                 105                 110Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>36</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 36Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Asp Thr Ile Phe Thr Ile            20                  25                  30Ala Ala Ala Trp Tyr Arg Gln Val Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Ala Ile Thr Ser Gly Gly Ala Thr Arg Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Ala Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Ala Pro Lys Gly Gly Ser Tyr Tyr Phe Pro Ala Val Gly Gly Tyr Asp            100                 105                 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>37</s210><s211>121</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 37Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asp Thr Ile Phe Ile Ser            20                  25                  30Ser Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Ser Ile Asp Ser Asp Asp Ile Ile Tyr Tyr Ala Ala Thr Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Asp Lys Pro Thr Met Tyr Leu65                  70                  75                  80Gln Met Asp Thr Leu Gln Pro Glu Asp Thr Ala Val Tyr Tyr Cys Arg                85                  90                  95Val Glu Ser Gln Asp Tyr Tyr Phe Asp Tyr Asp Arg Asp Ser Trp Gly            100                 105                 110Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>38</s210><s211>117</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 38Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Ala Val Glu Trp Val        35                  40                  45Ser Ala Ile Asp Asp Ile Gly Ala Tyr Ile Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys                85                  90                  95Ala Thr Gly Tyr Trp Tyr Thr Pro Gly Asp Trp Gly Gln Gly Thr Gln            100                 105                 110Val Thr Val Ser Ser        115</s400><s200><s210>39</s210><s211>116</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 39Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Glu1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr            20                  25                  30Val Met Asn Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Ala Ile Asp Asn Val Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Tyr Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Asn Ala Lys Arg Tyr Trp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val            100                 105                 110Thr Val Ser Ser        115</s400><s200><s210>40</s210><s211>127</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 40Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Asp Tyr Tyr            20                  25                  30Asp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Asp Trp Ile        35                  40                  45Ser Cys Ile Ser Ser Ser Asp Gly Ser Gln Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Asp Arg Phe Phe Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Glu Pro Gly Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Asp Phe Asp Thr Tyr Arg Phe Cys Ser Gly Phe Gly Pro Asp            100                 105                 110Ala Tyr Ser Ser Trp Gly Gln Gly Thr Gln Val Ile Val Ser Ser        115                 120                 125</s400><s200><s210>41</s210><s211>117</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 41Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Gly Tyr            20                  25                  30Thr Met Gly Trp Phe Arg Arg Ala Pro Gly Lys Glu Arg Glu Leu Ile        35                  40                  45Ala Asn Ile Leu Trp Asn Ser Ala Arg Arg Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Met Asn Thr Val Asp65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Val Leu Val Asp Ser Thr Tyr Arg Phe Ser Asn Gln Gly Thr Gln            100                 105                 110Val Thr Val Ser Ser        115</s400><s200><s210>42</s210><s211>121</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 42Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ala Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Val        35                  40                  45Ala Ser Ile Arg Val Ser Gly Gly Ile Thr Asp Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asp Thr Val Tyr65                  70                  75                  80Leu Gln Met Ile Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Asn Ala Asp Ile Ser Arg Tyr Arg Phe Ser Arg Gly Asp Tyr Trp Gly            100                 105                 110Lys Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>43</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 43Gln Val Gln Leu Val Glu Ser Gly Gly Gly Thr Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Gly Ser Tyr            20                  25                  30Ala Met Glu Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Thr Ile Ser Ser Gly Gly Asn Thr His Tyr Leu Ala Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Asp Lys Asn Thr Leu Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala                85                  90                  95Ala Lys Tyr Gly Trp Thr Gly Ile Trp Tyr Ala Pro Ser Asp Tyr Val            100                 105                 110His Leu Gly Pro Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>44</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 44Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asp Asn Phe Ser Arg Tyr            20                  25                  30Thr Phe Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Val Ile Asn Trp Ser Gly Ser Tyr Thr Tyr Val Ala Asp Ser Val    50                  55                  60Ala Gly Arg Phe Thr Met Ser Arg Asp Asn Ala Lys His Leu Val Tyr65                  70                  75                  80Leu Gln Met Asp Ser Leu Asn Thr Gly Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala His Trp Asp Tyr Gly Ser Ser Ser Arg Arg Gln Arg Glu Tyr            100                 105                 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Ile Val Ser Ser        115                 120                 125</s400><s200><s210>45</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 45Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Ser Ser Arg Tyr            20                  25                  30Val Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Ile Ser Ala Asn Gly Arg Ser Thr Asn Tyr Ala Gly Ser Val    50                  55                  60Asn Gly Arg Phe Lys Ile Ser Arg Asp Gly Ala Lys Asp Lys Val Asp65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Thr Asn Met Ala Phe Ser Ser Ser Ser Asn Phe Pro Ala Asn Tyr            100                 105                 110Asp Val Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>46</s210><s211>127</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 46Gln Val Gln Leu Ala Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Val Ser Ser Tyr            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Ile Ser Trp Ser Gly Glu Ser Thr His Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Glu Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ser Tyr Leu Ser Gly His Tyr Tyr Phe Gly Ile Gly Arg Asp Pro            100                 105                 110Pro Phe Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>47</s210><s211>116</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 47Arg Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Leu Pro Leu Asn Thr Ala            20                  25                  30Ala Met Ser Trp Tyr Arg Gln Thr Pro Gly Lys Glu Arg Glu Leu Val        35                  40                  45Ala Ser Ile Ser Ile Thr Gly Asp Ser Thr Thr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Ile Val Tyr65                  70                  75                  80Leu Gln Met Asp Ile Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Thr Arg Ala Pro Trp Asp Tyr Lys Tyr Trp Gly Gln Gly Thr Gln Val            100                 105                 110Thr Val Ser Ser        115</s400><s200><s210>48</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 48Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Val Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Thr Phe Ser Asn Tyr            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Thr Ala Ile Asn Trp Ser Gly Ala Ile Lys Asn Tyr Gly Asp Ser Ala    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Leu Asn Met Leu Tyr65                  70                  75                  80Leu Gln Met Asn Arg Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Arg Gln Gly Asn Met Gly Asp Leu Val Val Lys Ser Gly Asp            100                 105                 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>49</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 49Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Gly Arg His            20                  25                  30Val Met Ala Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Val        35                  40                  45Ala Ala Ile Ser Gly Asn Gly Arg Val Thr Asn Tyr Ala Leu Ser Met    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Asn Asp Met Val Tyr65                  70                  75                  80Leu Gln Met Asp Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr Ser Cys                85                  90                  95Ala Thr Arg Met Ala Phe Asp Ser Asp Ser Asn Phe Pro Ala Thr Tyr            100                 105                 110Asp Val Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>50</s210><s211>125</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 50Gln Val Gln Leu Thr Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Ala1               5                   10                  15Ser Leu Arg Leu Ser Cys Val Ala Ser Pro Asp Thr Pro Ser Thr Tyr            20                  25                  30Thr Ile Ala Trp Phe Arg Arg Ala Pro Gly Lys Glu Arg Asp Phe Val        35                  40                  45Ala Asn Ile Ala Arg Ala Gly Thr Thr Ile Thr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Arg Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Asn Leu Thr Pro Ala Asp Thr Ala Ile Tyr Tyr Cys                85                  90                  95Ala Ala Tyr Ser Pro Gly Ser Ile Ile Ala Arg Asp Ser Thr Gln Tyr            100                 105                 110Arg Tyr Trp Gly Gln Gly Thr Arg Val Thr Val Ser Glu        115                 120                 125</s400><s200><s210>51</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 51Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu1               5                   10                  15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Tyr            20                  25                  30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Phe Val        35                  40                  45Ala Arg Ile Ser Arg Arg Gly Thr Asn Thr Tyr Tyr Ala Asp Ser Val    50                  55                  60Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Asp Arg Ser Asp Val Phe Glu Lys Asp Pro Gly Tyr Tyr Asp            100                 105                 110Tyr Trp Gly Gln Gly Ala Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>52</s210><s211>116</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 52Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Leu Ser Thr Ser            20                  25                  30Pro Val Ser Trp Ala Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Leu        35                  40                  45Ala Gly Ile Tyr Ser Asp Gly Arg Thr Ser Asn Leu Val Ser Leu Arg    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Leu Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala                85                  90                  95Ile Gly Ala Ala Ala Val Gly Gly Leu Arg Gly Gln Gly Thr Gln Val            100                 105                 110Thr Val Ser Ser        115</s400><s200><s210>53</s210><s211>128</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 53Gln Val Ser Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Arg Arg Ser            20                  25                  30Ala Met Gly Trp Phe Arg Arg Pro Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Ile Thr Ser Ser Gly Gly Ser Ile Tyr Asp Pro Asp Ile Ala    50                  55                  60Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Thr Ser Val Tyr65                  70                  75                  80Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ser Leu Lys Thr Thr Tyr Ser Gly Gly Pro Tyr Asp Tyr Thr Lys Gly            100                 105                 110Pro Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>54</s210><s211>120</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 54Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Arg Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ala Phe Ser Ser Tyr            20                  25                  30Pro Met Gly Trp Phe Arg Arg Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Ala Ile Ser Leu Ser Gly Ser Lys Gln Tyr Tyr Val Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Leu Lys Asp Gly Glu Pro Pro Ala Val Asp Tyr Trp Gly Gln            100                 105                 110Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>55</s210><s211>126</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 55Gln Val Glu Leu Val Glu Ser Gly Gly Ala Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Lys Leu Ser Cys Val Asp Ser Gly Arg Ser Phe Ser Ser Tyr            20                  25                  30Val Val Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Arg Val Ser Ala Ser Gly Ala Ile Arg Thr Tyr Ala Asp Ser Val    50                  55                  60Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Ala Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Phe Phe Cys                85                  90                  95Ala Ala Gly Gly Val Ser Thr Ala Val His Pro Phe Lys Pro Thr Ser            100                 105                 110Tyr Asp Phe Trp Gly Gln Gly Thr Gln Val Thr Val Ser Val        115                 120                 125</s400><s200><s210>56</s210><s211>120</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 56Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ser Ile Arg Ser Ile Tyr            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val        35                  40                  45Ala Leu Val Thr Asp Asp Gly Ser Thr Asp Tyr Val Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Val Ser Arg Asp Ser Ala Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr His Cys Tyr                85                  90                  95Val Glu Gly Ser Thr His Tyr Asp Pro Val Arg Glu Tyr Trp Gly Lys            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>57</s210><s211>124</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 57Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Leu Phe Ser Gly Thr Phe Gly Ile Tyr Gly            20                  25                  30Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Ala Arg Glu Phe Val Ala        35                  40                  45Gly Val Ser Arg His Gly Leu Thr Thr Gln Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys Ala                85                  90                  95Arg Ser Arg Leu Ser Ala Ser Leu Leu Val Thr Ala Ser Asp Tyr Asp            100                 105                 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>58</s210><s211>122</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 58Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Thr Phe Asp Arg Tyr            20                  25                  30His Met Gly Trp Phe Arg Gln Ala Pro Gly Met Glu Arg His Val Val        35                  40                  45Ala His Ile Ser Trp Ser Gly Ala Asn Thr Tyr Val Ala Asp Ser Met    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Ala Tyr65                  70                  75                  80Leu Gln Ile Asn Asn Leu Lys Phe Glu Asp Thr Ala Leu Tyr Tyr Cys                85                  90                  95Ala Ala Gly Ser Tyr Leu Ala Val Pro Gly Ser Arg Trp Asp Tyr Trp            100                 105                 110Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>59</s210><s211>118</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 59Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Leu Ser Phe Tyr            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ser Pro Gly Lys Gln Arg Glu Val Val        35                  40                  45Ala Arg Ile Ala Gly Pro Gly Val Thr Asn Tyr Ala Asp Ser Val Met    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn                85                  90                  95Ala Gly Gly Thr Arg Trp Ser Val Gly Asp Tyr Trp Gly Lys Gly Thr            100                 105                 110Leu Val Thr Val Ser Ser        115</s400><s200><s210>60</s210><s211>121</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 60Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr            20                  25                  30Ala Met Ala Trp Phe Arg Arg Pro Pro Gly Lys Ala Arg Glu Phe Val        35                  40                  45Ala Leu Ile Arg Trp Ser Asn Gly Arg Thr Ala Val Val Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ala Ser Arg Asp Asn Ala Lys Asn Thr Gly Tyr65                  70                  75                  80Leu Gln Met Asp Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Cys Asp Gln Ala Leu Asp Pro Pro Arg Cys Asn Asp Trp Gly            100                 105                 110Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>61</s210><s211>122</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 61Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Phe Thr Tyr            20                  25                  30Pro Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Gln Phe Val        35                  40                  45Ala Ala Ile Ser Gly Asn Gly Asp Ser Ile Asp Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Ala Ala Leu Tyr Tyr Cys                85                  90                  95Asn Ala Val Ile Thr His Asp Tyr Thr Arg Pro Leu Phe Ala Ser Trp            100                 105                 110Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>62</s210><s211>122</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 62Arg Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ala Leu Arg Leu Ser Cys Val Gly Ser Gly Phe Thr Phe Arg Asp Thr            20                  25                  30Ala Met Ala Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Phe Val        35                  40                  45Ala Gly Phe Ser Ile Leu Ser Arg Tyr Ala Asp Ser Val Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asn Asp Lys Asn Thr Val Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly                85                  90                  95Asp Gly Thr Ile Ala Ser Val Leu Thr Thr Ser Gly Val Asn Phe Trp            100                 105                 110Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>63</s210><s211>24</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>NGS sequencing primer</s223></s220></s200><s400> 63gcagtggctg caggtgtcca ctcg                                            24</s400><s200><s210>64</s210><s211>24</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>NGS sequencing primer</s223></s220></s200><s400> 64gcaggtcccc aaggtgtcct gtcc                                            24</s400><s200><s210>65</s210><s211>18</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>NGS sequencing primer</s223></s220></s200><s400> 65ggtggtcctg gctgctct                                                   18</s400><s200><s210>66</s210><s211>21</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>NGS sequencing primer</s223></s220></s200><s400> 66ttgtggtttt ggtgtcttgg g                                               21</s400><s200><s210>67</s210><s211>21</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>NGS sequencing primer</s223></s220></s200><s400> 67ggggtcttcg ctgtggtgcg c                                               21</s400><s200><s210>68</s210><s211>4</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 68Ala Asp Tyr Lys1</s400><s200><s210>69</s210><s211>16</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 69Ala Ala Ser Thr Met Val Val Thr Thr Val Ala Ala Asp Tyr Lys Tyr1               5                   10                  15</s400><s200><s210>70</s210><s211>22</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 70Ala Ala Gly Leu Lys Ala Asp Tyr Gly Asp Ser Tyr Val Asp Thr Ser1               5                   10                  15Thr Arg Asn Tyr Asn Tyr            20</s400><s200><s210>71</s210><s211>18</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 71Ala Ala Asp Tyr Asn Arg Leu Gln Ile Gly Gln Arg Ser Arg Asp Tyr1               5                   10                  15Asp Tyr</s400><s200><s210>72</s210><s211>18</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 72Ala Gly Arg Pro Phe Gly Leu Gln Leu Asp Thr His Gln Ala Asp Tyr1               5                   10                  15Asn Ile</s400><s200><s210>73</s210><s211>17</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 73Gly Val Asp Arg Arg Gln Tyr Gly Leu Gly Ile Pro Pro Leu Ala Asp1               5                   10                  15Tyr</s400><s200><s210>74</s210><s211>18</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 74Val Ala Asp Tyr Arg Val Trp Gly Thr Arg Ile Ala Gly Thr Lys Tyr1               5                   10                  15Asp Ser</s400><s200><s210>75</s210><s211>21</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 75Ala Ala Asp Gly Asp Ala Ser Asp Arg Ser Tyr Ala Pro Pro Arg Asp1               5                   10                  15Tyr Lys Tyr Glu Tyr            20</s400><s200><s210>76</s210><s211>16</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 76Ala Ala Asp Asn Val Gly Asp Ser Trp Tyr Ser Asp Asp Tyr Lys Tyr1               5                   10                  15</s400><s200><s210>77</s210><s211>19</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 77Asn Ala Arg Pro Thr Phe Gly Ala Tyr Tyr Ser Asp Tyr Lys Ser Gly1               5                   10                  15Val Asp Tyr</s400><s200><s210>78</s210><s211>13</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 78Asn Arg Gly Asn Tyr Tyr Arg Asp Tyr Lys Pro Glu Phe1               5                   10</s400><s200><s210>79</s210><s211>18</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 79Thr Thr Glu Val Ala Cys Tyr Ser Asp Tyr Lys Ser Thr Gln Ile Ser1               5                   10                  15Arg Ile</s400><s200><s210>80</s210><s211>16</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 80Asn Tyr Lys Arg Gly His Tyr Pro Asp Gly Val Ser Thr Tyr Glu Tyr1               5                   10                  15</s400><s200><s210>81</s210><s211>16</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 81Ser Tyr Lys Arg Gly Arg Tyr Pro Asp Gly Val Ser Thr Leu Glu Tyr1               5                   10                  15</s400><s200><s210>82</s210><s211>14</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 82Ala Asn Ser Thr Tyr Phe Asn Asp Asp Pro Glu Tyr Asp Arg1               5                   10</s400><s200><s210>83</s210><s211>17</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 83Asn Ala Gly Arg Leu Ser Tyr Gly Gly Ser Tyr Tyr Pro Asn Asp Asp1               5                   10                  15Tyr</s400><s200><s210>84</s210><s211>18</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 84Asn Thr Asp Tyr Thr Phe Ala Lys Leu Thr Ala Pro Asp Arg Arg Asn1               5                   10                  15Asp Asp</s400><s200><s210>85</s210><s211>12</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 85Asn Ala Asp Thr Ile Ala Thr Met Thr Asp Asp Tyr1               5                   10</s400><s200><s210>86</s210><s211>18</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 86Asn Ala Thr Arg Pro Arg Asp Asp Tyr Tyr Tyr Thr Gly Gly Phe Leu1               5                   10                  15Tyr Tyr</s400><s200><s210>87</s210><s211>16</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 87Arg Pro Tyr Ser Asp Tyr Val Thr Tyr Asp Pro Asp Asp Tyr Asp Tyr1               5                   10                  15</s400><s200><s210>88</s210><s211>16</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 88Asn Thr Asp Pro Asp Tyr Ser Asp Tyr Asp Asp Met Tyr Val Arg Ser1               5                   10                  15</s400><s200><s210>89</s210><s211>17</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 89Ala Ala Thr Asn Ser Asn Thr Asp Trp Arg Thr Tyr Thr Glu Tyr Asn1               5                   10                  15Tyr</s400><s200><s210>90</s210><s211>19</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 90Ala Ala Lys Phe Thr Ser Ser Ser Phe Tyr Tyr Arg Ser Pro Arg Glu1               5                   10                  15Tyr Ser Ser</s400><s200><s210>91</s210><s211>20</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 91Ala Ala Lys Asn Val Pro Gly Phe Tyr Tyr Ser Asp Tyr Ala Asn His1               5                   10                  15Glu Tyr Asp Tyr            20</s400><s200><s210>92</s210><s211>18</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 92Asn Ala Pro Lys Gly Gly Ser Tyr Tyr Phe Pro Ala Val Gly Gly Tyr1               5                   10                  15Asp Tyr</s400><s200><s210>93</s210><s211>15</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 93Arg Val Glu Ser Gln Asp Tyr Tyr Phe Asp Tyr Asp Arg Asp Ser1               5                   10                  15</s400><s200><s210>94</s210><s211>10</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 94Ala Thr Gly Tyr Trp Tyr Thr Pro Gly Asp1               5                   10</s400><s200><s210>95</s210><s211>9</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 95Asn Ala Lys Arg Tyr Trp Tyr Asp Tyr1               5</s400><s200><s210>96</s210><s211>20</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 96Ala Ala Asp Phe Asp Thr Tyr Arg Phe Cys Ser Gly Phe Gly Pro Asp1               5                   10                  15Ala Tyr Ser Ser            20</s400><s200><s210>97</s210><s211>10</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 97Ala Val Leu Val Asp Ser Thr Tyr Arg Phe1               5                   10</s400><s200><s210>98</s210><s211>14</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 98Asn Ala Asp Ile Ser Arg Tyr Arg Phe Ser Arg Gly Asp Tyr1               5                   10</s400><s200><s210>99</s210><s211>17</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 99Ala Ile Gly Ala Pro Asp Pro Phe Asn Tyr Ser Gly Trp Arg Arg Asn1               5                   10                  15Leu</s400><s200><s210>100</s210><s211>16</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 100Ala Ile Gly Ile Ser Pro His Tyr Gly Ser Asp Trp Tyr Ala Leu Arg1               5                   10                  15</s400><s200><s210>101</s210><s211>13</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 101Ala Ile Gly Leu Ser Pro Gly Tyr Arg Asp Pro Asn Leu1               5                   10</s400><s200><s210>102</s210><s211>13</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 102Ala Ile Gly Leu Ser Pro Gly Tyr Ser Asp Pro Asn Leu1               5                   10</s400><s200><s210>103</s210><s211>13</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 103Ala Leu Gly Ala Met Arg Glu Gly Val Tyr Ser Asp Leu1               5                   10</s400><s200><s210>104</s210><s211>13</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 104Ala Val Gly Ala Pro Leu Val Ser Ser Pro Tyr Arg Ser1               5                   10</s400><s200><s210>105</s210><s211>15</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 105Ala Val Gly Ala Trp Tyr Glu Lys Arg Lys Lys Glu Lys Gly Leu1               5                   10                  15</s400><s200><s210>106</s210><s211>17</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 106Ala Val Gly Ile Val Val Pro Tyr Ser Glu Asp Ala Trp Tyr Ser Thr1               5                   10                  15Leu</s400><s200><s210>107</s210><s211>15</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 107Gly Ile Gly Arg Trp Tyr Asp Gln Arg Lys Lys Glu Glu Gly Leu1               5                   10                  15</s400><s200><s210>108</s210><s211>16</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 108Asn Ala Ala Pro Trp Gly Ser Tyr His Pro Gln Thr Asp Ile Val Ser1               5                   10                  15</s400><s200><s210>109</s210><s211>17</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 109Asn Ala Ala Pro Trp Gly Ser Tyr Ser Pro Gly Pro Gly Asp Ile Ala1               5                   10                  15Ser</s400><s200><s210>110</s210><s211>14</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 110Asn Gly Ala Pro Trp Gly Asp His Ala Pro Val Val Gly Ser1               5                   10</s400><s200><s210>111</s210><s211>14</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 111Asn Gly Ala Pro Trp Gly Asp Ile Ala Pro Val Ala Val Ser1               5                   10</s400><s200><s210>112</s210><s211>15</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 112Asn Pro Ala Pro Trp Gly Asp Tyr Thr Ala Thr Asp Phe His Ser1               5                   10                  15</s400><s200><s210>113</s210><s211>9</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 113Gln Leu Gly Ile His Pro Gly Ala Phe1               5</s400><s200><s210>114</s210><s211>13</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 114Gln Val Gly Arg Tyr Val Ser Gly Val Asp Tyr Gln Pro1               5                   10</s400><s200><s210>115</s210><s211>13</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 115Gln Val Gly Arg Tyr Val Ser Gly Val Tyr Tyr Gln Pro1               5                   10</s400><s200><s210>116</s210><s211>14</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 116Val Ile Gly Arg Gly Gly Tyr Ala Met Gly Asp Arg Arg Leu1               5                   10</s400><s200><s210>117</s210><s211>14</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 117Val Ile Gly Arg Arg Gly Tyr Ala Met Gly Asp Arg Thr Leu1               5                   10</s400><s200><s210>118</s210><s211>14</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 118Val Val Gly Arg Arg Gly Tyr Ala Met Gly Ser Arg Gln Leu1               5                   10</s400><s200><s210>119</s210><s211>127</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 119Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr            20                  25                  30Thr Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val        35                  40                  45Ser Cys Ile Asn Asn Gly Asp Asp Ser Thr Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Val Tyr Ile Trp Cys Thr Val Ala Ala Gly Ile Gly Ser Leu Gly            100                 105                 110Asp Leu Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>120</s210><s211>131</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 120Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Thr Gly Phe Thr Ser Asp Tyr Tyr            20                  25                  30Ala Leu Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val        35                  40                  45Ser Cys Ile Ser Ser Arg Gly Gly Asp Gly Thr Ile Tyr Tyr Ala Asp    50                  55                  60Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Tyr Ala Lys Asn Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr                85                  90                  95Tyr Cys Ala Ala Asp Leu Arg Val Pro Val Glu Glu Met Cys Val Met            100                 105                 110Ala Asp Asn Tyr Gly Met Asp Tyr Trp Gly Lys Gly Thr Pro Val Thr        115                 120                 125Val Ser Ser    130</s400><s200><s210>121</s210><s211>119</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 121Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Val Val Ser Arg Ser Ile Ser Ser Met Asn            20                  25                  30Ser Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Met Val        35                  40                  45Ala Val Met Tyr Ser Gly Asp Ser Thr Leu Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Phe Cys Lys                85                  90                  95Gly Glu Asp Trp Thr Thr Pro Val Arg Ser Asp Tyr Trp Gly Gln Gly            100                 105                 110Thr Gln Val Thr Val Ser Ser        115</s400><s200><s210>122</s210><s211>130</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 122Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Tyr Tyr            20                  25                  30Tyr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val        35                  40                  45Ser Cys Ile Ser Ser Ser Asp Gly Ser Thr Asp Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Glu Gly Ser Trp Asn Phe Asp Ala Met Arg Pro Cys Ser Ile            100                 105                 110Gln Glu Ala Asp Phe Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val        115                 120                 125Ser Ser    130</s400><s200><s210>123</s210><s211>119</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 123Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Glu Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Pro Leu Ser Gly Leu Gly Phe Ser Pro Asn            20                  25                  30His Met Cys Trp Tyr Arg Gln Ser Pro Gly Lys Leu Arg Glu Met Val        35                  40                  45Ala Cys Ile Thr Ser Gly Gly Ser Pro Asn Tyr Ser Asp Thr Ala Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Arg Thr Thr Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asp Ser Leu Lys Pro Asp Asp Thr Ala Ile Tyr Tyr Leu Lys                85                  90                  95Ala Glu Asp Trp Thr Thr Thr Pro Arg Ser Asp Tyr Trp Gly Gln Gly            100                 105                 110Thr Gln Val Thr Val Ser Ser        115</s400><s200><s210>124</s210><s211>116</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 124Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Val Gly Gly1               5                   10                  15Ser Leu Lys Leu Thr Cys Ala Ala Ser Gly Ser Ile Ser Arg Ile Ala            20                  25                  30Val Gly Trp Tyr Arg Gln Ile Pro Gly Lys Gln Arg Glu Leu Val Ala        35                  40                  45Arg Val Ser Ser Gly Gly Ile Leu Trp Tyr Asp Asp Ser Val Lys Gly    50                  55                  60Arg Phe Ile Ile Thr Arg Asp Asn Ala Lys Asn Met Val Tyr Leu Gln65                  70                  75                  80Met Asp Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Phe Cys Arg Gly                85                  90                  95Ser Asp Ser Asp Arg Phe Leu Gly Ser Trp Gly Gln Gly Thr Gln Val            100                 105                 110Thr Val Ser Ser        115</s400><s200><s210>125</s210><s211>127</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 125Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Asn Tyr            20                  25                  30Val Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val        35                  40                  45Ser Cys Phe Thr Ser Ala Asp Asn Arg Thr Tyr Tyr Ala Gly Ser Val    50                  55                  60Glu Gly Arg Phe Thr Ile Ser Ser Asp Asn Thr Lys Asn Thr Gly Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Lys Leu Glu Asp Glu Ala Val Tyr Ser Cys                85                  90                  95Ser Val Arg Val Tyr Arg Cys Thr Gly Arg Lys Cys Cys Asp Pro Leu            100                 105                 110Gly Met Asp Tyr Trp Gly Lys Gly Thr Pro Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>126</s210><s211>132</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 126Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ile Ala Ser Gly Ile Asp Leu Arg Asp Leu            20                  25                  30Thr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val        35                  40                  45Ser Phe Ile Ser Val Ser Gly Gly Asp Thr Tyr Tyr Ala Glu Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala His Ser Thr Ala Tyr65                  70                  75                  80Leu Gln Met Asn Asn Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Ala Asp Lys Thr Asp Ile Gly Phe Trp Met Leu Val Gly Gly Asp            100                 105                 110Gly Gly Gly Gly Val His Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val        115                 120                 125Thr Val Ser Ser    130</s400><s200><s210>127</s210><s211>115</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 127Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ile Ser Gly Phe Thr Phe Asp Arg Phe            20                  25                  30Pro Met Thr Trp Tyr Arg Gln Val Pro Gly Met Glu Arg Glu Leu Val        35                  40                  45Ala Arg Val Ser Thr Thr Gly Leu Thr Glu Tyr Phe Ala Asn Ala Leu    50                  55                  60Glu Gly Arg Phe Thr Ala Ser Arg Asp Asn Ala Lys Asn Thr Gly Tyr65                  70                  75                  80Leu Gln Met Asn Asp Leu Lys Pro Gly Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Asn Val Val Pro Pro Leu Arg Gln Trp Gly Gln Gly Thr Gln Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>128</s210><s211>131</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 128Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Asn Tyr            20                  25                  30Ala Val His Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val        35                  40                  45Ser Ser Ile Ala Ile Ile Asp Asp Thr Tyr Tyr Gly Glu Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Asp Ala Asn Ala Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ala                85                  90                  95Ala Asp Arg Thr Asp Ile Ala Phe Trp Leu Gln Val Gly Gly Asp Gly            100                 105                 110Gly Ser Gly Arg His Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr        115                 120                 125Val Ser Ser    130</s400><s200><s210>129</s210><s211>119</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 129Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Thr Leu Ser Cys Ala Ala Ser Arg Gly Ile Phe Thr Phe Asn            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Val Val        35                  40                  45Val His Phe Thr Ser Gly Asp Ser Glu Phe Trp Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Ser Arg Lys Asn Thr Val Tyr Leu65                  70                  75                  80Tyr Met Asn Asn Leu Gln Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys                85                  90                  95Ala Glu Asp Trp Thr Thr Ser Pro Arg Thr Asp Tyr Trp Gly Gln Gly            100                 105                 110Thr Gln Val Thr Val Ser Ser        115</s400><s200><s210>130</s210><s211>247</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Cetuximab</s223></s220></s200><s400> 130Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln1               5                   10                  15Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr            20                  25                  30Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu        35                  40                  45Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr    50                  55                  60Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe65                  70                  75                  80Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala                85                  90                  95Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly        115                 120                 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ala Ser Asp Ile Leu Leu    130                 135                 140Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly Glu Arg Val Ser145                 150                 155                 160Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile His Trp Tyr                165                 170                 175Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser            180                 185                 190Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly        195                 200                 205Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser Glu Asp Ile Ala    210                 215                 220Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr Thr Phe Gly Ala225                 230                 235                 240Gly Thr Lys Leu Glu Leu Lys                245</s400><s200><s210>131</s210><s211>119</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 131Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Ser            20                  25                  30Ala Met Ser Trp Ala Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ser Asp Ile Tyr Pro Asp Gly Arg Thr Asp Tyr Ala Asp Ser Ile Lys    50                  55                  60Gly Arg Phe Thr Met Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65                  70                  75                  80Leu Met Asp Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr His Cys Gln                85                  90                  95Val Gly Arg Tyr Val Ser Gly Val Tyr Tyr Gln Pro Arg Gly Gln Gly            100                 105                 110Thr Gln Val Thr Val Ser Ser        115</s400><s200><s210>132</s210><s211>120</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 132Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser            20                  25                  30Ala Met Ser Trp Ala Arg Gln Ala Pro Gly Lys Gly Leu Glu Cys Val        35                  40                  45Ser Asp Ile Tyr Pro Asp Gly Thr Ser Ser Tyr Ala Asp Ser Met Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Arg Asn Thr Met Tyr Leu65                  70                  75                  80Gln Met Asn Val Leu Lys Pro Glu Asp Thr Ala Thr Tyr Tyr Cys Val                85                  90                  95Ile Gly Arg Gly Gly Tyr Ala Met Gly Asp Arg Arg Leu Arg Gly Gln            100                 105                 110Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>133</s210><s211>120</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 133Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Ser Ser Ile Tyr            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Leu Arg Glu Leu Val        35                  40                  45Ala Ala Ile Thr Thr Gly Gly Ser Thr Phe Tyr Arg Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Ala Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr His Cys Asn                85                  90                  95Gly Ala Pro Trp Gly Asp Ile Ala Pro Val Ala Val Ser Trp Gly Gln            100                 105                 110Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>134</s210><s211>119</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 134Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Pro Ser            20                  25                  30Ala Met Ser Trp Ala Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Arg Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Met Val Tyr Leu65                  70                  75                  80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala                85                  90                  95Leu Gly Ala Met Arg Glu Gly Val Tyr Ser Asp Leu Leu Gly Gln Gly            100                 105                 110Thr Gln Val Thr Val Ser Ser        115</s400><s200><s210>135</s210><s211>120</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 135Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Glu Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Ser Ile Tyr            20                  25                  30Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Gly Leu Val        35                  40                  45Ala Ala Ile Thr Ser Gly Gly Asp Thr Phe Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Val Tyr Leu65                  70                  75                  80Gln Met Asn Asn Leu Lys Ser Glu Asp Thr Ala Val Tyr Asp Cys Asn                85                  90                  95Gly Ala Pro Trp Gly Asp His Ala Pro Leu Val Ala Ser Trp Gly Gln            100                 105                 110Gly Thr Gln Val Thr Val Ser Ser        115                 120</s400><s200><s210>136</s210><s211>117</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 136Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val His Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Asp Cys Ala Val Ser Glu Arg Ile Ala Ser Phe Asn            20                  25                  30Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Gln Gln Arg Glu Val Val        35                  40                  45Ala Thr Ile Thr Ser Val Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Ala Lys Asp Asn Asp Lys Asn Thr Tyr Leu Gln65                  70                  75                  80Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Ala                85                  90                  95Val Ile Val Gly Thr Tyr Asp Thr Glu Tyr Trp Gly Gln Gly Thr Leu            100                 105                 110Val Thr Val Ser Ser        115</s400><s200><s210>137</s210><s211>117</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 137Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val His Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ala Cys Ala Ala Ser Glu Arg Ile Leu Ser Phe Asn            20                  25                  30Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Gln Gln Arg Glu Val Val        35                  40                  45Ala Thr Ile Thr Ser Val Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys    50                  55                  60Gly Arg Phe Thr Ile Phe Lys Asp Asn Gly Lys Asn Thr Tyr Leu Gln65                  70                  75                  80Met Ser Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Ala                85                  90                  95Val Thr Val Gly Asp Val Asp Thr Glu Tyr Trp Gly Gln Gly Thr Gln            100                 105                 110Val Thr Val Ser Ser        115</s400><s200><s210>138</s210><s211>20</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 138Ser Phe Val Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp1               5                   10                  15Lys Leu Ala Ala            20</s400><s200><s210>139</s210><s211>19</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 139Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala Gln Ile Lys Glu1               5                   10                  15Ser Leu Arg</s400><s200><s210>140</s210><s211>39</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 140Ser Phe Val Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp1               5                   10                  15Lys Leu Ala Ala Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala            20                  25                  30Gln Ile Lys Glu Ser Leu Arg        35</s400><s200><s210>141</s210><s211>32</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 141Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Lys Asn Ile Ile1               5                   10                  15Gln Phe Val His Gly Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr            20                  25                  30</s400><s200><s210>142</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>PD1PDL1 screening peptide 2</s223></s220></s200><s400> 142Asp Tyr Lys Arg1</s400><s200><s210>143</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>5 aa PD-1 screeing peptide</s223></s220></s200><s400> 143Ala Asp Tyr Lys Arg1               5</s400><s200><s210>144</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>polar peptide contact PD-1PD-L1 complex</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(3)</s222><s223>X can be any amino acid      dipeptide can be longer than 2 amino acids</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(6)</s222><s223>X can be any amino acid      dipeptide can be longer than 2 amino acids</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(9)</s222><s223>X can be any amino acid      dipeptide can be longer than 2 amino acids</s223></s220></s200><s400> 144Phe Xaa Xaa Asp Xaa Xaa Gln Xaa Xaa Ala Asp Tyr Lys Arg1               5                   10</s400><s200><s210>145</s210><s211>14</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 145Asn Gly Ala Pro Trp Gly Asp His Ala Pro Leu Val Ala Ser1               5                   10</s400><s200><s210>146</s210><s211>12</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 146Lys Ala Val Ile Val Gly Thr Tyr Asp Thr Glu Tyr1               5                   10</s400><s200><s210>147</s210><s211>12</s211><s212>PRT</s212><s213>alpaca</s213></s200><s400> 147Lys Ala Lys Thr Val Gly Asp Val Asp Thr Glu Tyr1               5                   10</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002758A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002758</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17841618</doc-number><date>20220615</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>10</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>P</subclass><main-group>21</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>P</subclass><main-group>19</main-group><subgroup>34</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>70</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>1041</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>P</subclass><main-group>21</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>P</subclass><main-group>19</main-group><subgroup>34</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>70</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">TETHERED RIBOSOMES AND METHODS OF MAKING AND USING THEREOF</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>63202555</doc-number><date>20210616</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><orgname>Northwestern University</orgname><address><city>Evanston</city><state>IL</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Kim</last-name><first-name>Do Soon</first-name><address><city>Evanston</city><state>IL</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Jewett</last-name><first-name>Michael Christopher</first-name><address><city>Evanston</city><state>IL</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present disclosure relates to methods to evolve macromolecular machines and improved macromolecular machines identified and made by the methods. In some embodiments, the improved macromolecular machines include improved tethered ribosomes. Also disclosed are systems and methods for making and using the improved tethered ribosomes.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="89.07mm" wi="158.75mm" file="US20230002758A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="255.52mm" wi="145.54mm" orientation="landscape" file="US20230002758A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="253.92mm" wi="145.12mm" orientation="landscape" file="US20230002758A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="223.10mm" wi="149.52mm" orientation="landscape" file="US20230002758A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="262.38mm" wi="115.15mm" orientation="landscape" file="US20230002758A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="258.15mm" wi="107.95mm" orientation="landscape" file="US20230002758A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="254.59mm" wi="113.71mm" orientation="landscape" file="US20230002758A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="262.21mm" wi="116.84mm" orientation="landscape" file="US20230002758A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="274.07mm" wi="133.10mm" orientation="landscape" file="US20230002758A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="253.32mm" wi="129.96mm" orientation="landscape" file="US20230002758A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="249.77mm" wi="127.51mm" orientation="landscape" file="US20230002758A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="235.54mm" wi="122.17mm" orientation="landscape" file="US20230002758A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="252.31mm" wi="130.39mm" orientation="landscape" file="US20230002758A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="215.82mm" wi="133.69mm" orientation="landscape" file="US20230002758A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="237.57mm" wi="136.14mm" orientation="landscape" file="US20230002758A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="176.95mm" wi="148.59mm" orientation="landscape" file="US20230002758A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="240.96mm" wi="145.97mm" orientation="landscape" file="US20230002758A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="261.03mm" wi="101.43mm" orientation="landscape" file="US20230002758A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="210.57mm" wi="149.18mm" orientation="landscape" file="US20230002758A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="262.21mm" wi="149.78mm" orientation="landscape" file="US20230002758A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="264.24mm" wi="120.57mm" orientation="landscape" file="US20230002758A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="203.79mm" wi="138.09mm" orientation="landscape" file="US20230002758A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="276.27mm" wi="116.84mm" orientation="landscape" file="US20230002758A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="271.36mm" wi="144.70mm" orientation="landscape" file="US20230002758A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="273.13mm" wi="114.64mm" orientation="landscape" file="US20230002758A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="258.66mm" wi="140.04mm" orientation="landscape" file="US20230002758A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00026" num="00026"><img id="EMI-D00026" he="265.77mm" wi="148.51mm" orientation="landscape" file="US20230002758A1-20230105-D00026.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00027" num="00027"><img id="EMI-D00027" he="265.01mm" wi="151.30mm" orientation="landscape" file="US20230002758A1-20230105-D00027.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00028" num="00028"><img id="EMI-D00028" he="241.72mm" wi="128.27mm" orientation="landscape" file="US20230002758A1-20230105-D00028.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00029" num="00029"><img id="EMI-D00029" he="244.26mm" wi="146.98mm" orientation="landscape" file="US20230002758A1-20230105-D00029.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00030" num="00030"><img id="EMI-D00030" he="255.35mm" wi="154.94mm" orientation="landscape" file="US20230002758A1-20230105-D00030.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00031" num="00031"><img id="EMI-D00031" he="203.54mm" wi="146.47mm" orientation="landscape" file="US20230002758A1-20230105-D00031.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00032" num="00032"><img id="EMI-D00032" he="264.33mm" wi="110.91mm" orientation="landscape" file="US20230002758A1-20230105-D00032.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00033" num="00033"><img id="EMI-D00033" he="251.46mm" wi="148.25mm" orientation="landscape" file="US20230002758A1-20230105-D00033.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00034" num="00034"><img id="EMI-D00034" he="259.84mm" wi="154.01mm" orientation="landscape" file="US20230002758A1-20230105-D00034.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00035" num="00035"><img id="EMI-D00035" he="229.36mm" wi="150.28mm" orientation="landscape" file="US20230002758A1-20230105-D00035.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00036" num="00036"><img id="EMI-D00036" he="274.40mm" wi="118.62mm" orientation="landscape" file="US20230002758A1-20230105-D00036.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00037" num="00037"><img id="EMI-D00037" he="277.03mm" wi="111.34mm" orientation="landscape" file="US20230002758A1-20230105-D00037.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00038" num="00038"><img id="EMI-D00038" he="260.86mm" wi="141.56mm" orientation="landscape" file="US20230002758A1-20230105-D00038.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00039" num="00039"><img id="EMI-D00039" he="258.57mm" wi="132.08mm" orientation="landscape" file="US20230002758A1-20230105-D00039.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CROSS-REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application claims the benefit of U.S. Provisional Patent Application No. 63/202,555 filed Jun. 16, 2021, the entire content of which is incorporated herein by reference in its entirety.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?federal-research-statement description="Federal Research Statement" end="lead"?><heading id="h-0002" level="1">STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT</heading><p id="p-0003" num="0002">This invention was made with government support under W911NF-16-1-0372 awarded by the Army Research Office, Department of Defense, and 1716766 awarded by the National Science Foundation. The government has certain rights in the invention.</p><?federal-research-statement description="Federal Research Statement" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0003" level="1">SEQUENCE LISTING</heading><p id="p-0004" num="0003">A Sequence Listing accompanies this application and is submitted as an ASCII text file of the sequence listing named &#x201c;702581_02153_ST25.txt&#x201d; which is 116,528 bytes in size and was created on May 19, 2022. The sequence listing is electronically submitted via EFS-Web with the application and is incorporated herein by reference in its entirety.</p><heading id="h-0004" level="1">FIELD OF INVENTION</heading><p id="p-0005" num="0004">The present disclosure relates to methods to evolve macromolecular machines and improved macromolecular machines identified and made by the methods. In some embodiments, the improved macromolecular machines include improved tethered ribosomes. Also disclosed are systems and methods for making and using the same.</p><heading id="h-0005" level="1">BACKGROUND</heading><p id="p-0006" num="0005">The ribosome is a molecular machine responsible for the polymerization of &#x3b1;-amino acids into proteins. In all kingdoms of life, the ribosome is made up of two subunits. In bacteria, these correspond to the small (30S) subunit and the large (50S) subunit. The 30S subunit contains the 16S ribosomal RNA (rRNA) and 21 ribosomal proteins (r-proteins), and is involved in translation initiation and decoding the mRNA message. The 50S subunit contains the 5S and 23S rRNAs and 33r-proteins, and is responsible for accommodation of amino acid substrates, catalysis of peptide bond formation, and protein excretion.</p><p id="p-0007" num="0006">The extraordinarily versatile catalytic capacity of the ribosome has driven extensive efforts to harness it for novel functions, such as reprogramming the genetic code. For example, the ability to modify the ribosome's active site to work with substrates beyond those found in nature such as mirror-image (D-&#x3b1;-) and backbone-extended (&#x3b2;- and &#x3b3;-) amino acids, could enable the synthesis of new classes of sequence-defined polymers to meet many goals of biotechnology and medicine. Unfortunately, cell viability constraints limit the alterations that can be made to the ribosome.</p><p id="p-0008" num="0007">To bypass this limitation, recent developments have focused on the engineering of specialized ribosome systems. The concept is to create an independent, or orthogonal, translation system within the cell dedicated to production of one or a few target proteins while wild-type ribosomes continue to synthesize genome-encoded proteins to ensure cell viability. Pioneering efforts by Hui and DeBoer, and subsequent improvements by Chin and colleagues, first created a specialized small ribosomal subunit. By modifying the Shine-Dalgarno (SD) sequence of an mRNA and the corresponding anti-Shine Dalgarno (ASD) sequence in 16S rRNA, they generated orthogonal 30S subunits capable of primarily translating a specific kind of engineered mRNA, while largely excluding them from translating endogenous cellular mRNAs. These advances enabled the selection of mutant 30S ribosomal subunits capable of re-programming cellular logic and enabling new decoding properties.</p><p id="p-0009" num="0008">Unfortunately, such techniques have been restricted to the small subunit because the large subunits freely exchange between pools of native and orthogonal 30S. This limited the engineering potential of the large subunit, which contains the peptidyl transferase center (PTC) active site and the nascent peptide exit tunnel. This limitation has been addressed with a fully orthogonal ribosome (termed Ribo-T), whereby the small and large subunits are tethered together via helix h44 of the 16S rRNA and helix H101 of the 23S rRNA.</p><p id="p-0010" num="0009">Since the initial discovery of Ribo-T and a subsequent stapled design<sup>15</sup>, new orthogonal Ribo-T/mRNA pairs as well as tether sequences have been optimized using directed evolution methods<sup>9,14</sup>. Specifically, tether residues have been randomized in sequence but not in length<sup>9</sup>, or mutations to surrounding residues surrounding a fixed RNA linker (the J5/5a junction from the <i>Tetrahymena </i>group I intron) have been investigated<sup>14</sup>. Despite the improvement, the potential of tethered ribosome systems remains limited by their low activity.</p><p id="p-0011" num="0010">The untapped potential and existing inefficiencies of tethered ribosome systems motivate the need for new directed evolution-based approaches to engineer these systems for improving their activity.</p><heading id="h-0006" level="1">SUMMARY</heading><p id="p-0012" num="0011">Disclosed herein are tethered ribosomes and methods of making and using the ribosomes. Also disclosed are novel methods for evolving macromolecular machines, termed &#x201c;Evolink.&#x201d;</p><p id="p-0013" num="0012">Disclosed herein are engineered ribosomes. In some embodiments, the engineered ribosomes comprise a) a small subunit comprising a 16S rRNA polynucleotide sequence or variant thereof; b) a large subunit comprising a 23S rRNA polynucleotide sequence or variant thereof, c) a linking moiety comprising a T1 polynucleotide domain and a T2 polynucleotide domain, wherein the linking moiety links the 16s RNA and the 23S rRNA, thereby linking the large and small ribosomal subunits. In some embodiments, the linking moiety covalently bonds helix 101 of the 23S rRNA large subunit to helix 44 of the 16s rRNA of the small subunit. In some embodiments, the T1 polynucleotide domain comprises 5&#x2032;-GUUAUA-3&#x2032; or 5&#x2032;-AGUCAAUAA-3&#x2032; and the T2 polynucleotide domain comprises 5&#x2032;-UCACAAG-3&#x2032;; or 5&#x2032;-GACCUUCG-3&#x2032;. In some embodiments, the T1 polynucleotide domain comprises 5&#x2032;-GUUAUA-3&#x2032; and the T2 polynucleotide domain comprises 5&#x2032;-UCACAAG-3&#x2032;. In some embodiments, the T1 polynucleotide domain comprises 5&#x2032;-AGUCAAUAA-3&#x2032; and T2 polynucleotide comprises 5&#x2032;-GACCUUCG-3&#x2032;. In some embodiments, the engineered ribosome comprises SEQ ID NO: 1.</p><p id="p-0014" num="0013">Also disclosed are polynucleotides encoding the rRNA of the engineered ribosomes, such as, for example, SEQ ID NO: 1, and cells comprising the polynucleotides. Also disclosed are methods for preparing a sequence-defined polymer using the engineered ribosomes disclosed herein.</p><p id="p-0015" num="0014">Also disclosed are methods for evolving molecular machines comprising RNA and/or protein regions of interest that are far apart in primary sequence, but proximal in three-dimensional space. In some embodiments, the methods comprise a design step, a build step, a test step, and an analyze step, the test step involving Evolink, comprising a first PCR, a ligation, and a second PCR.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0007" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0016" num="0015">Non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying figures, which are schematic and are not intended to be drawn to scale. In the figures, each identical or nearly identical component illustrated is typically represented by a single numeral. For purposes of clarity, not every component is labeled in every figure, nor is every component of each embodiment of the invention shown where illustration is not necessary to allow those of ordinary skill in the art to understand the invention.</p><p id="p-0017" num="0016"><figref idref="DRAWINGS">FIG. <b>1</b>A-<b>1</b>C</figref>. (A) illustrates the secondary structure of a large subunit rRNA (<b>101</b>) and a small subunit rRNA (<b>102</b>) of a wild-type ribosome. (B) illustrates a tethered ribosome having a large subunit, a small subunit, and a linking moiety (<b>103</b>). (C) provides an illustrative transcript for a tethered ribosome rRNA.</p><p id="p-0018" num="0017"><figref idref="DRAWINGS">FIG. <b>2</b>A-<b>2</b>E</figref> provides illustrations of the Ribo-T system. (A) schematic of the Ribo-T showing tether and orthogonal ribosome binding site in the 30S subunit. (B) The tether is optimized in cells growing exclusively from the Ribo-T plasmid. (C) Previously published Ribo-T tether sequence, T1 and T2. (D) Orthogonal function evolved for Ribo-T. (E) Previously published orthogonal mRNA (o-mRNA) Shine-Dalgarno (SD) sequence and orthogonal 16S rRNA anti-SD (o-ASD) sequence shown.</p><p id="p-0019" num="0018"><figref idref="DRAWINGS">FIG. <b>3</b>A-<b>3</b>C</figref>. (A) Ribo-T v1 previously published tether sequences T1 and T2. (B) Ribo-T v2 previously published tether sequences T1 and T2. (C) T1 and T2 regions evaluated for optimization as described herein.</p><p id="p-0020" num="0019"><figref idref="DRAWINGS">FIG. <b>4</b>A-<b>4</b>C</figref>. Overview of Evolink and tethered ribosome design and evolution. (A) RNA- and protein based enzymes with regions that are distal in primary sequence but proximate in 3D space (Regions 1 &#x26; 2, blue and red, respectively), and likely functionally linked. Molecular biology steps of Evolink (PCR-1, LIG-1, PCR-2) to link regions together in a single amplicon that enable overlapping next-generation sequencing (NGS) readouts. DNA oligos (green), can be flexibly designed depending on the machine architecture encoded on a plasmid. (B) Rosetta-predicted structure of a previously reported tethered ribosome showing tethers, denoted T1 and T2, in 3D space as well as likely secondary structure representation. Representative encoding plasmid (right) is shown. (C) The Design, Build, Test, &#x26; Analyze evolution scheme. (Test) includes selection, Evolink, and the resulting NGS reads. (Analyze) involves Rosetta modeling to infer tether structure and predicted stability. Results from each round feed into (Design) and (Build).</p><p id="p-0021" num="0020"><figref idref="DRAWINGS">FIG. <b>5</b>A-<b>5</b>C</figref>. Results of the Broad Sampling Library. (A) Residues targeted in this library (red) depicted with surrounding residues (black) in native secondary structure. (B) Fold-enrichment (log 2) of tether sequence pairs during selection in liquid culture over four time points (1 time point per day for 4 days). (C) Analysis of the NGS results reveals convergence towards 9 and 12 nucleotides for T1 and T2 regions, respectively. Data representative of three independent experiments.</p><p id="p-0022" num="0021"><figref idref="DRAWINGS">FIG. <b>6</b>A-<b>6</b>C</figref>. Investigation of the Tether-H101 junction. (A) Rosetta modeling of the Ribo-T v2 tether and surrounding residues. The junction (cyan) consists of nucleotides that connect the tether (red) to the rest of H101 (blue) in the 23S rRNA. (B) Secondary structure depiction of the library for testing deletion effects in the junction. (C) Results from Evolink showing convergence towards specific Ribo-T v2 Tether-H101 junction sequence. Heatmap data representative of three independent experiments.</p><p id="p-0023" num="0022"><figref idref="DRAWINGS">FIG. <b>7</b>A-<b>7</b>H</figref>. Integration and validation of designed junction into library design. (A) The sequence of T1 and T2 tethers selected from the Broad Sampling Library. (B-C) Rosetta modeling of the Tether-23S junction (purple) show significant differences between enforcing or not enforcing (constrained vs. unconstrained, respectively) native base pairing. (D) Rosetta score vs. Root-Mean-Standard-Deviation (RMSD) for constrained and unconstrained models of the enriched sequence. (E) Library with the designed Tether-23S junction, reinforced by three synthetic base pairs (gold). (F) Representative fold-enrichment (log 2) of tether sequences from selection and Evolink on the designed Tether-23S junction library. Data representative of three independent experiments. (G) Heatmap of relative abundance of tether lengths showing convergence towards 6 and 8 nucleotides for T1 and T2, respectively. (H) Rosetta score vs. RMSD for constrained and unconstrained models of an enriched sequence from the designed library.</p><p id="p-0024" num="0023"><figref idref="DRAWINGS">FIG. <b>8</b>A-<b>8</b>G</figref>. Clonal isolation and test of Ribo-Tv3 function. (A) The final library which combines the designed Tether-23S junction and lengths informed by Evolink results from the Designed Tether-23S junction library. (B) Cartoon schematic for orthogonal sfGFP synthesis. (C) Orthogonal sfGFP synthesis by 16 candidates Ribo-Tv3 tether pairs based on the four most popular T1 and T2 genotypes. Data are from three biological replicates (n=3) and error bars indicate standard deviation, representative of two independent experiments. (D-E) Growth of SQ171 cells living on Ribo-Tv3 and Ribo-Tv2 on rich Luria broth media (D) and minimal M9 media (E). Data are from twenty biological replicates (n=20) and error shown represents a 95% confidence interval on each estimated parameter in the sigmoid curve fit. Data representative of three independent experiments. (F-G) Incorporation of 2-amino-3-(7-(diethylamino)-2-oxo-2H-chromene-3-carboxamido) propanoate (DECP) into a sequence-defined peptide by a purified sample of Ribo-Tv3 (F) and Ribo-T v2 (G) in an in vitro protein synthesis reaction using flexizymes. MALDI data representative of three independent experiments.</p><p id="p-0025" num="0024"><figref idref="DRAWINGS">FIG. <b>9</b></figref> Showing the preparation of DECP-CME (Appendix II).</p><p id="p-0026" num="0025"><figref idref="DRAWINGS">FIG. <b>10</b>A-<b>10</b>D</figref> Tertiary interactions (RNA:RNA) in the ribosome between regions far apart in primary sequence. (A) Helix 96 (red; nucleotides 2702-2704) of the 23S rRNA base pairs with Helix 57 (green; nucleotides 1455-1457). (B) Helix 88 (orange; nucleotides 2407-2411) of Domain V/Central Protuberance makes contacts with Helix 22 (cyan; nucleotides 412-416) in Domain I. (C) RNA:RNA contacts also exist between the large and small subunits, as evidenced by Helix 8 (blue; nucleotides 147-148 and 174-175) in the 16S rRNA and Helix 56 (green; nucleotides 1446-1447) in the 23S rRNA. (D) Helix 44 (green; nucleotides 1418 &#x26; 1483) of the 16S makes possible tertiary contacts with Helix 71 (gold; nucleotides 1947-1948 &#x26; 1958-1959).</p><p id="p-0027" num="0026"><figref idref="DRAWINGS">FIG. <b>11</b>A-<b>11</b>B</figref>. Proof of concept study for library preparation workflow of Evolink. (A) A clonal sample of the tethered ribosome (Ribo-T v2) is linearized using different oligos compatible with multiple ligation protocols. (B) From the different ligation products, generation of final amplicon for next-generation sequencing can happen with a wide range of ligation methods and starting template amounts in the PCR. Gel data representative of two independent experiments.</p><p id="p-0028" num="0027"><figref idref="DRAWINGS">FIG. <b>12</b>A-<b>12</b>C</figref>. Enrichment of individual genotypes throughout full Evolink experiment. Positively enriched genotypes (purple) and negative enriched genotypes (dark gray) can be tracked throughout multiple time points throughout selection. Genotypes that drop out during selection can also be identified (light gray). Generally, across the three libraries tested in this work, (A) the Broad Sampling Library, (B) the Designed Junction Library, and (C) the Designed Junction+Length Refined Library, log<sub>2</sub>-fold enrichment values between &#x2212;6 to 6 are observed. Enrichment data representative of three independent experiments</p><p id="p-0029" num="0028"><figref idref="DRAWINGS">FIG. <b>13</b>A-<b>13</b>C</figref>. Distribution of T2 sequences for most enriched T1 sequences. Distribution of T2 sequences for most popular T1 sequences displayed for the three libraries tested ((A)Broad Sampling Library, (B) Designed Junction Library, (C) Designed Junction+Length Sampling Library). Scatter plot represents unique T2 sequences for a given T1 sequence. Violin plot and scatter plot data representative of three independent experiments.</p><p id="p-0030" num="0029"><figref idref="DRAWINGS">FIG. <b>14</b>A-<b>14</b>C</figref>. Distribution of T1 sequences for most enriched T2 sequences. Distribution of T1 sequences for most popular T2 sequences displayed for the three libraries tested (Broad Sampling Library, Designed Junction Library, Designed Junction+Length Sampling Library). Scatter plot represents unique T1 sequences for a given T2 sequence. Violin plot and scatter plot data representative of three independent experiments</p><p id="p-0031" num="0030"><figref idref="DRAWINGS">FIG. <b>15</b>A-<b>15</b>D</figref>. Analysis of enriched genotypes from the Broad Sampling Library. Each panel shows an enriched sequence modeled using RNAcofold. For three of the genotypes, (A), (C), and (D), the same tether base pairs are formed in the constrained and unconstrained minimum free energy (MFE) structures. (B) For one of the genotypes, significant rearrangement is observed between the constrained vs. unconstrained MFE structures.</p><p id="p-0032" num="0031"><figref idref="DRAWINGS">FIG. <b>16</b>A-<b>16</b>B</figref>. Representative constrained and unconstrained 3D models of Designed Junction Library winner. The winning genotype from <figref idref="DRAWINGS">FIG. <b>4</b>H</figref> was modeled using Rosetta, and representative outputs are shown. In both the (A) unconstrained and (B) constrained model, the Designed Junction residues are predicted to base pair, reinforcing structural stability to this region.</p><p id="p-0033" num="0032"><figref idref="DRAWINGS">FIG. <b>17</b>A-<b>17</b>H</figref>. Score vs. Root-Mean-Standard-Deviation analysis of FARFAR2 simulations of enriched tether sequences. (A-D) For the Broad Sampling Library, we observe significant differences between simulations that constrained (blue) or did not constrain (orange) 3D structures of the Tether-H101 junction. Of the four modeled genotypes, two sequence (C-D) exhibit particularly significant differences, hinting at structural instability in the Tether-H101 junction. (E-H) When similar simulations are performed with enriched tether sequences from the Designed Junction Library (designed sequences at the Tether-H101 junction), the results of FARFAR2 simulations reach similarly low scores in constrained vs. unconstrained modeling runs.</p><p id="p-0034" num="0033"><figref idref="DRAWINGS">FIG. <b>18</b></figref>. Heatmap of lengths by enrichment for the Designed Junction+Length Refined Library. Lengths of 6 and 8 nt are enriched, as seen in the Designed Junction Library. No constructs of length 9 nt for the T2 region was observed in the final time point. Heatmap data (relative frequency of next-generation sequencing read) representative of three independent experiments.</p><p id="p-0035" num="0034"><figref idref="DRAWINGS">FIG. <b>19</b>A-<b>19</b>B</figref>. Growth curves and parameters for Ribo-T v3 compared to Ribo-T v2 in cells lacking genomic ribosomal operons. Sigmoidal functions were fit to kinetic data (left) to calculate parameters (right). (A) In rich Luria broth (LB), Ribo-T v2 and Ribo-T v3 have equivalent slopes &#x2dc;0.08 A<sub>600</sub>/hour (doubling rates in exponential phase), but Ribo-T v3 has shorter lag time in growth. (B) In minimal M9 media, the difference in slopes and lag are more pronounced. Notably, Ribo-T v2 does not reach full stationary phase in 24 hours while Ribo-T v3 grows to stationary phase between 18-20 hours. Error bars represent one standard deviation calculated for six replicates (n=6). Growth data are representative of three independent experiments, each performed with six replicates.</p><p id="p-0036" num="0035"><figref idref="DRAWINGS">FIGS. <b>20</b>A-<b>20</b>B</figref>. (A)<sup>1</sup>H and (B)<sup>13</sup>C NMR spectra of DECP-CME (5).</p><p id="p-0037" num="0036"><figref idref="DRAWINGS">FIG. <b>21</b></figref>. Acylation of microhelix with DECP. The Fx-mediated acylation reaction was monitored using microhelix (a tRNA mimic) under the two different pH (7.5 and 8.8) over 16 h with three different flexizymes (eFx, dFx, and aFx) at 0&#xb0; C. The highest acylation yield (86%) was found when aFx was used in pH 7.5, which was used to charge the substrate into tRNA<sup>fMet</sup>(CAU) and incorporate it into the N-terminus of a peptide in vitro. Gel representative of three independent experiments.</p><p id="p-0038" num="0037"><figref idref="DRAWINGS">FIG. <b>22</b>A-<b>22</b>B</figref>. Characterization of N-terminus functionalized peptide hybridized with DECP. (A) Structure and molecular weight of byproduct peptides in the in vitro translation reaction that are produced. (B) MALDI mass spectrometry data (<figref idref="DRAWINGS">FIG. <b>5</b>E</figref>) obtained from attempt to incorporate DECP with Ribo-T v3. The truncated peptide (P1) was produced likely because Ribo-T v3 skipped the incorporation of DECP at the initiating codon (AUG) on mRNA. P2 was produced presumably because of the contaminations of either amino acid or Met-charged tRNA (tRNA<sup>fMet</sup>) when Ribo-T v3 obtained from <i>E. coli </i>cell was supplemented into the in vitro translation reaction. The percent yield (76%) of the target peptide (P3) was determined based on the relative peak area (PA) of P3 over a total amount of the byproducts (P1 and P2) and P3 (i.e., relative yield (%)=&#x3a3; of PA (P3)/&#x3a3; of PA (P1+P2+P3)&#xd7;100). MALDI data representative of three independent experiments.</p><p id="p-0039" num="0038"><figref idref="DRAWINGS">FIG. <b>23</b></figref> is a Table showing tether pairs T1 and T2 and the percent improvement in activity relative to RiboT-v2. Tether pairs 1-14 perform better than RiboT-V2, while tether pairs 15 and 16 perform worse than RiboT-v2. The performance of wild-type ribosomes is shown in the last row of the table. Tether pairs were ranked based on metric &#x201c;Norm_RFU&#x201d;, which is the normalized GFP yield. The full sequence of modified ribosomal RNA including the 16 tether pairs is provided in the Examples.</p><p id="p-0040" num="0039"><figref idref="DRAWINGS">FIG. <b>24</b>A-<b>24</b>B</figref>. Cryo-EM structure of the Ribo-Tv3 ribosome at 4.18 angstroms resolution. A 4.18 angstrom density of the Ribo-Tv3 ribosome was generated through single-particle analysis. (A) The 4YBB ribosome structure fit into the Ribo-Tv3 density. (B) Zoom-in on the density of the Ribo-Tv3 tether region with top 10 DRRAFTER models of the tether built into the density.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0008" level="1">DETAILED DESCRIPTION</heading><p id="p-0041" num="0040">Terminology</p><p id="p-0042" num="0041">Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of skill in the art to which the invention pertains. All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.</p><p id="p-0043" num="0042">The indefinite articles &#x201c;a&#x201d; and &#x201c;an,&#x201d; as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean &#x201c;at least one.&#x201d;</p><p id="p-0044" num="0043">A range includes each individual member. Thus, for example, a group having 1-3 members refers to groups having 1, 2, or 3 members.</p><p id="p-0045" num="0044">It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.</p><p id="p-0046" num="0045">The modal verb &#x201c;may&#x201d; refers to the preferred use or selection of one or more options or choices among the several described embodiments or features contained within the same. Where no options or choices are disclosed regarding a particular embodiment or feature contained in the same, the modal verb &#x201c;may&#x201d; refers to an affirmative act regarding how to make or use an aspect of a described embodiment or feature contained in the same, or a definitive decision to use a specific skill regarding a described embodiment or feature contained in the same. In this latter context, the modal verb &#x201c;may&#x201d; has the same meaning and connotation as the auxiliary verb &#x201c;can.&#x201d;</p><p id="p-0047" num="0046">In the claims, as well as in the specification above, all transitional phrases such as &#x201c;comprising,&#x201d; &#x201c;including,&#x201d; &#x201c;carrying,&#x201d; &#x201c;having,&#x201d; &#x201c;containing,&#x201d; &#x201c;involving,&#x201d; &#x201c;holding,&#x201d; &#x201c;composed of,&#x201d; and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases &#x201c;consisting of&#x201d; and &#x201c;consisting essentially of&#x201d; shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.</p><p id="p-0048" num="0047">As used herein, &#x201c;about,&#x201d; &#x201c;approximately,&#x201d; &#x201c;substantially,&#x201d; and &#x201c;significantly&#x201d; will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which they are used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, &#x201c;about&#x201d; and &#x201c;approximately&#x201d; will mean up to plus or minus 10% of the particular term and &#x201c;substantially&#x201d; and &#x201c;significantly&#x201d; will mean more than plus or minus 10% of the particular term.</p><p id="p-0049" num="0048">The terms &#x201c;nucleic acid&#x201d; and &#x201c;oligonucleotide,&#x201d; as used herein, refer to polydeoxyribonucleotides (containing 2-deoxy-DRibose), polyribonucleotides (containing DRibose), and to any other type of polynucleotide that is an N glycoside of a purine or pyrimidine base. There is no intended distinction in length between the terms &#x201c;nucleic acid&#x201d;, &#x201c;oligonucleotide&#x201d; and &#x201c;polynucleotide&#x201d;, and these terms will be used interchangeably. These terms refer only to the primary structure of the molecule. Thus, these terms include double- and single-stranded DNA, as well as double- and single-stranded RNA. For use in the present invention, an oligonucleotide also can comprise nucleotide analogs in which the base, sugar or phosphate backbone is modified as well as non-purine or non-pyrimidine nucleotide analogs.</p><p id="p-0050" num="0049">Oligonucleotides can be prepared by any suitable method, including direct chemical synthesis by a method such as the phosphotriester method of Narang et al., 1979, Meth. Enzymol. 68:90-99; the phosphodiester method of Brown et al., 1979, Meth. Enzymol. 68:109-151; the diethylphosphoramidite method of Beaucage et al., 1981, Tetrahedron Letters 22:1859-1862; and the solid support method of U.S. Pat. No. 4,458,066, each incorporated herein by reference. A review of synthesis methods of conjugates of oligonucleotides and modified nucleotides is provided in Goodchild, 1990, Bioconjugate Chemistry 1(3): 165-187, incorporated herein by reference.</p><p id="p-0051" num="0050">The term &#x201c;primer,&#x201d; as used herein, refers to an oligonucleotide capable of acting as a point of initiation of DNA synthesis under suitable conditions. Such conditions include those in which synthesis of a primer extension product complementary to a nucleic acid strand is induced in the presence of four different nucleoside triphosphates and an agent for extension (for example, a DNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature.</p><p id="p-0052" num="0051">A primer is preferably a single-stranded DNA. The appropriate length of a primer depends on the intended use of the primer but typically ranges from about 6 to about 225 nucleotides, including intermediate ranges, such as from 15 to 35 nucleotides, from 18 to 75 nucleotides and from 25 to 150 nucleotides. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. A primer need not reflect the exact sequence of the template nucleic acid, but must be sufficiently complementary to hybridize with the template. The design of suitable primers for the amplification of a given target sequence is well known in the art and described in the literature cited herein.</p><p id="p-0053" num="0052">Primers can incorporate additional features which allow for the detection or immobilization of the primer but do not alter the basic property of the primer, that of acting as a point of initiation of DNA synthesis. For example, primers may contain an additional nucleic acid sequence at the 5&#x2032; end which does not hybridize to the target nucleic acid, but which facilitates cloning or detection of the amplified product, or which enables transcription of RNA (for example, by inclusion of a promoter) or translation of protein (for example, by inclusion of a 5&#x2032;-UTR, such as an Internal Ribosome Entry Site (IRES) or a 3&#x2032;-UTR element, such as a poly(A)n sequence, where n is in the range from about 20 to about 200). The region of the primer that is sufficiently complementary to the template to hybridize is referred to herein as the hybridizing region.</p><p id="p-0054" num="0053">The term &#x201c;promoter&#x201d; refers to a cis-acting DNA sequence that directs RNA polymerase and other trans-acting transcription factors to initiate RNA transcription from the DNA template that includes the cis-acting DNA sequence.</p><p id="p-0055" num="0054">The terms &#x201c;target, &#x201c;target sequence&#x201d;, &#x201c;target region&#x201d;, and &#x201c;target nucleic acid,&#x201d; as used herein, are synonymous and refer to a region or sequence of a nucleic acid which is to be amplified, sequenced or detected.</p><p id="p-0056" num="0055">The term &#x201c;hybridization,&#x201d; as used herein, refers to the formation of a duplex structure by two single-stranded nucleic acids due to complementary base pairing. Hybridization can occur between fully complementary nucleic acid strands or between &#x201c;substantially complementary&#x201d; nucleic acid strands that contain minor regions of mismatch. Conditions under which hybridization of fully complementary nucleic acid strands is strongly preferred are referred to as &#x201c;stringent hybridization conditions&#x201d; or &#x201c;sequence-specific hybridization conditions&#x201d;. Stable duplexes of substantially complementary sequences can be achieved under less stringent hybridization conditions; the degree of mismatch tolerated can be controlled by suitable adjustment of the hybridization conditions. Those skilled in the art of nucleic acid technology can determine duplex stability empirically considering a number of variables including, for example, the length and base pair composition of the oligonucleotides, ionic strength, and incidence of mismatched base pairs, following the guidance provided by the art (see, e.g., Sambrook et al., 1989, Molecular Cloning-A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; Wetmur, 1991, Critical Review in Biochem. and Mol. Biol. 26(3/4):227-259; and Owczarzy et al., 2008, Biochemistry, 47: 5336-5353, which are incorporated herein by reference).</p><p id="p-0057" num="0056">The term &#x201c;amplification reaction&#x201d; refers to any chemical reaction, including an enzymatic reaction, which results in increased copies of a template nucleic acid sequence or results in transcription of a template nucleic acid. Amplification reactions include reverse transcription, the polymerase chain reaction (PCR), including Real Time PCR (see U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds, 1990)), and the ligase chain reaction (LCR) (see Barany et al., U.S. Pat. No. 5,494,810). Exemplary &#x201c;amplification reactions conditions&#x201d; or &#x201c;amplification conditions&#x201d; typically comprise either two or three step cycles. Two-step cycles have a high temperature denaturation step followed by a hybridization/elongation (or ligation) step. Three step cycles comprise a denaturation step followed by a hybridization step followed by a separate elongation step.</p><p id="p-0058" num="0057">As used herein, a &#x201c;polymerase&#x201d; refers to an enzyme that catalyzes the polymerization of nucleotides. &#x201c;DNA polymerase&#x201d; catalyzes the polymerization of deoxyribonucleotides. Known DNA polymerases include, for example, <i>Pyrococcus furiosus </i>(Pfu) DNA polymerase, <i>E. coli </i>DNA polymerase I, T7 DNA polymerase and <i>Thermus aquaticus </i>(Taq) DNA polymerase, among others. &#x201c;RNA polymerase&#x201d; catalyzes the polymerization of ribonucleotides. The foregoing examples of DNA polymerases are also known as DNA-dependent DNA polymerases. RNA-dependent DNA polymerases also fall within the scope of DNA polymerases. Reverse transcriptase, which includes viral polymerases encoded by retroviruses, is an example of an RNA-dependent DNA polymerase. Known examples of RNA polymerase (&#x201c;RNAP&#x201d;) include, for example, T3 RNA polymerase, T7 RNA polymerase, SP6 RNA polymerase and <i>E. coli </i>RNA polymerase, among others. The foregoing examples of RNA polymerases are also known as DNA-dependent RNA polymerase. The polymerase activity of any of the above enzymes can be determined by means well known in the art.</p><p id="p-0059" num="0058">As used herein, the term &#x201c;sequence defined polymer&#x201d; refers to a polymer having a specific primary sequence. A sequence defined polymer can be equivalent to a genetically-encoded defined polymer in cases where a gene encodes the polymer having a specific primary sequence.</p><p id="p-0060" num="0059">As used herein, a primer is &#x201c;specific,&#x201d; for a target sequence if, when used in an amplification reaction under sufficiently stringent conditions, the primer hybridizes primarily to the target nucleic acid. Typically, a primer is specific for a target sequence if the primer-target duplex stability is greater than the stability of a duplex formed between the primer and any other sequence found in the sample. One of skill in the art will recognize that various factors, such as salt conditions as well as base composition of the primer and the location of the mismatches, will affect the specificity of the primer, and that routine experimental confirmation of the primer specificity will be needed in many cases. Hybridization conditions can be chosen under which the primer can form stable duplexes only with a target sequence. Thus, the use of target-specific primers under suitably stringent amplification conditions enables the selective amplification of those target sequences that contain the target primer binding sites.</p><p id="p-0061" num="0060">As used herein, &#x201c;expression template&#x201d; refers to a nucleic acid that serves as substrate for transcribing at least one RNA that can be translated into a polypeptide or protein. Expression templates include nucleic acids composed of DNA or RNA. Suitable sources of DNA for use a nucleic acid for an expression template include genomic DNA, plasmid DNA, cDNA and RNA that can be converted into cDNA. Genomic DNA, cDNA and RNA can be from any biological source, such as a tissue sample, a biopsy, a swab, sputum, a blood sample, a fecal sample, a urine sample, a scraping, among others. The genomic DNA, cDNA and RNA can be from host cell or virus origins and from any species, including extant and extinct organisms. As used herein, &#x201c;expression template&#x201d; and &#x201c;transcription template&#x201d; have the same meaning and are used interchangeably.</p><p id="p-0062" num="0061">As used herein, &#x201c;tethered,&#x201d; &#x201c;conjoined,&#x201d; &#x201c;linked,&#x201d; &#x201c;connected,&#x201d; &#x201c;coupled&#x201d; and &#x201c;covalently-bonded&#x201d; have the same meaning as modifiers.</p><p id="p-0063" num="0062">As used herein, &#x201c;tethered ribosome,&#x201d; &#x201c;engineered ribosome,&#x201d; and &#x201c;Ribo-T&#x201d; will be used interchangeably.</p><p id="p-0064" num="0063">As used here, &#x201c;CP&#x201d; refers to a circularly permuted subunit. As used herein, when CP is followed by &#x201c;23S&#x201d; that refers to a circularly permuted 23S rRNA. As used herein, when CP followed by a number may refer to the location of the new 5&#x2032; end in a secondary structure, e.g. CP101 means the new 5&#x2032; end is in helix 101 of the 23S rRNA, or to the location of the new 5&#x2032; nucleotide, e.g. CP2861 means the new 5&#x2032; nucleotide is the nucleotide 2861 of the 23 rRNA, depending on context.</p><p id="p-0065" num="0064">As used herein, &#x201c;translation template&#x201d; refers to an RNA product of transcription from an expression template that can be used by ribosomes to synthesize polypeptide or protein.</p><p id="p-0066" num="0065">Methods for Improved Molecular Evolution of Biological Machines and Compositions Derived Therefrom</p><p id="p-0067" num="0066">Disclosed herein is a new technique for evolving macromolecular machines, which combines molecular biology techniques with next-generation sequencing to allow co-evolution of functionally-linked residues previous out of reach for next generation sequencing reads with length limitations (&#x2dc;300 nts). Termed Evolink, this technique is broadly applicable to large RNA or protein machines, and can be implemented with very basic techniques available in many molecular biology laboratories.</p><p id="p-0068" num="0067">Also disclosed herein is a new sequence for an RNA machine, the ribosome, which improves upon the previous tethered ribosome (see e.g., Ref 9). The new ribosome system, termed Ribo-T v3, is capable of orthogonal protein synthesis and improved cellular fitness when supporting life.</p><p id="p-0069" num="0068">Ribo-T v3 features new ribosomal RNA sequences that link together the 16S and 23S rRNA of the small (30S) and large (50S) subunits of the <i>E. coli </i>ribosome. This new RNA sequence was achieved by applying a newly invented technique called Evolink, in which distal regions of a machine (e.g., functional protein or nucleic acid sequence) encoded on a plasmid can be linked together in an amplicon for next-generation reads to enable co-evolution of previously separated parts. Evolink can be applied to any machine encoded on a plasmid, and can link together multiple regions. Such regions are abundant in many macromolecular machines (both protein and RNA), and have been precluded from high throughput evolution due to limitations in assay techniques.</p><p id="p-0070" num="0069">Ribosome engineering is emerging as a powerful approach for expanding the catalytic potential of the protein synthesis apparatus and for elucidating its origin, evolution and function. Because the properties of the engineered ribosome might be detrimental for the general protein synthesis, the designer ribosome needs to be functionally isolated from the translation machinery synthesizing cellular proteins. The initial solution to this problem has been offered by Ribo-T, an engineered ribosome with the tethered subunits which, while translating a desired protein, could be excluded from translation of the cellular proteome. In the present disclosure, the inventors present a new paradigm for designing and evolving macromolecular machines. The inventors herein demonstrate the combination of computational modeling with a molecular biology workflow that enables high-throughput evolution of distant regions in a large molecular machine. To showcase the utility of the approach, the inventors evolved a tethered ribosome which improves upon the previous state-of-the-art by over 50% in orthogonal protein translation.</p><p id="p-0071" num="0070">Applications and Advantages of Evolink</p><p id="p-0072" num="0071">The improved molecular evolution methods for biological machines, and compositions derived therefrom, e.g., improved tethered ribosomes, have many applications and advantages. The following are examples only, and are not intended to be limiting.</p><p id="p-0073" num="0072">Ribosome evolution/engineering (for example towards more efficient non-canonical amino acid incorporation); expanded genetic codes for non-canonical amino acid incorporation; enabling detailed in vivo studies of antibiotic resistance mechanisms, enabling antibiotic development process; biopharmaceutical production; orthogonal circuits in cells; synthetic biology; production of engineered peptides by incorporating new functionality inaccessible to peptides synthesized by native (or wild type) ribosome or their post-translationally modified derivatives; production of novel protease-resistant peptides that could transform medicinal chemistry.</p><p id="p-0074" num="0073">For evolution of the ribosomes, the inventors present a new paradigm for directed evolution that integrates computational structural modeling of RNA machines as well as a new molecular biology technique that enables evolution of distant regions on molecular machines compatible with next-generation sequencing.</p><p id="p-0075" num="0074">This improved upon a previous state-of-the-art design for a tethered ribosome (Ribo-T v2.0, see Ref. 9). It outperforms Ribo-T v2.0 in both supporting cellular life (faster and more robust growth) as well as orthogonal protein production (improved orthogonal GFP synthesis).</p><p id="p-0076" num="0075">Improvements to orthogonal ribosomes could play a vital role in successful directed evolution towards new functions, such as new polymerization chemistries and orthogonal genetic circuits.</p><p id="p-0077" num="0076">The inventors further show compatibility of orthogonal, tethered ribosomes with other synthetic translation machinery, specifically the flexizyme system for non-standard amino acid incorporation to produce a peptide containing a coumarin derivative non-canonical monomer in an in vitro translation reaction. This combination of engineered translation machinery has not previously been shown.</p><p id="p-0078" num="0077">The novel evolutionary molecular method disclosed herein greatly increases throughput of directed evolution efforts on large protein or RNA enzymes. The unmet need is the current limitation in the number of genotypes that can be linked to advantageous phenotypes. Notably, it is impossible to evolve sequence-distal parts of molecular machines and interactions between those sequences although based on structure they are likely linked in function. The invention described herein allows a research group to rapidly assess which parts of macromolecular machines are functionally linked, and then to perform directed evolution on them with readouts that allow them to link sequence-distal parts in Next Generation Sequencing (NGS) readouts without having to rely on clonal screening or using statistics to infer functional linkage. This invention could increase throughput by orders of magnitude and with greater fidelity than previously available methods.</p><p id="p-0079" num="0078">Engineered Ribosomes</p><p id="p-0080" num="0079">Engineered ribosomes and methods of making and using the ribosomes, are described in U.S. Pat. No. 10,590,456, Ref. 9, and Ref. 18, each of which is incorporated herein by reference in its entirety.</p><p id="p-0081" num="0080">The engineered ribosome comprises a small subunit, a large subunit, and a linking moiety, wherein the linking moiety tethers the small subunit with the large subunit. In some embodiments, the engineered ribosome is capable of supporting translation of a sequence-defined polymer. In some embodiments, the engineered ribosome comprises a linking moiety that links the 16S and 23S rRNA of the small (30S) and large (50S) subunits of the <i>E. coli </i>ribosome.</p><p id="p-0082" num="0081">In the following discussion, the rRNA component of ribosomes is the focus. As is well known in the art, ribosomes, including the engineered ribosomes disclosed herein, comprise ribosomal proteins as well as RNA. For example, bacterial ribosomes, such as <i>E. coli </i>ribosomes, include 31 ribosomal proteins in the 50S (large) subunit, and 21 ribosomal proteins in the 30S (small) subunit. Ribosomal proteins and methods of making ribosomes are well known in the art (see e.g., references above). While the RNA is the focus of the discussion, it is to be understood that ribosomes and their subunits also include ribosomal proteins.</p><p id="p-0083" num="0082">In contrast to a naturally occurring ribosome, the engineered ribosome has a large and a small subunit that are not separable. <figref idref="DRAWINGS">FIG. <b>1</b>A</figref> depicts a portion of a wild-type ribosome <b>100</b> having a small subunit and a large subunit that are separable. <figref idref="DRAWINGS">FIG. <b>1</b>A</figref> illustrates the secondary structure of a large subunit rRNA <b>101</b> and a small subunit rRNA <b>102</b> that together form a portion of a functional ribosome.</p><p id="p-0084" num="0083">An embodiment of a portion of an engineered tethered ribosome is illustrated in <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>, which illustrates the secondary structure of an exemplary large subunit rRNA <b>301</b> and an exemplary small subunit rRNA <b>302</b> that together form a portion of a functional engineered ribosome. The engineered ribosome comprises a large subunit rRNA <b>301</b>, a small subunit rRNA <b>302</b>, and a linking moiety <b>303</b> that tethers the small subunit with the large subunit. The engineered ribosome may also comprise a connector <b>304</b>, that closes the ends of a native large subunit rRNA.</p><p id="p-0085" num="0084">Large Subunit</p><p id="p-0086" num="0085">The large ribosome subunit <b>301</b> comprises a subunit capable of joining amino acids to form a polypeptide chain. The large subunit <b>301</b> may comprise a ribosomal RNA comprising a first large subunit domain (&#x201c;L1 polynucleotide domain&#x201d; or &#x201c;L1 domain&#x201d;), a second large subunit domain (&#x201c;L2 polynucleotide domain&#x201d; or &#x201c;L2 domain&#x201d;), and a connector domain (&#x201c;C polynucleotide domain&#x201d; or &#x201c;C domain&#x201d;) <b>304</b>, wherein the L1 domain is followed, in order, by the C domain and the L2 domain, from 5&#x2032; to 3&#x2032;.</p><p id="p-0087" num="0086"><figref idref="DRAWINGS">FIG. <b>1</b>C</figref> illustrates an example of an rRNA gene <b>400</b> that encodes the engineered ribosome rRNA <b>300</b>, and provides an alternative representation for understanding the engineered ribosome. The encoding polynucleotide <b>400</b> may comprise different sequences that encode the various domains of the engineered ribosome rRNA <b>300</b>. As illustrated in <figref idref="DRAWINGS">FIG. <b>1</b>C</figref>, the polynucleotide encoding the large subunit rRNA <b>301</b> comprises the polynucleotide encoding the L1 domain <b>402</b>, the polynucleotide encoding the C domain <b>406</b>, and the polynucleotide encoding the L2 domain <b>403</b>.</p><p id="p-0088" num="0087">In some embodiment, the large subunit rRNA <b>301</b> may be a permuted variant of a separable large subunit rRNA. In some embodiments, the permuted variant is a circularly permuted variant of a separable large subunit rRNA. The separable large subunit may be any functional large subunit. In some embodiments, the separable large subunit may be a 23S rRNA. In some embodiments, the separable large subunit comprises a wild-type large subunit rRNA. In some embodiments, the separable large subunit is a wild-type 23S rRNA. In some embodiments, the separable large subunit is at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least 99% identical to a wild-type 23S rRNA.</p><p id="p-0089" num="0088">In some embodiment, if the large subunit <b>301</b> is a permuted variant of a large subunit rRNA, then the polynucleotide sequences consisting essentially of the L2 domain, followed by the L1 domain, from 5&#x2032; to 3&#x2032;, may be substantially identical to a large subunit rRNA. In some embodiments, the polynucleotide sequence consisting essentially of the L2 domain followed by sequence consisting essentially of the L1 domain, from 5&#x2032; to 3&#x2032;, is at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least 99% identical to the large subunit rRNA.</p><p id="p-0090" num="0089">In some embodiments where the large subunit <b>301</b> is a permuted variant of a separable large subunit rRNA, the large subunit <b>301</b> may further comprise a C domain <b>304</b> that connects the native 5&#x2032; and 3&#x2032; ends of the separable large subunit rRNA. The C domain may comprise a polynucleotide having a length ranging from 1-200 nucleotides. In some embodiments, the C domain <b>304</b> comprises a polynucleotide having a length ranging from 1-150 nucleotides 1-100 nucleotides, 1-90 nucleotides, from 1-80 nucleotides, 1-70 nucleotides, 1-60 nucleotides, 1-50 nucleotides, 1-40 nucleotides, 1-30 nucleotides, 1-20 nucleotides, 1-10 nucleotides, 1-9 nucleotides, 1-8 nucleotides, 1-7 nucleotides, 1-6 nucleotides, 1-5 nucleotides, 1-4 nucleotides, 1-3 nucleotides, or 1-2 nucleotides. In certain embodiments, the C domain comprises a GAGA polynucleotide.</p><p id="p-0091" num="0090">Small Subunit</p><p id="p-0092" num="0091">The small subunit <b>302</b> is capable of binding mRNA. The small subunit <b>302</b> comprises a first small subunit rRNA domain (&#x201c;S1 polynucleotide domain&#x201d; or &#x201c;S1 domain&#x201d;) and a second small subunit domain (&#x201c;S2 polynucleotide domain&#x201d; or &#x201c;S2 domain&#x201d;), wherein the S1 domain is followed, in order, by S2 domain, from 5&#x2032; to 3&#x2032;. Referring again to <figref idref="DRAWINGS">FIG. <b>1</b>C</figref>, the polynucleotide encoding the small subunit rRNA <b>302</b> comprises the polynucleotide encoding the S1 domain <b>401</b> and the polynucleotide encoding the S2 domain <b>404</b>.</p><p id="p-0093" num="0092">The small subunit rRNA <b>302</b> may be a permuted variant of a separable small subunit rRNA. In certain embodiments, the permuted variant is a circularly permuted variant of a separable small subunit rRNA. The separable small subunit may be any functional small subunit. In certain embodiments, the separable small subunit may be a 16S rRNA. In certain embodiments, the separable small subunit is a wild-type small subunit rRNA. In specific embodiments, the separable small subunit is a wild-type 23S rRNA. In some embodiments, the separable small subunit is at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least 99% identical to the small subunit rRNA.</p><p id="p-0094" num="0093">In some embodiments, if the small subunit <b>302</b> is a permuted variant of a small subunit rRNA, then the polynucleotide sequence consisting essentially of the S1 domain followed by the polynucleotide sequence consisting essentially of the S2 domain, from 5&#x2032; to 3&#x2032;, may be substantially identical to a small subunit rRNA. In certain embodiments, the polynucleotide sequence consisting essentially of the S1 domain followed by the S2 domain, from 5&#x2032; to 3&#x2032;, is at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least 99% identical to the small subunit rRNA.</p><p id="p-0095" num="0094">The small subunit may further comprise a modified-anti-Shine-Dalgarno sequence. In some embodiments, the modified anti-Shine-Dalgarno sequence facilitates the translation of templates having a complementary Shine-Dalgarno sequence different from an endogenous cellular mRNA.</p><p id="p-0096" num="0095">Linking Moiety</p><p id="p-0097" num="0096">Referring again to <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>, the linking moiety <b>303</b> tethers the small subunit <b>302</b> with the large subunit <b>301</b>. In certain embodiments the linking moiety covalently bonds a helix of the large subunit <b>301</b> to a helix of the small subunit <b>302</b>.</p><p id="p-0098" num="0097">In some embodiments, the linking moiety comprises a first tether domain (&#x201c;T1 polynucleotide domain&#x201d; or &#x201c;T1 domain&#x201d;) and a second tether domain (&#x201c;T2 polynucleotide domain&#x201d; or &#x201c;T2 domain&#x201d;). Referring again to <figref idref="DRAWINGS">FIGS. <b>1</b>B and <b>1</b>C</figref> the polynucleotide encoding the linking moiety <b>303</b> comprises the polynucleotide encoding the T1 domain <b>405</b> and the polynucleotide encoding the T2 domain <b>407</b>.</p><p id="p-0099" num="0098">In some embodiments, the T1 domain links the S1 domain and the L1 domain, wherein the S1 domain is followed, in order, by the T1 domain and the L1 domain, from 5&#x2032; to 3&#x2032;. In some embodiments, the T1 domain comprises a polynucleotide having a length ranging from 5-200 nucleotide, 5-150 nucleotides, 5-100 nucleotides, 5-90 nucleotide, 5-80 nucleotides, 5-70 nucleotides, 5-60 nucleotides, 5-50 nucleotides, 5-40 nucleotides, 5-30 nucleotides, or 5-20 nucleotides, including polynucleotides having 5 nucleotides, 6 nucleotides, 7 nucleotides, 8 nucleotides, 9 nucleotides, 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, or 20 nucleotides. In some embodiments, T1 comprises polyadenine. In some embodiments, T1 comprises polyuridine. In some embodiments, T1 comprises an unstructured polynucleotide. In some embodiments, T1 comprises nucleotides that base-pairs with the T2 domain.</p><p id="p-0100" num="0099">In some embodiments, the T2 domain links that L2 domain and the S2 domain, wherein the L2 domain is followed, in order, by the T2 domain and the S2 domain, from 5&#x2032; to 3&#x2032;. In some embodiments, the T2 domain comprises a polynucleotide having a length ranging from 5-200 nucleotides, 5-150 nucleotides, 5-100 nucleotides, 5-90 nucleotide, 5-80 nucleotides, 5-70 nucleotides, 5-60 nucleotides, 5-50 nucleotides, 5-40 nucleotides, 5-30 nucleotides, or 5-20 nucleotides, including polynucleotides having 5 nucleotides, 6 nucleotides, 7 nucleotides, 8 nucleotides, 9 nucleotides, 10 nucleotides, 11 nucleotides, 12 nucleotides, 13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, or 20 nucleotides. In certain embodiments, T1 comprises polyadenine. In certain embodiments, T2 comprises polyuridine. In certain embodiments, T12comprises an unstructured polynucleotide. In certain embodiments, T2 comprises nucleotides that base-pairs with the T1 domain.</p><p id="p-0101" num="0100">In embodiments having a T1 domain and a T2 domain, the T1 domain and the T2 domain may have the same number of polynucleotides. In other embodiments, the T1 domain and the T2 domain may have a different number of polynucleotides.</p><p id="p-0102" num="0101">In some embodiments, the engineered ribosome may comprise a S1 domain followed, in order, by a T1 domain, a L1 domain, a C domain, a L2 domain, a T2 domain, and a S2 domain, from 5&#x2032; to 3&#x2032;. In specific embodiments, the engineered ribosome may consist essentially of a S1 domain followed, in order, by a T1 domain, a L1 domain, a C domain, a L2.</p><p id="p-0103" num="0102">In some embodiments, the ribosomal RNA and the linking moiety of an engineered ribosome comprises the general structure shown below, from 5&#x2032; to 3&#x2032;, wherein 16S (5&#x2032;) represents S1, 23S includes L1 and L2, and optionally, a connector (not shown), and 16S(3&#x2032;) represents S2: <?img id="EMI-00001" he="10.67mm" wi="163.07mm" file="US20230002758A1-20230105-P00001.TIF" alt="embedded image" img-content="drawing" img-format="tif" ?></p><p id="p-0104" num="0103">In some embodiments, the T1 domain comprises 5&#x2032;-GUUAUA-3&#x2032; and the T2 domain comprises 5&#x2032;-UCACAAG-3&#x2032;. In some embodiments, the T1 domain comprises 5&#x2032;-AGUCAAUAA-3&#x2032; and T2 comprises 5&#x2032;-GACCUUCG-3&#x2032;.</p><p id="p-0105" num="0104">An engineered ribosome, which includes T1 5&#x2032;-AGUCAAUAA-3&#x2032; and T2 5&#x2032;-GACCUUCG-3&#x2032; and which comprises a variant of a 16S and a 23S rRNA sequence, adapted to accommodate the T1 and T2 sequences as disclosed herein, is termed Ribo-T v3 and is shown below as SEQ ID NO: 1.</p><p id="p-0106" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="294pt" align="left"/><colspec colname="2" colwidth="147pt" align="left"/><tbody valign="top"><row><entry>5&#x2032;</entry><entry/></row><row><entry> </entry></row><row><entry>aauugaagaguuugaucauggcucagauugaacgcuggcggcaggccuaacacaugcaagucgaacggua</entry></row><row><entry> </entry></row><row><entry>acaggaagaagcuugcuucuuugcugacgaguggcggacgggugaguaaugucugggaaacugccugaug</entry></row><row><entry> </entry></row><row><entry>gagggggauaacuacuggaaacgguagcuaauaccgcauaacgucgcaagaccaaagagggggaccuucg</entry></row><row><entry> </entry></row><row><entry>ggccucuugccaucggaugugcccagaugggauuagcuaguaggugggguaacggcucaccuaggcgacg</entry></row><row><entry> </entry></row><row><entry>aucccuagcuggucugagaggaugaccagccacacuggaacugagacacgguccagacuccuacgggagg</entry></row><row><entry> </entry></row><row><entry>cagcaguggggaauauugcacaaugggcgcaagccugaugcagccaugccgcguguaugaagaaggccuu</entry></row><row><entry> </entry></row><row><entry>cggguuguaaaguacuuucagcggggaggaagggaguaaaguuaauaccuuugcucauugacguuacccg</entry></row><row><entry> </entry></row><row><entry>cagaagaagcaccggcuaacuccgugccagcagccgcgguaauacggagggugcaagcguuaaucggaau</entry></row><row><entry> </entry></row><row><entry>uacugggcguaaagcgcacgcaggcgguuuguuaagucagaugugaaauccccgggcucaaccugggaac</entry></row><row><entry> </entry></row><row><entry>ugcaucugauacuggcaagcuugagucucguagagggggguagaauuccagguguagcggugaaaugcgu</entry></row><row><entry> </entry></row><row><entry>agagaucuggaggaauaccgguggcgaaggcggcccccuggacgaagacugacgcucaggugcgaaagcg</entry></row><row><entry> </entry></row><row><entry>uggggagcaaacaggauuagauacccugguaguccacgccguaaacgaugucgacuuggagguugugccc</entry></row><row><entry> </entry></row><row><entry>uugaggcguggcuuccggagcuaacgcguuaagucgaccgccuggggaguacggccgcaagguuaaaacu</entry></row><row><entry> </entry></row><row><entry>caaaugaauugacgggggcccgcacaagcgguggagcaugugguuuaauucgaugcaacgcgaagaaccu</entry></row><row><entry> </entry></row><row><entry>uaccuggucuugacauccacggaaguuuucagagaugagaaugugccuucgggaaccgugagacaggugc</entry></row><row><entry> </entry></row><row><entry>ugcauggcugucgucagcucguguugugaaauguuggguuaagucccgcaacgagcgcaacccuuauccu</entry></row><row><entry> </entry></row><row><entry>uuguugccagcgguccggccgggaacucaaaggagacugccagugauaaacuggaggaagguggggauga</entry></row><row><entry> </entry></row><row><entry>cgucaagucaucauggcccuuacgaccagggcuacacacgugcuacaauggcgcauacaaagagaagcga</entry></row><row><entry> </entry></row><row><entry>ccucgcgagagcaagcggaccucauaaagugcgucguaguccggauuggagucugcaacucgacuccaug</entry></row><row><entry> </entry></row><row><entry>aagucggaaucgcuaguaaucguggaucagaaugccacggugaauacguucccgggccuuguacacaccg</entry></row><row><entry> </entry></row><row><entry>cccgucacaccaugggaguggguugcaaaagaaguagguagcuuaaccagucaauaagucuugagcuaac</entry></row><row><entry> </entry></row><row><entry>cgguacuaaugaaccgugaggcuuaaccgagagguuaagcgacuaagcguacacgguggaugcccuggca</entry></row><row><entry> </entry></row><row><entry>gucagaggcgaugaaggacgugcuaaucugcgauaagcgucgguaaggugauaugaaccguuauaaccgg</entry></row><row><entry> </entry></row><row><entry>cgauuuccgaauggggaaacccaguguguuucgacacacuaucauuaacugaauccauagguuaaugagg</entry></row><row><entry> </entry></row><row><entry>cgaaccgggggaacugaaacaucuaaguaccccgaggaaaagaaaucaaccgagauucccccaguagcgg</entry></row><row><entry> </entry></row><row><entry>cgagcgaacggggagcagcccagagccugaaucaguguguguguuaguggaagcgucuggaaaggcgcgc</entry></row><row><entry> </entry></row><row><entry>gauacagggugacagccccguacacaaaaaugcacaugcugugagcucgaugaguagggcgggacacgug</entry></row><row><entry> </entry></row><row><entry>guauccugucugaauauggggggaccauccuccaaggcuaaauacuccugacugaccgauagugaaccag</entry></row><row><entry> </entry></row><row><entry>uaccgugagggaaaggcgaaaagaaccccggcgaggggagugaaaaagaaccugaaaccguguacguaca</entry></row><row><entry> </entry></row><row><entry>agcagugggagcacgcuuaggcgugugacugcguaccuuuuguauaaugggucagcgacuuauauucugu</entry></row><row><entry> </entry></row><row><entry>agcaagguuaaccgaauaggggagccgaagggaaaccgagucuuaacugggcguuaaguugcaggguaua</entry></row><row><entry> </entry></row><row><entry>gacccgaaacccggugaucuagccaugggcagguugaagguuggguaacacuaacuggaggaccgaaccg</entry></row><row><entry> </entry></row><row><entry>acuaauguugaaaaauuagcggaugacuuguggcugggggugaaaggccaaucaaaccgggagauagcug</entry></row><row><entry> </entry></row><row><entry>guucuccccgaaagcuauuuagguagcgccucgugaauucaucuccggggguagagcacuguuucggcaa</entry></row><row><entry> </entry></row><row><entry>gggggucaucccgacuuaccaacccgaugcaaacugcgaauaccggagaauguuaucacgggagacacac</entry></row><row><entry> </entry></row><row><entry>ggcgggugcuaacguccgucgugaagagggaaacaacccagaccgccagcuaaggucccaaagucauggu</entry></row><row><entry> </entry></row><row><entry>uaagugggaaacgaugugggaaggcccagacagccaggauguuggcuuagaagcagccaucauuuaaaga</entry></row><row><entry> </entry></row><row><entry>aagcguaauagcucacuggucgagucggccugcgcggaagauguaacggggcuaaaccaugcaccgaagc</entry></row><row><entry> </entry></row><row><entry>ugcggcagcgacgcuuaugcguuguuggguaggggagcguucuguaagccugcgaaggugugcugugagg</entry></row><row><entry> </entry></row><row><entry>caugcuggagguaucagaagugcgaaugcugacauaaguaacgauaaagcgggugaaaagcccgcucgcc</entry></row><row><entry> </entry></row><row><entry>ggaagaccaaggguuccuguccaacguuaaucggggcagggugagucgaccccuaaggcgaggccgaaag</entry></row><row><entry> </entry></row><row><entry>gcguagucgaugggaaacagguuaauauuccuguacuugguguuacugcgaaggggggacggagaaggcu</entry></row><row><entry> </entry></row><row><entry>auguuggccgggcgacgguugucccgguuuaagcguguaggcugguuuuccaggcaaauccggaaaauca</entry></row><row><entry> </entry></row><row><entry>aggcugaggcgugaugacgaggcacuacggugcugaagcaacaaaugcccugcuuccaggaaaagccucu</entry></row><row><entry> </entry></row><row><entry>aagcaucagguaacaucaaaucguaccccaaaccgacacagguggucagguagagaauaccaaggcgcuu</entry></row><row><entry> </entry></row><row><entry>gagagaacucgggugaaggaacuaggcaaaauggugccguaacuucgggagaaggcacgcugauauguag</entry></row><row><entry> </entry></row><row><entry>gugaggucccucgcggauggagcugaaaucagucgaagauaccagcuggcugcaacuguuuauuaaaaac</entry></row><row><entry> </entry></row><row><entry>acagcacugugcaaacacgaaaguggacguauacggugugacgccugcccggugccggaagguuaauuga</entry></row><row><entry> </entry></row><row><entry>ugggguuagcgcaagcgaagcucuugaucgaagccccgguaaacggcggccguaacuauaacgguccuaa</entry></row><row><entry> </entry></row><row><entry>gguagcgaaauuccuugucggguaaguuccgaccugcacgaauggcguaaugauggccaggcugucucca</entry></row><row><entry> </entry></row><row><entry>cccgagacucagugaaauugaacucgcugugaagaugcaguguacccgcggcaagacggaaagaccccgu</entry></row><row><entry> </entry></row><row><entry>gaaccuuuacuauagcuugacacugaacauugagccuugauguguaggauaggugggaggcuuugaagug</entry></row><row><entry> </entry></row><row><entry>uggacgccagucugcauggagccgaccuugaaauaccacccuuuaauguuugauguucuaacguugaccc</entry></row><row><entry> </entry></row><row><entry>guaauccggguugcggacagugucugguggguaguuugacuggggcggucuccuccuaaagaguaacgga</entry></row><row><entry> </entry></row><row><entry>ggagcacgaagguuggcuaauccuggucggacaucaggagguuagugcaauggcauaagccagcuugacu</entry></row><row><entry> </entry></row><row><entry>gcgagcgugacggcgcgagcaggugcgaaagcaggucauagugauccggugguucugaauggaagggcca</entry></row><row><entry> </entry></row><row><entry>ucgcucaacggauaaaagguacuccggggauaacaggcugauaccgcccaagaguucauaucgacggcgg</entry></row><row><entry> </entry></row><row><entry>uguuuggcaccucgaugucggcucaucacauccuggggcugaaguaggucccaaggguauggcuguucgc</entry></row><row><entry> </entry></row><row><entry>cauuuaaagugguacgcgagcuggguuuagaacgucgugagacaguucggucccuaucugccgugggcgc</entry></row><row><entry> </entry></row><row><entry>uggagaacugaggggggcugcuccuaguacgagaggaccggaguggacgcaucacugguguucggguugu</entry></row><row><entry> </entry></row><row><entry>caugccaauggcacugcccgguagcuaaaugcggaagagauaagugcugaaagcaucuaagcacgaaacu</entry></row><row><entry> </entry></row><row><entry>ugccccgagaugaguucucccugacccuuuaaggguccugaaggaacguugaagacgacgacguugauag</entry></row><row><entry> </entry></row><row><entry>gccggguguguaaggacgaccuucgggagggcgcuuaccacuuugugauucaugacuggggugaagucgu</entry></row><row><entry> </entry></row><row><entry>aacaagguaaccguaggggaaccugcgguuggaucaccuccuua&#x2003;3&#x2032;.</entry></row></tbody></tgroup></table></tables></p><p id="p-0107" num="0105">Mutations</p><p id="p-0108" num="0106">In certain embodiments, the engineered ribosomes disclosed herein, such as Ribo-T v3, may comprise one or more mutations (in addition to those of the rRNA of Ribo-T V3, for example). In some embodiments the mutation is a change-of-function mutation. A change-of-function mutation may be a gain-of-function mutation or a loss-of-function mutation. A gain-of-function mutation may be any mutation that confers a new function. A loss-of-function mutation may be any mutation that results in the loss of a function possessed by the parent.</p><p id="p-0109" num="0107">In some embodiments, the change-of-function mutation may be in the peptidyl transferase center of the ribosome. In specific embodiments, the change-of-function mutation may be in an A-site of the peptidyl transferase center. In other embodiments, the change-of-function mutation may be in the exit tunnel of the engineered ribosome.</p><p id="p-0110" num="0108">In some embodiments the change-of-function mutation may be an antibiotic resistance mutation. The antibiotic resistance mutation may be either in the large subunit or the small subunit. In some embodiments antibiotic resistance mutation may render the engineered ribosome resistant to an aminoglycoside, a tetracycline, a pactamycin, a streptomycin, an edein, or any other antibiotic that targets the small ribosomal subunit. In some embodiments antibiotic resistance mutation may render the engineered ribosome resistant to a macrolide, a chloramphenicol, a lincosamide, an oxazolidinone, a pleuromutilin, a streptogramin, or any other antibiotic that targets the large ribosomal subunit.</p><p id="p-0111" num="0109">Methods</p><p id="p-0112" num="0110">In some embodiments, methods for preparing a sequence defined polymer are provided. In some embodiments, an engineered ribosome as disclosed herein (e.g., RiboT-v3, or functional variants thereof), is contacted with a nucleic acid encoding the sequence defined polymer under conditions for transcription (if the nucleic acid encoding the sequence defined polymer comprises DNA) by transcriptional components, and/or translation (if the nucleic acid encoding the sequence defined polymer comprises mRNA) by the tethered ribosomes. In some embodiments, translation by the tethered ribosomes may include the use non-canonical or unnatural codons and corresponding tRNAs (e.g., using the flexizyme system). Such codons, in combination with a system such as flexizyme, may allow for the production of polymers comprising, for example, non-canonical amino acids, or non-amino acid monomers.</p><p id="p-0113" num="0111">In some embodiments, conditions for translation by the tethered ribosomes may include the use of tethered ribosomes comprising modified anti Shine-Dalgarno sequences, and mRNA comprising complementary modified Shine-Dalgarno sequences.</p><p id="p-0114" num="0112">In some embodiments, the sequence defined polymer is prepared in vitro, for example, in a ribosome-depleted cellular extract or purified translation system.</p><p id="p-0115" num="0113">In some embodiments, the sequence defined polymer is prepared in vivo, for example, in a host cell, such as a bacterial host cell, e.g., an <i>Escherichia coli </i>cell.</p><p id="p-0116" num="0114">Polynucleotides</p><p id="p-0117" num="0115">Disclosed herein are polynucleotides encoding the rRNA of the engineered ribosomes of the present technology (e.g., RiboT-v3, or functional variants thereof). In some embodiments, the polynucleotide comprise a vector. In some embodiments, a vector encoding the rRNA of an engineered ribosome of the present technology also encodes a gene, gene fragment, or other nucleic acid sequence that after transcription, can be translated by the engineered ribosomes. By way of example, in some embodiments, the gene, gene fragment, or other nucleic acid sequence is first transcribed, either in vitro or in vivo (e.g., by bacterial host cell transcription machinery) and is then translated by the engineered ribosomes. In some embodiments, a gene, gene fragment, or other nucleic acid sequence is provided as a separate vector or as a separate nucleic acid (either as DNA or mRNA).</p><p id="p-0118" num="0116">Cells</p><p id="p-0119" num="0117">Disclosed herein are cells comprising one or more polynucleotides encoding rRNA of the engineered ribosomes of the present technology (e.g., RiboT-v3, or functional variants thereof). In some embodiments, one or more of the polynucleotides comprises a vector. In some embodiments, the cells express the encoded rRNA and comprise a functional tethered ribosome as described herein (e.g., RiboT-v3, or functional variants thereof). In some embodiments, the cell comprises a mammalian cell, a yeast cell, an insect cell, an algal cell, a plant cell, a protozoan cell, or a bacterial cell. In some embodiments, the cells is an <i>Escherichia coli </i>cell.</p><p id="p-0120" num="0118">In some embodiments, the cell comprises a first protein translation mechanism and a second protein translation mechanism. In some embodiments, the first protein translation mechanism comprises a ribosome, wherein the ribosome lacks a linking moiety between the large subunit and the small subunit. In some embodiments, the first translation mechanism comprises canonical ribosomes. In some embodiments, the first translation mechanism comprises non-canonical ribosomes. In some embodiments, the second protein translation mechanism comprises an engineered, tethered ribosome as disclosed herein (e.g., RiboT-v3, or functional variants thereof).</p><p id="p-0121" num="0119">Methods of Directed Evolution</p><p id="p-0122" num="0120">Disclosed herein are methods for directed evolution of a target nucleic acid sequence. In some embodiments, the target nucleic acid sequence comprises at least two regions of interest, wherein the regions of interest are separated by an intervening sequence of at least 300 nucleotides in length. In some embodiments, the methods include generating a library of test nucleic acid sequences, wherein each test nucleic acid sequence has a different nucleotide sequence for at least one of the regions of interest; screening the library for functional test nucleic acid sequences; sequencing the functional test nucleic acid sequences. In some embodiments, the sequencing comprises: performing a first polymerase chain reaction (PCR), wherein the first PCR provides a first PCR product comprising the least two regions of interest but does not include at least a portion of the intervening sequence; performing a ligation reaction, wherein the ligation reaction provides a first ligation product comprising the two regions of interest, wherein the two regions of interest are positioned less than 300 nucleotides apart; performing a second PCR, wherein the second PCR provides a second PCR product comprising the two regions of interest; sequencing the second PCR product and the two regions of interest. In some embodiments, the sequencing comprises next generation sequencing (NGS).</p><p id="p-0123" num="0121">In some embodiments, the two regions of interest are positioned more than about 5, 10, 50, 100, 200, 300, 500, 1000, 1500, 2000, 2500, or 5000 nucleotides apart. In some embodiments, the two regions of interest are positioned more than about 300 nucleotides apart.</p><p id="p-0124" num="0122">NGS sequencing methods are well known in the art, with a variety of platforms and chemistries. One non-limiting example includes the Illumina NGS sequencing methods.</p><p id="p-0125" num="0123">Exemplary Advantages of Ribo-T v3</p><p id="p-0126" num="0124">Ribo-T v3 features new tether RNA sequences (T1: 5&#x2032;-AGUCAAUAA-3&#x2032; and T2: 5&#x2032;-GACCUUCG-3&#x2032;) as well as designed base pairs at the Tether-H101 junction. Ribo-T v3 exhibits up to a 58% improvement in orthogonal sfGFP translation and a 97% improvement in growth rate as well as a 77% improvement in lag time in SQ171 cells growing in M9 minimal media. Interestingly, cells supported by Ribo-T v3 in rich LB-Miller media exhibit comparable growth rates to those living on Ribo-T v2, but a 59% improvement in lag time. This is consistent with our evolution experiments which favor cells that emerge from stationary phase most quickly.</p><p id="p-0127" num="0125">Additionally, we showcase Ribo-T v3's potential for expanding the chemical toolbox of orthogonal translation systems through the incorporation of a new non-canonical amino acid featuring a bulky side chain (DECP) into a peptide using an in vitro transcription and translation reaction supplemented with synthetic tRNAs charged with flexizyme.</p><p id="p-0128" num="0126">Miscellaneous</p><p id="p-0129" num="0127">All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., &#x201c;such as&#x201d;) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.</p><p id="p-0130" num="0128">Preferred aspects of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred aspects may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect a person having ordinary skill in the art to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.</p><heading id="h-0009" level="1">EXAMPLES</heading><heading id="h-0010" level="1">Example 1. 3D-Structure-Guided Evolution of a Ribosome with Tethered Subunits</heading><p id="p-0131" num="0129">Abstract</p><p id="p-0132" num="0130">RNA-based macromolecular machines, such as the ribosome, have functional parts reliant on structural interactions spanning sequence-distant regions. These features hamper the engineering potential of such machines because they limit evolutionary exploration of mutant libraries and confound 3D structure-guided design. To address these challenges, the inventors describe Evolink (evolution and linkage), a method that enables high-throughput evolution of sequence-distant regions in large molecular machines, and library design guided by computational RNA modeling to enable thorough exploration of structurally stable designs. To showcase the utility of this approach, the inventors evolved a tethered ribosome, which improves upon previous iterations by 58% in orthogonal protein translation and a nearly two-fold improvement in growth in minimal media. The Evolink approach enhances the engineering of macromolecular machines for new and improved functions with implications for synthetic biology.</p><p id="p-0133" num="0131">Introduction</p><p id="p-0134" num="0132">Directed evolution of RNA- and protein-based enzymes can elucidate principles of biological design and generate new catalytic activities for synthetic biology<sup>1-8</sup>. Unfortunately, methods for directed evolution can be hindered by practical considerations. For example, the combinatorial space for evolution is immense (i.e., for an average protein of length 300 amino acids, there are a seemingly infinite number of theoretically possible amino acid sequences (&#x2dc;20<sup>300</sup>)), and random mutagenesis alone cannot screen all possible variants<sup>9-12</sup>. In addition, macromolecular machines often have complex tertiary structures that contribute to their function<sup>13</sup>, which bring residues that are distant in primary sequence close in three-dimensional space <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>. This limits the ability to recover in high throughput winning designs even when effective selections can be employed. Such practical limitations are exacerbated in large macromolecular machines, such as the bacterial ribosome, which has 3 ribosomal RNAs (rRNAs) comprising &#x2dc;4500 nucleotides (i.e., the 16S rRNA, 23S rRNA, and 5S rRNA) and 54 proteins<sup>1-4,8,9,14</sup>.</p><p id="p-0135" num="0133">Despite these challenges, directed evolution of the ribosome has emerged as a promising opportunity in chemical and synthetic biology<sup>1-5,7-9,14-21</sup>. A major goal of ribosome evolution efforts is to repurpose the ribosome for diverse genetically encoded chemistries to create new classes of enzymes, therapeutics, and materials by selectively incorporating non-canonical monomers into peptides and proteins. While the natural ribosome works well for many noncanonical &#x3b1;-amino acids, there is poor compatibility with the natural translation apparatus for numerous classes of non-&#x3b1;-amino acids (e.g., backbone-extended amino acids (&#x3b3;-, &#x3b4;-, &#x3b5;-, etc.)) leading to inefficiencies in incorporation<sup>1-4,22,23</sup>.</p><p id="p-0136" num="0134">Methods for engineering ribosomes have been developed to address these inefficiencies<sup>7,16,17,24,25</sup>. In vivo, ribosome engineering methods have focused on the development of specialized ribosome systems. Recently, the advent of tethered ribosomes has made possible the first fully orthogonal ribosome-mRNA system in cells, where a sub-population of ribosomes are available for engineering and are independent from wild-type ribosomes supporting cell life<sup>18</sup>. Tethered ribosome systems have two key features. First, the anti-Shine-Dalgarno sequence of the 16S ribosomal RNA (rRNA) of the small 30S subunit can be mutated to function as orthogonal ribosomes that selectively initiate translation of orthogonal messenger RNAs (mRNAs) with mutated Shine-Dalgarno sequences<sup>19,26,27</sup>. Second, the small and large subunits are covalently linked together <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>. In the first tethered ribosome system, termed Ribo-T, the core 16S and 23 S rRNAs were joined together to form a single chimeric molecule via helix h44 of the 16S rRNA and helix H101 of the 23S rRNA18. Importantly, by selecting otherwise dominantly lethal rRNA mutations in the large ribosomal subunit, Ribo-T was evolved to synthesize protein sequences that are inaccessible to the natural ribosome<sup>18</sup>. Since the initial discovery of Ribo-T and a subsequent stapled design<sup>15</sup>, new orthogonal Ribo-T/mRNA pairs as well as tether sequences have been optimized using directed evolution methods<sup>9,14</sup>. Specifically, tether residues have been randomized in sequence but not in length<sup>9</sup>, or mutations to surrounding residues surrounding a fixed RNA linker (the J5/5a junction from the <i>Tetrahymena </i>group I intron) have been investigated<sup>14</sup>. Despite the improvement, the potential of tethered ribosome systems remains limited by their low activity.</p><p id="p-0137" num="0135">The untapped potential and existing inefficiencies of tethered ribosome systems motivate the need for new directed evolution-based approaches to engineer these systems for improving their activity. Previous works were limited in throughput in evaluating designs (e.g., 48 and 108 members were evaluated in two different efforts<sup>9,14</sup>) due to their reliance on clonal isolation and functional testing. A bottleneck in these efforts has been that the regions of interest in the tethered ribosomes are separated by around 2,900 nucleotides (the length of the circularly permuted 23S rRNA18), and current readily available methods for next-generation sequencing are typically limited to overlapping read lengths of &#x2dc;300 nucleotides. While methods have been developed to address these shortcomings<sup>28,29</sup>, they face limitations that hinder broad applications to macromolecular machines as large as the ribosome, which feature many examples of distantly sequence encoded, but physically interacting regions <figref idref="DRAWINGS">FIG. <b>10</b>A-<b>10</b>D</figref>. Briefly, they rely on custom bioinformatic pipelines, barcoding strategies inherent to protein-based machines, or are limited in the distance between regions of interest<sup>28+</sup>.</p><p id="p-0138" num="0136">Here, to address existing limitations and facilitate evolution of ribosomes, we present a molecular biology technique called Evolink (evolution and linkage) <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>. Evolink connects two or more regions of nucleic acid sequence that are distant in primary space but close in 3D structure (in RNA or protein form) to enable next generation sequencing readouts of winning phenotypes. We apply Evolink to tethered ribosomes <figref idref="DRAWINGS">FIG. <b>4</b>B</figref> and augment the method by integrating computational modeling with the design-build-test cycles of directed evolution to inform library design <figref idref="DRAWINGS">FIG. <b>4</b>C</figref>. We use this integrated method to evolve tethered ribosomes for improved function by targeting the rRNA residues involved in connecting the 16S and 23 S rRNAs. We identify a newly evolved tethered ribosome (termed Ribo-T v3) that improves ribosome function nearly two-fold when supporting cellular growth in minimal media. Further, we demonstrate the compatibility Ribo-T v3 with non-canonical monomer incorporation in an in vitro protein synthesis reaction. The combination of Evolink with computational modeling allows for efficient evolution of macromolecular machines with complex structures, such as the ribosome, featuring regions distant in primary sequence but functionally linked in spatial proximity. We anticipate the Evolink approach will be valuable for future engineering of ribosomes and other macromolecular machines.</p><p id="p-0139" num="0137">Results</p><p id="p-0140" num="0138">Linking of Sequence-Distant Regions on a Single Next-Generation Sequencing Read</p><p id="p-0141" num="0139">We aimed to develop a generalizable method, guided by computational design, for directed evolution of sequence-distant sites of macromolecular machines. As a model, we focused on evolving the tether sequences of covalently tethered ribosomes. To achieve our goal, we first developed the molecular biology methods needed, termed Evolink. Evolink is a three-step process that uses polymerase chain reaction (PCR), ligation, and a second PCR reaction to bring together sequence-separated regions of a plasmid into a single next-generation sequencing (NGS) read. This process is analogous to amplifying and closing the &#x201c;backbone&#x201d; of a plasmid, where the &#x201c;insert&#x201d; omitted from amplification is the RNA sequence separating the two regions of interest. Because Evolink relies on simple, general-purpose molecular biology (e.g., PCR and ligation), it can be adapted to any plasmid-encoded molecular machine <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>.</p><p id="p-0142" num="0140">To start, we demonstrated the three key molecular biology steps of Evolink (termed PCR-1, LIG-1, PCR-2) <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>, right. Using a clonal plasmid sample encoding Ribo-T v29 <figref idref="DRAWINGS">FIG. <b>11</b>A-<b>11</b>B</figref>, we initially carried out around-the-world PCR (PCR-1) with a high-fidelity polymerase (Q5 DNA Polymerase) using oligonucleotide primers specific to the plasmid. In our architecture, in which T1 is upstream (5&#x2032;) of T2, the forward primer binds upstream of T2, and the reverse primer binds immediately downstream (3&#x2032;) of T1, so the first set of primers for PCR-1 are &#x201c;inside&#x201d; the two regions of interest. The PCR-1 primers play two key roles. First, the sequence between each respective primer and region of interest (reverse primer-T1 and forward primer-T2 in this case) determines the length of the final amplicon for use in NGS. Second, the primers can encode compatible DNA sequences with either an overhang (for restriction enzyme-based or isothermal assembly31) or blunt ends to be used in the subsequent ligation step (LIG-1). We assessed the compatibility of PCR-1 with multiple primer sets that feature designed overhangs for Type I/II restriction enzyme digestion, 5&#x2032; phosphorylation for blunt-end ligation, or overlapping complimentary sequences for isothermal assembly. We found the first PCR step (PCR-1) to be successful with all four primer sets that featured different 5&#x2032; modifications (either phosphorylation or custom sequences) <figref idref="DRAWINGS">FIG. <b>11</b>A-<b>11</b>B</figref>.</p><p id="p-0143" num="0141">Following the first PCR, LIG-1 was carried out to cyclize the product of PCR-1 in a unimolecular ligation, proximally linking the previously distant regions. Prior to ligation, PCR-1 products that used primers compatible with restriction enzyme digests were processed with enzymatic digest and purification. Those that used 5&#x2032; phosphorylated primers or enzymatic digestion were purified and used in ligation with T4 ligase, and those which featured overlapping complementary sequences were ligated together using isothermal assembly<sup>31</sup>.</p><p id="p-0144" num="0142">Finally, we carried out PCR-2 with a different set of primers to amplify the now-linked regions of interest. In this step, the primers are designed with the forward primer upstream of T1 and the new reverse primer downstream of T2, such that now the primers are &#x201c;outside&#x201d; of the regions of interest. The sequences between each respective primer and region of interest (forward primer-T1 and reverse primer-T2 in this case) contribute to the final amplicon length for sequencing. We designed primers such that the final amplicon product is &#x2dc;200 nucleotides in length and can be directly used in NGS library preparation. To demonstrate robustness, we tested the PCR-2 with four different ligation methods (Type I/II restriction enzyme digestion and ligation, blunt end ligation, and isothermal assembly), each with eight different input template amounts into the ligation (1, 2, 5, 10, 20, 30, 40, 50 ng). We observed successful generation of the desired amplicon for NGS for all 32 reactions tested <figref idref="DRAWINGS">FIG. <b>11</b>A-<b>11</b>B</figref>. To reduce any possible biases, we moved forward with blunt-end ligation because it did not rely on any particular DNA sequence and proved successful at the minimum amount of template tested (1 ng).</p><p id="p-0145" num="0143">Applying Evolink to Tethered Ribosomes</p><p id="p-0146" num="0144">With the Evolink method in hand, we sought to apply it to develop mutant tethered ribosomes for improved activity, with a focus on tether design and evolution <figref idref="DRAWINGS">FIG. <b>4</b>B</figref>. Specifically, we looked to improve upon the function of Ribo-T v232 by optimizing the tether residues for length and sequence composition. The guiding principle was to leverage the throughput of Evolink and post-facto structural modeling to evolve the RNA residues that make up the tethers. Central to our efforts was the iterative application of a design-build-test-analyze (DBTA) cycle <figref idref="DRAWINGS">FIG. <b>4</b>C</figref>, in which multiple libraries can be tested, each library subsequently building upon results and analysis of the ones prior, to improve molecular function. This departs from previous efforts that carried out a single pass of library design, building, and selection/screening, which limits the breadth of the libraries to be tested. Our study was carried out with the notion that we would first start broadly, then through our DBTA cycles, test our hypotheses on tether design and narrow our search space with each cycle to arrive at an improved molecular machine. Because Evolink makes use of next-generation sequencing, our approach also allows for substantially larger sampling and screening of the solution space compared to past efforts.</p><p id="p-0147" num="0145">In the first library, we elected to broadly sample possible lengths and sequences of T1 and T2, with a degenerate library ranging from 5-15 nucleotides <figref idref="DRAWINGS">FIG. <b>5</b>A</figref>. Following construction, the library of tether designs was cloned and transformed into an <i>E. coli </i>strain lacking rrn operons on the genome<sup>33 </sup>and viable cells, which were growing exclusively off the tethered ribosomes, were identified by growth on agar plates<sup>9,18</sup>. Resulting colonies were collected and selection was carried out in liquid culture <figref idref="DRAWINGS">FIG. <b>5</b>B</figref>. By passaging cells in liquid culture for multiple generations (&#x2dc;40 generations in this work), we hypothesized that faster growing mutants would become more enriched in the culture. Cells were subject to Evolink and analysis of subsequent NGS reads were carried out daily for four days. In the NGS reads, T1 and T2 sequences, which represent the two strands of RNA that make up the tether, were directly linked in a single amplicon, taking advantage of overlapping reads with high sequencing fidelity to improve our confidence in identifying pairwise interactions between the two regions. NGS analysis revealed a range of enrichments for many genotypes observed over the passaging time course <figref idref="DRAWINGS">FIG. <b>5</b>B</figref>. Specifically, we observed enrichment (log 2-fold change) values between &#x2212;5 to 6, and &#x2dc;1800 unique genotypes after the LB agar-based selection converging to &#x2dc;450 unique genotypes over the time course <figref idref="DRAWINGS">FIG. <b>5</b>B</figref>, <figref idref="DRAWINGS">FIG. <b>12</b>A-<b>12</b>C</figref>. Two key features emerged from these data. First, the same T1 sequences paired with multiple T2 sequences <figref idref="DRAWINGS">FIG. <b>13</b>A-<b>13</b>C</figref>. For example, T1: 5&#x2032;-CAGGGUACACC-3&#x2032; paired with T2: 5&#x2032;-CCCAUUCA-3&#x2032;, 5&#x2032;-AUUCACUUGG-3&#x2032;, and 5&#x2032;-CGACGAGCG-3&#x2032; to yield enrichment values of 5.69, 2.17, and &#x2212;1.5, respectively. These data suggest that contributions of the two tether sequences to overall ribosome assembly and function depend on each other and are not simply additive. Second, we observed a trend in the sequencing data towards specific optimal tether lengths, converging upon a length of 9 nucleotides for T1 and 12 nucleotides for T2 <figref idref="DRAWINGS">FIG. <b>5</b>C</figref>.</p><p id="p-0148" num="0146">Structural Fragility of the Tether-H101 Junction</p><p id="p-0149" num="0147">Based on previous literature that showed stapled ribosome function is sensitive to the connection between the tether and 23S rRNA residues<sup>14 </sup>(henceforth referred to as the Tether-H101 junction), we wondered if the Tether-H101 junction would also be significant in the Ribo-T design context<sup>9,18 </sup><figref idref="DRAWINGS">FIG. <b>6</b>A</figref>. To explore this hypothesis, we next fixed the tether identity according to the Ribo-T v2 sequence<sup>9 </sup>and constructed a library that consisted of every possible combination of base deletions in the Tether-H101 junction region <figref idref="DRAWINGS">FIG. <b>6</b>B</figref>. This allowed us to approach the problem from an unbiased perspective, without preexisting assumptions on whether these residues indeed exist in a base-paired helical form or in another rearranged architecture. Following library construction, we again tested for the ability of these library members to support growth in the SQ171 strain. Evolink results on this library converged to 5&#x2032;-GCG-3&#x2032; and 5&#x2032;-CGC-3&#x2032; in Region 1 and Region 2, respectively, revealing that base changes in the Tether-H101 junction indeed affect ribosome function <figref idref="DRAWINGS">FIG. <b>6</b>C</figref>. These results suggested that the folding behavior of this junction may have a significant influence on both tethered ribosome structure and function.</p><p id="p-0150" num="0148">To further test and understand this hypothesis, we turned to computational modeling to gauge structural stability of the Tether-H101 junction <figref idref="DRAWINGS">FIG. <b>15</b>A-<b>15</b>D</figref>. The key idea was to use modeling (secondary structure modeling with ViennaRNA34 and tertiary structure modeling with Rosetta FARFAR235) to understand possible structural features that may contribute to improved tether RNAs and overall ribosome function, and use those insights to inform subsequent library design. First, we used RNAcofold to conduct secondary structure predictions on the four most prevalent tether sequences that emerged from the Broad Sampling Library (e.g., a 10 nucleotide (nt)/12 nt tether, T1: 5&#x2032;-AUGACAUGGU-3&#x2032; and T2: 5&#x2032;-CCGGCUUCGGAA-3&#x2032;) to assess the degree to which each tether's structure was dependent on its structural context <figref idref="DRAWINGS">FIG. <b>15</b>A-<b>15</b>D</figref>. If the tether's structure is perfectly independent of the surrounding residues, the same base-pairing would be observed regardless of surrounding residues including in the RNAcofold analysis. To test this, we computed the minimum free energy secondary structure of the tether under two different conditions. The first, &#x2018;unconstrained&#x2019; calculation, allowed the adjacent 23S rRNA junction (Helix 101 in the wild-type ribosomal 23S rRNA) to &#x2018;re-fold&#x2019; rather than constraining it to assume the base pairing observed in experimental structures of the <i>E. coli </i>ribosome36. In the second, &#x2018;constrained&#x2019; calculation, the 23S rRNA junction residues are instead required to assume that experimental base pairing. For three of four tethers, we observed the same tether base pairs in the constrained and unconstrained structures, but the adjacent 23S junction only maintained its wildtype structure in one case <figref idref="DRAWINGS">FIG. <b>15</b>A</figref>, C, D. For the remaining tether, significantly different RNA secondary structures were observed between the &#x2018;constrained&#x2019; and &#x2018;unconstrained&#x2019; models <figref idref="DRAWINGS">FIG. <b>15</b>B</figref>.</p><p id="p-0151" num="0149">We conducted 3D modeling of these tethers to augment our understanding <figref idref="DRAWINGS">FIGS. <b>7</b>A-D</figref> and <figref idref="DRAWINGS">FIG. <b>17</b>A-D</figref>. Specifically, we used Rosetta's RNA fragment assembly code35 to model analogous constrained and unconstrained states of the tether with FARFAR2 <figref idref="DRAWINGS">FIGS. <b>7</b>B and <b>7</b>C</figref>, respectively, and <figref idref="DRAWINGS">FIG. <b>17</b>A-D</figref>. For each tether, the constrained and unconstrained simulations resulted in significantly different structures and energy distributions compare <figref idref="DRAWINGS">FIGS. <b>7</b>B, <b>7</b>C</figref>; see also <figref idref="DRAWINGS">FIG. <b>7</b>D</figref>, <figref idref="DRAWINGS">FIG. <b>17</b>A-D</figref>, suggesting that the Tether-H101 junction may not be particularly stable. Our results from investigating the Tether-H101 junction, both experimentally and computationally, led us to reinforce the structure of the Tether-H101 junction, as well as to optimize tether length and sequence together in subsequent rounds of directed evolution.</p><p id="p-0152" num="0150">Evolink and Computational Validation of a Designed Tether Library</p><p id="p-0153" num="0151">With the range of tether lengths informed by the Broad Sampling Library and the designed base pairs at the Tether-H101 junction, we next performed Evolink on a tether library followed by 3Dstructure analysis. The library featured 6 to 9 random nucleotides for both T1 and T2 regions, with the addition of three synthetic base pairs at the Tether-H101 junction to encourage its formation and increase the independence of tether folding from junction folding <figref idref="DRAWINGS">FIG. <b>7</b>E</figref>. Selection and analysis were carried out as described above (over four time points/days)[<figref idref="DRAWINGS">FIG. <b>7</b>F</figref>. Tether lengths converged to a length of 6 and 8 nucleotides for T1 and T2, respectively, with the winning sequence being T1: 5&#x2032;-GUUAUA-3&#x2032; and T2: 5&#x2032;-AUCCCAGG-3&#x2032; <figref idref="DRAWINGS">FIG. <b>7</b>G</figref>. Post-facto modeling of select highly enriched genotypes as described previously (see Structural fragility of the Tether-H101 junction) revealed improved agreement between constrained and unconstrained conditions compared to the Broad Sampling Library <figref idref="DRAWINGS">FIG. <b>7</b>H</figref>, <figref idref="DRAWINGS">FIG. <b>17</b>E-H</figref>. Most notably, models revealed predicted base pairing in the designed junction residues in both the constrained and unconstrained models, as well as predicted base pairing in the Tether-H101 junction compared to the Broad Sampling Library winner compare <figref idref="DRAWINGS">FIG. <b>16</b>A-B</figref> with <figref idref="DRAWINGS">FIG. <b>7</b>B-C</figref>.</p><p id="p-0154" num="0152">Clonal Isolation of Enriched Genotypes and Test of Orthogonal Protein Synthesis</p><p id="p-0155" num="0153">We then carried out a final round of randomized library building and selection. The goal of this selection was to identify candidates for clonal isolation and characterization of improved tethered ribosome genotypes. The library combined the lessons learned from our three previous libraries. First, we tested tether lengths ranging from 5 to 9 nucleotides for T1 and 6 to 9 nucleotides for T2 based on the previous round of Evolink converging to 6 and 8 nucleotides for T1 and T2, respectively <figref idref="DRAWINGS">FIG. <b>8</b>A</figref>. Second, the library featured a designed Tether-H101 junction, which was reinforced by base pairs that we hoped would contribute to improved structural stability in the tethers. Evolink was carried out to identify enriched pairs of sequences encoding T1 and T2 <figref idref="DRAWINGS">FIG. <b>12</b>A-C</figref>. Of the highly enriched genotypes, we sought to more explicitly test if T1 and T2 sequences displayed cooperativity as we had previously observed enrichment of specific combinations between T1 and T2 sequences during evolution <figref idref="DRAWINGS">FIG. <b>13</b>A-C</figref>.</p><p id="p-0156" num="0154">To test this cooperativity hypothesis and isolate a final winning genotype, we built 16 individual genotypes from the final library by combining the top 4 enriched sequences for the T1 and T2 regions from this round of Evolink and tested the combinations individually for their ability to carry out orthogonal superfolder GFP (sfGFP) synthesis compared to a previously improved orthogonal tethered ribosome, oRibo-T v2 <figref idref="DRAWINGS">FIG. <b>8</b>B, <b>8</b>C</figref>. The measurement of custom (orthogonal) translation output is a unique application for tethered ribosomes and an important measure of their function. In this experiment, the anti-Shine-Dalgarno of the tethered ribosome's small subunits are mutated to selectively translate mRNAs (encoding sfGFP) with correspondingly mutated Shine-Dalgarno sequences. Of the 16 tested genotypes, 14 T1/T2 pairs outperformed oRibo-T v2 in orthogonal GFP synthesis <figref idref="DRAWINGS">FIG. <b>8</b>C</figref>, highlighting that our evolutionary strategy had worked to improve tethered ribosome function. Further, we observed combinatorial behavior amongst the 16 individual genotypes tested: as an extreme example, depending on the paired T1, the sequence T2: 5&#x2032;-ACAUAAUG-3&#x2032; could perform 30% better than oRibo-Tv2 or 30% worse <figref idref="DRAWINGS">FIG. <b>8</b>C</figref>, supporting the hypothesis that the tethers interact with functional consequences. The two highest performing tether genotypes were 1) T1: 5&#x2032;-GUUAUA-3&#x2032; and T2: 5&#x2032;-UCACAAG-3&#x2032;; and 2) 5&#x2032;-AGUCAAUAA-3&#x2032; and T2: 5&#x2032;-GACCUUCG-3&#x2032;, which each showed increased orthogonal protein synthesis over Ribo-T v2.0 by 56% and 58%, respectively <figref idref="DRAWINGS">FIG. <b>8</b>C</figref>. Of these, we chose further characterization for T1: 5&#x2032;-AGUCAAUAA-3&#x2032; and T2: 5&#x2032;-GACCUUCG-3&#x2032;, which we termed Ribo-T v3. The choice of this genotype was further supported by enrichment trends observed during selection which suggested a length of 8 nucleotides for T2 was more broadly enriched compared to a T1 length of 6 <figref idref="DRAWINGS">FIG. <b>18</b></figref>.</p><p id="p-0157" num="0155">Functional Characterization of Ribo-T v3</p><p id="p-0158" num="0156">We next tested the ability of Ribo-T v3 to support cellular life in the SQ171 strain as a general measure of ribosome function9,18. We compared growth rates of cells supported by Ribo-T v3 and Ribo-T v2 on both minimal M9 media as well as rich LB-Miller media <figref idref="DRAWINGS">FIG. <b>8</b>D</figref>. This revealed improved growth characteristics for cells growing on Ribo-T v3 especially in minimal M9 media as well as rich Luria Broth (LB) media FIGS. 58 &#x26; 8E, FIG. S19A-B. Notably, although doubling times in LB media were equal within error, cells growing on Ribo-T v3 exhibited a 97% improvement in doubling time in M9 media. Additionally, SQ171 cells living on Ribo-T v3 exhibited 59% and 77% improvements in lag time for LB and M9 media, respectively <figref idref="DRAWINGS">FIG. <b>19</b>A-B</figref>. Interestingly, this suggests that differences between Ribo-T v2 and Ribo-T v3 extend beyond ribosome function at the molecular scale, but also has implications at the phenotypic level when considering coordination with other cellular machinery during the process of cellular growth. Considering that evolution for Ribo-T v3 was carried out in LB media, improvements of cellular growth on Ribo-T v3 over Ribo-T v2 in minimal M9 media as well as improvements in orthogonal protein yield suggest that evolutionary advantages in fitness can extend to multiple contexts.</p><p id="p-0159" num="0157">Towards this vision of genetic code expansion with tethered ribosomes, we tested the ability of Ribo-T v3 to incorporate a non-canonical amino acid into a peptide. The idea was not to engineer Ribo-T v3 further to be better than a natural ribosome at incorporating non-canonical amino acids, but rather to show that oRibo-T was compatible with applications geared towards expanding the chemistry of life<sup>1-4,14,23</sup>. We chose a non-canonical L-&#x3b1;-amino acid ((R)-2-amino-3-(7-(diethylamino)-2-oxo-2H-chromene-3-carboxamido)propanoic acid, DECP) featuring a diethylamino coumarin group on its sidechain. The monomer, which features a bulky side chain, has not yet been shown to be incorporated into a peptide ribosomally, and thus presented a new and attractive target to showcase Ribo-T v3's ability to expand the chemical biology toolbox of engineered translation machinery. For demonstration purposes, and since evolved aminoacyltRNA synthetases do not exist for this monomer, we used a cell-free transcription and translation platform based on the PURExpress system<sup>37-39</sup>. In this platform, the monomer DECP was charged onto tRNAfMet(CAU) using a flexizyme<sup>38 </sup><figref idref="DRAWINGS">FIG. <b>21</b></figref>, and added to the PURExpress reaction with a sample of Ribo-T v3 or Ribo-T v2 purified from cells <figref idref="DRAWINGS">FIG. <b>8</b>E</figref>. Mass spectrometry analysis revealed that DECP was successfully incorporated into the N-terminus of a peptide by both Ribo-T v3 and Ribo-T v2 <figref idref="DRAWINGS">FIGS. <b>8</b>F &#x26; <b>8</b>G</figref>, <figref idref="DRAWINGS">FIG. <b>21</b></figref>. We observed improved incorporation of DECP by Ribo-T v3 compared to Ribo-T v2 based on less prominent peaks of mis-incorporated or truncated products observed in MALDI-MS. These results suggest that Ribo-T v3's improved ribosome function may be applied to genetic code expansion.</p><heading id="h-0011" level="1">Discussion</heading><p id="p-0160" num="0158">In this work, we present an improved tethered ribosome platform, termed Ribo-T v3, evolved from the previous state-of-the-art (Ribo-T v2). Key to our effort was the development of Evolink, a technique for evolving regions in macromolecular machines far apart in primary sequence but proximal (and potentially functionally linked) in three-dimensional space. Evolink uses widely available molecular biology protocols (PCR and ligation) to link together distant sites of a plasmid in a single next-generation sequencing (NGS) read, alleviating previous limitations to ribosome evolution enforced by short NGS read lengths (&#x2dc;300 nucleotides). We carried out four iterations of our design-build-test-analyze directed evolution experiment, featuring library designs informed by NGS results as well as structural modeling. Libraries explored simultaneous variation of tether sequence and length, as well as interaction between the tether and its junction with H101, culminating in design of a library that yielded Ribo-T v3.</p><p id="p-0161" num="0159">Ribo-T v3 features new tether RNA sequences (T1: 5&#x2032;-AGUCAAUAA-3&#x2032; and T2: 5&#x2032;-GACCUUCG-3&#x2032;) as well as designed base pairs at the Tether-H101 junction. Ribo-T v3 exhibits up to a 58% improvement in orthogonal sfGFP translation and a 97% improvement in growth rate as well as a 77% improvement in lag time in SQ171 cells growing in M9 minimal media. Interestingly, cells supported by Ribo-T v3 in rich LB-Miller media exhibit comparable growth rates to those living on Ribo-T v2, but a 59% improvement in lag time. This is consistent with our evolution experiments which favor cells that emerge from stationary phase most quickly. Additionally, we showcase Ribo-T v3's potential for expanding the chemical toolbox of orthogonal translation systems through the incorporation of a new non-canonical amino acid featuring a bulky side chain (DECP) into a peptide using an in vitro transcription and translation reaction supplemented with synthetic tRNAs charged with flexizyme. Looking forward, we predict that Ribo-T v3 will accelerate new advances in orthogonal translation systems to expand the palette of genetically encoded chemistries<sup>9,14,16,40</sup>. Moreover, we expect Evolink will advance directed evolution efforts, especially those for large macromolecular machines, for synthetic biology.</p><p id="p-0162" num="0160">Materials and Methods</p><p id="p-0163" num="0161">Library Construction</p><p id="p-0164" num="0162">Plasmid libraries of Ribo-T tethers were generated using polymerase chain reaction (PCR) with the plasmid encoding Ribo-T v2.09, as the template. Oligonucleotides (IDT, USA) encoding degenerate bases (Ns) in place of the tethers were used to amplify the insert which includes both tethers and the 23S rRNA (referred to as the insert) [<figref idref="DRAWINGS">FIG. <b>1</b>C</figref>]. For the Tether-23S junction, oligos encoded deletions in the specified region, not degenerate bases [<figref idref="DRAWINGS">FIG. <b>2</b>E</figref>]. Another pair of oligos amplified the remainder of the plasmid (referred to as the backbone) [Table S1].</p><p id="p-0165" num="0163">Resulting amplicons were purified using the Omega Cycle-Pure kit (Omega Bio-Tek), then digested with DpnI (NEB) to remove the template. The insert and backbone were ligated using isothermal DNA assembly31, and transformed into POP2136 cells via electroporation. Post-transformation, the cells were recovered in 800 &#x3bc;L of SOC at 30&#xb0; C. for 90-120 minutes, then plated on LB-agar plates containing 100 &#x3bc;g/mL carbenicillin. The plates were incubated at 30&#xb0; C. for 16-18 h until colonies appeared. All colonies were scraped from the agar plates and plasmid extraction was performed using a Zymo-PURE Midiprep II kit (Zymo Research).</p><p id="p-0166" num="0164">Selection of Tethered Ribosomes</p><p id="p-0167" num="0165">The libraries of Ribo-T tethers were transformed into SQ171 cells lacking chromosomal ribosomes32. 100 ng of the plasmid library was transformed into 50 &#x3bc;L of SQ171 cells via electroporation, then recovered with 500 &#x3bc;L SOC at 37&#xb0; C. with shaking at 250 rpm for 2 h. After, another 1.5 mL of SOC was added to the cells and the final 2 ml culture was brought to 100 &#x3bc;g/Ml carbenicillin and 0.25% sucrose. These cells were then incubated at 37&#xb0; C. with shaking at 250 rpm for 16-18 h. After incubation, cells were plated onto LB-agar plates containing: carbenicillin (100 &#x3bc;g/mL), sucrose (5% w/v), and erythromycin (250 &#x3bc;g/mL) and incubated at 37&#xb0; C. for 20-24 h until colonies appeared. Colonies were then washed from the agar plates with LB containing 100 &#x3bc;g/mL carbenicillin (&#x2dc;5 mL of LB-carbenicillin per 100 mm petri dish) and grown to saturation at 37&#xb0; C. with 250 rpm shaking. 1 mL of the solution was reserved and plasmids were extracted using the Zymo-PURE Miniprep kit (Zymo Research). The saturated culture was then subject to passaging over 4 days in LB containing 100 &#x3bc;g/mL carbenicillin, and plasmids were extracted each day for sequencing.</p><p id="p-0168" num="0166">Preparation of Amplicons for Next-Generation Sequencing</p><p id="p-0169" num="0167">Plasmids extracted from selection cultures were linearized using PCR and purified using the Omega Cycle-Pure kit. 20 ng of the purified product was then used in a 20 &#x3bc;L ligation reaction containing T4 ligase (NEB) and the appropriate accompanying buffer. After incubation at 37&#xb0; C. for 2 h, 2 &#x3bc;L of the ligation reaction was used directly in a 20 &#x3bc;L PCR with 15 cycles of amplification, which generated the amplicon for next-generation sequencing. The resulting product was then purified and prepared for next-generation sequencing using the NEBNext Ultra II DNA Library Prep kit (NEB). The resulting library was run on a MiSeq (Illumina) using a 150-cycle MiSeq Reagent Kit v3 (Illumina).</p><p id="p-0170" num="0168">Analysis of Next-Generation Sequencing Results</p><p id="p-0171" num="0169">Paired end reads from Illumina sequencing were assembled using PANDASeq39. Reads that had coverage (number of redundant reads) of less than ten were filtered and excluded from analysis. Pairs of sequences were then identified, and the following parameters were calculated.</p><p id="p-0172" num="0170">Abundance was calculated using the following formula:</p><p id="p-0173" num="0000"><maths id="MATH-US-00001" num="00001"><math overflow="scroll"> <mrow>  <msub>   <mi>Abundance</mi>   <mrow>    <mi>i</mi>    <mo>,</mo>    <mi>n</mi>   </mrow>  </msub>  <mo>=</mo>  <mfrac>   <msub>    <mi>reads</mi>    <mrow>     <mi>i</mi>     <mo>,</mo>     <mi>n</mi>    </mrow>   </msub>   <mrow>    <msubsup>     <mo>&#x2211;</mo>     <mi>i</mi>     <mi>S</mi>    </msubsup>    <msub>     <mi>reads</mi>     <mrow>      <mi>i</mi>      <mo>,</mo>      <mi>n</mi>     </mrow>    </msub>   </mrow>  </mfrac> </mrow></math></maths></p><p id="p-0174" num="0171">for a specific genotype i at timepoint n, and S represents the total number of unique genotypes at timepoint n after filtering as described above.</p><p id="p-0175" num="0172">Fold-enrichment was calculated using the following formula:</p><p id="p-0176" num="0000"><maths id="MATH-US-00002" num="00002"><math overflow="scroll"> <mrow>  <msub>   <mi>Enrichment</mi>   <mrow>    <mi>i</mi>    <mo>,</mo>    <mi>n</mi>   </mrow>  </msub>  <mo>=</mo>  <mrow>   <msub>    <mi>log</mi>    <mn>2</mn>   </msub>   <mo>&#x2062;</mo>   <mfrac>    <msub>     <mi>abundance</mi>     <mrow>      <mi>i</mi>      <mo>,</mo>      <mi>n</mi>     </mrow>    </msub>    <mrow>     <mi>abundancei</mi>     <msub>      <mo>,</mo>      <mn>0</mn>     </msub>    </mrow>   </mfrac>  </mrow> </mrow></math></maths></p><p id="p-0177" num="0173">for a specific genotype i at timepoint n, and abundance<sub>0 </sub>represents the abundance after selection on agar plates as previously described before any liquid culture.</p><p id="p-0178" num="0174">Post Facto Computational Modeling of Tether</p><p id="p-0179" num="0175">For 3D modeling studies, we set up FARFAR2 simulations<sup>34 </sup>using a crystal structure of the <i>E. coli </i>ribosome<sup>40 </sup>(PDB code: 4YBB). Starting from that structure, we truncated the stemloops 23S rRNA Helix 101 (H101) and 16S rRNA helix 44 (h44), removing the residues that are deleted in all tethered ribosome constructs, and renumbered those residues to facilitate building a continuous RNA chain.</p><p id="p-0180" num="0176">Using that initial structure as a template, we built the remaining residues of the tether using the FARFAR2 algorithm, conducted on 200 CPUs for 24 h, generating several thousand structures. We conducted simulations under two conditions: in one, only tether residues were resampled; in another, a junction on the 23S side of the tether was resampled as well.</p><p id="p-0181" num="0177">All inputs and command files used in setting up computational modeling are available at github.com/everyday847/ribotv3_simulations.</p><p id="p-0182" num="0178">Measurement of Orthogonal GFP Production</p><p id="p-0183" num="0179">Combinations of potentially high-performant tether designs were identified from next generation sequencing results and built into a plasmid containing both an orthogonal tethered ribosome gene (oRibo-T) and an orthogonal superfolder GFP (o-sfGFP) coding sequence (mutated Shine-Dalgarno sequence)<sup>9</sup>. 10 ng of sequence-confirmed plasmids were then transformed into 25 &#x3bc;L of BL21(DE3) cells via electroporation, recovered in 1 mL of SOC, and plated on agar plates containing 100 &#x3bc;g/mL of carbenicillin. Individual colonies were picked (n=3) for inoculation of 100 &#x3bc;L of LB media containing 100 &#x3bc;g/mL carbenicillin. Cultures were incubated at 37&#xb0; C. for 14-16 h with 2 mm continuous linear shaking in a plate reader (Agilent BioTek Synergy H1) and absorbance at 600 nm (OD600) was monitored to ensure saturation. After cultures reached saturation, each culture was diluted to an of &#x2dc;0.01 OD600 in fresh LB media containing 100 &#x3bc;g/mL of carbenicillin and 1 mM isopropyl &#x3b2;-D-1-thiogalactopyranoside (IPTG) to induce transcription of the orthogonal GFP gene. Cultured were incubated at 37&#xb0; C. for 14-16 h with 2 mm continuous linear shaking in a plate reader and OD600 was monitored along with fluorescence (485/528 nm excitation/emission). Orthogonal GFP production (fluorescence) was normalized by OD600.</p><p id="p-0184" num="0180">Growth Rate Characterization of Ribo-Tv3</p><p id="p-0185" num="0181">A plasmid encoding tether sequences corresponding to Ribo-Tv3 (named pRTv3), was constructed using Gibson assembly31. 10 ng of pRTv3 was transformed into 50 &#x3bc;L of SQ171 cells 18 via electroporation and recovered in 500 &#x3bc;L of SOC at 37&#xb0; C. for 2 h with shaking at 250 rpm.</p><p id="p-0186" num="0182">After recovery, 1.5 mL of SOC was added and supplemented with 100 &#x3bc;g/mL carbenicillin and 0.25% (w/v) sucrose (final concentrations). After overnight (16-18 h) recovery at 37&#xb0; C. with 250 rpm shaking, the cells were spun down (4000&#xd7;g, 10 minutes) and plated on LB-agar plates containing 100 mg/m: carbenicillin, 5% sucrose, and 250 &#x3bc;g/mL erythromycin. Individual colonies were picked, and resistance to 100 &#x3bc;g/mL carbenicillin and sensitivity to 50 &#x3bc;g/mL kanamycin was checked on LB-agar plates to confirm successful swapping of ribosome plasmids in the SQ171 cells. Colonies that successfully replaced pCSacB32 with pRTv3 were carried through for analysis.</p><p id="p-0187" num="0183">In a 96 well plate, 100 &#x3bc;L of LB media containing 100 &#x3bc;g/mL carbenicillin, 5% sucrose, and 250 &#x3bc;g/mL erythromycin was inoculated with a colony from an LB agar plate containing 100 &#x3bc;g/mL carbenicillin, 5% sucrose, and 250 &#x3bc;g/mL erythromycin and incubated for 14-16 h at 37&#xb0; C. with 2 mm lateral shaking in a plate reader (Agilent BioTek Synergy H1). Absorbance at 600 nm was monitored to ensure cultures reached saturation. After incubation, cultures were diluted to A600 &#x2dc;0.05 (&#x2dc;20-fold) in 100 &#x3bc;L of LB media containing 100 &#x3bc;g/mL carbenicillin, 5% sucrose, and 250 &#x3bc;g/mL erythromycin and incubated for 18 h at 37&#xb0; C. with 2 mm lateral shaking, and absorbance at 600 nm (A600) was monitored.</p><p id="p-0188" num="0184">Preparation of DECP-CME</p><p id="p-0189" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="168.15mm" wi="75.95mm" file="US20230002758A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0190" num="0000">Cyanomethyl-2-amino-3-(7-(diethylamino)-2-oxo-2H-chromene-3-carboxamido) propanoate (DECP-CME, 5) was prepared with three steps using the synthetic methods previously described 36,41. First, 268 mg (1 mmol) of 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylic acid (1) and 162 mg (1 mmol) of carbonyldiimidazole (CDI) were added to a flask and sealed with a septum. 5 mL of anhydrous DMF was added into the flask using an oven-dried syringe and stirred at room temperature for 2 h. 204 mg (1 mmol) of (R)-3-amino-2-((tert-butoxycarbonyl)amino)propanoic acid (2) was added and stirred overnight. The product was extracted with ethyl acetate after washing the crude reaction mixture with 1 M HCl, water, and brine. Second, 38 mL (0.6 mmol) of chloroacetonitrile and 104 mL (0.75 mmol) of triethylamine were added to 223 mg (0.5 mmol) of the purified 2-((tert-butoxycarbonyl)amino)-3-(7-(diethylamino)-2-oxo-2H-chromene-3-carboxamido) propanoic acid (3) in 1 mL of DCM and stirred overnight. The organic layer was washed with 1 M HCl, water, and brine and dried over MgSO4. 3) 1 mL of 50% of TFA solution in DCM was added to the purified cyanomethyl 2-((tert-butoxycarbonyl)amino)-3-(7-(diethylamino)-2-oxo-2H-chromene-3-carboxamido)propanoate (4) to deprotect the Boc group. The final product was dried under high vacuum and obtained as pale yellow powder (yield: 57%).</p><heading id="h-0012" level="2">Purification of RTv3 for In Vitro Translation Reactions</heading><p id="p-0191" num="0185">In brief, SQ171 cells harboring pRTv3 as the sole source of ribosomes were grown to mid-exponential phase (0.3-0.8 A600) in 500 mL of LB media containing 100 &#x25a1;g/mL carbenicillin and 250 &#x25a1;g/mL erythromycin. Cells were spun down, lysed using homogenization, and ribosomes were harvested using a sucrose cushion as described previously 25. Ribosome pellets were resuspended in Buffer C (10 mM pH 7.5 Tris Acetate, 60 mM ammonium chloride, 7.5 mM magnesium acetate, 0.5 mM ethylenediaminetetraacetic acid, and 2 mM dithiothreitol) and brought to a concentration of 15 mM (A260=625). Resuspended ribosomes were used directly in in vitro translation reactions.</p><heading id="h-0013" level="2">In Vitro Translation Reactions for Incorporation of DECP by RTv3</heading><p id="p-0192" num="0186">Preparation of DNA templates for RNAs. The DNA templates for flexizmyes and tRNAs preparation were synthesized as previously described 22,36. Sequences of the final DNA templated used for in vitro transcription by the T7 polymerase are:</p><p id="p-0193" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="245pt" align="left"/><thead><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>fMet&#x2003;(CAU)</entry><entry>5&#x2032;-</entry></row><row><entry/><entry>G<u style="single">TAATACGACTCACTATA</u>GGCGGGGTGGAGCAGCCTGGTAGCTCGTCGGGCTCATAA</entry></row><row><entry/><entry>CCCGAAGATCGTCGGTTCAAATCCGGCCCCCGCAACCA-3&#x2032;&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;17)</entry></row><row><entry> </entry></row><row><entry>eFx</entry><entry>5&#x2032;-</entry></row><row><entry/><entry>G<u style="single">TAATACGACTCACTATA</u>GGATCGAAAGATTTCCGCGGCCCCGAAAGGGGATTAGCG</entry></row><row><entry/><entry>TTAGGT-3&#x2032;&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;18)</entry></row><row><entry> </entry></row><row><entry>dFx</entry><entry>5&#x2032;-</entry></row><row><entry/><entry>G<u style="single">TAATACGACTCACTATA</u>GGATCGAAAGATTTCCGCATCCCCGAAAGGGTACATGGC</entry></row><row><entry/><entry>GTTAGGT-3&#x2032;&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;19)</entry></row><row><entry> </entry></row><row><entry>aFx</entry><entry>5&#x2032;-</entry></row><row><entry/><entry>G<u style="single">TAATACGACTCACTATA</u>GGATCGAAAGATTTCCGCACCCCCGAAAGGGGTAAGTGG</entry></row><row><entry/><entry>CGTTAGGT-3&#x2032;&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;20)</entry></row><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0194" num="0187">Preparation of Fxs and tRNAs.</p><p id="p-0195" num="0188">Flexizymes (Fxs) and tRNAs were prepared using an in vitro transcription kit (HiScribe&#x2122; T7 High yield RNA synthesis kit, NEB E2040S) and purified by the previously reported methods 22.</p><p id="p-0196" num="0189">Charging DECP into tRNA by Fx.</p><p id="p-0197" num="0190">The acylation experiment was performed first using flexizyme with three flexizymes (e, d, and aFx). The Fx reaction was carried out as follows: 1 &#x3bc;L of 0.5 M HEPES (pH 7.5) or bicine (pH 8.8), 1 &#x3bc;L of 10 &#x3bc;M microhelix (mihx, tRNA mimic), and 3 &#x3bc;L of nuclease-free water were mixed in a PCR tube with 1 &#x3bc;L of 10 &#x3bc;M eFx, dFx, and aFx, respectively. The mixture was heated for 2 min at 95&#xb0; C. and cooled down to room temperature over 5 min. 2 &#x3bc;L of 0.3 M MgCl2 in water was added to the mixture and incubated for 5 min at room temperature. Followed by the incubation of the reaction mixture on ice for 2 min, 2 &#x3bc;L of 25 mM DECP-CME in DMSO was then added to the reaction mixture. The reaction mixture was incubated for 16 h on ice in cold room. The optimal acylation reaction was determined by measuring the acylation yield using an acidic polyacrylamide gel (pH 5.2). tRNAfMet(AUG) was charged with DECP under the condition obtained from the mihx acylation experiment. The charged tRNA was precipitated using ethanol and used for in vitro translation without further purification.</p><p id="p-0198" num="0191">In Vitro Protein Translation Reaction.</p><p id="p-0199" num="0192">The non-canonical substrate incorporation experiment was performed using the PURExpress&#x2122; (&#x394;ribosome, &#x394;aa, &#x394;tRNA, E3315Z) system. DECP-charged tRNAfMet(CAU) was dissolved in 1 &#x3bc;L of 1 mM NaOAc (pH 5.2) and added into 9 &#x3bc;L solution mixture containing 2 &#x3bc;L of Solution A, 1.2 &#x3bc;L of Factor mix, 1.8 &#x3bc;L of Ribo-T v3 (2.4 &#x3bc;M in final reaction), 1 &#x3bc;L of</p><p id="p-0200" num="0193">endogenous tRNA mixture, 1 &#x3bc;L of DNA plasmid (130 ng &#x3bc;L-1), 1 &#x3bc;L of nuclease-free water, and</p><p id="p-0201" num="0194">1 &#x3bc;L of 5 mM amino acid mixtures (Trp, Ser, His, Pro, Gln, Phe, Glu, Lys, and Thr). The reaction mixture was incubated in 37&#xb0; C. for 2 h.</p><p id="p-0202" num="0195">The target peptide produced in the PURE reaction was purified by using MagStrep (type 3) XT beads 5% suspension (IBA Lifesciences) which selectively pull down the target peptide bearing the Strep tag (WSHPQFEK) at the C-terminal region. After pulling down the target peptide, the magnetic beads were washed with the Strep-Tactin XT wash buffer (IBA Lifesciences) and treated with 0.1% SDS solution in water. The beads were heated at 95&#xb0; C. in a PCR machine to denature the target peptide bound to the beads. The magnetic beads were removed on a magnet rack and the obtained peptide was analyzed by mass spectrometry.</p><p id="p-0203" num="0196">DNA Primers Used in this Study.</p><p id="p-0204" num="0197">Sequences are listed 5&#x2032; to 3&#x2032;. For primers indicated with &#x2018;\Phos\&#x2019;, Phosphorylation performed on oligos with polynucleotide kinase (PNK) prior to PCR for use in blunt end ligation. &#x2018;N&#x2019; indicates degenerate oligonucleotides. All oligonucleotides purchased from Integrated DNA Technologies (IDT).</p><p id="p-0205" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="84pt" align="left"/><colspec colname="3" colwidth="133pt" align="left"/><colspec colname="4" colwidth="154pt" align="left"/><thead><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Use</entry><entry>Primer&#x2003;Name</entry><entry>Sequence&#x2003;(5&#x2032;&#x2192;3&#x2032;)</entry><entry>Description</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>Broad</entry><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;5</entry></row><row><entry>Sampling</entry><entry>5N-f</entry><entry>TTGAGCTAACCGGTACTAATGAAC</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;Tl&#x2003;region,</entry></row><row><entry>Library</entry><entry/><entry>C&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;21)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry>construction,</entry><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;5</entry></row><row><entry>insert</entry><entry>5N-r</entry><entry>CnnnnnCTTACACACCCGGCCTATCA</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>A&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;22)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;6</entry></row><row><entry/><entry>6N-f</entry><entry>nTTGAGCTAACCGGTACTAATGAA</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>CC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;23)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;6</entry></row><row><entry/><entry>6N-r</entry><entry>CnnnnnnCTTACACACCCGGCCTATC</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>AA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;24)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;7</entry></row><row><entry/><entry>7N-f</entry><entry>nTTGAGCTAACCGGTACTAATGAA</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>CC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;25)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;7</entry></row><row><entry/><entry>7N-r</entry><entry>CnnnnnnnCTTACACACCCGGCCTAT</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>CAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;26)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;8</entry></row><row><entry/><entry>8N-f</entry><entry>nnnTTGAGCTAACCGGTACTAATGA</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>ACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;27)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;8</entry></row><row><entry/><entry>8N-r</entry><entry>CnnnnnnnCTTACACACCCGGCCTAT</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>CAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;28)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;9</entry></row><row><entry/><entry>9N-f</entry><entry>nnnnTTGAGCTAACCGGTACTAATG</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>AACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;29)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;9</entry></row><row><entry/><entry>9N-r</entry><entry>CnnnnnnnnnCTTACACACCCGGCCTA</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>TCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;30)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;10</entry></row><row><entry/><entry>10N-f</entry><entry>nnnnTTGAGCTAACCGGTACTAATG</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>AACC&#x2003;(SEQIDNO:&#x2003;31)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;10</entry></row><row><entry/><entry>10N-r</entry><entry>CnnnnnnnnnnCTTACACACCCGGCCT</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>ATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;32)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;11</entry></row><row><entry/><entry>11N-f</entry><entry>nnnnnnTTGAGCTAACCGGTACTAAT</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>GAACC&#x2003;(SEQIDNO:&#x2003;33)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;11</entry></row><row><entry/><entry>11N-r</entry><entry>CnnnnnnnnnnnCTTACACACCCGGCC</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>TATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;34)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;12</entry></row><row><entry/><entry>12N-f</entry><entry>nnnnnnnTTGAGCTAACCGGTACTAA</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>TGAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;35)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;12</entry></row><row><entry/><entry>12N-r</entry><entry>CnnnnnnnnnnnnCTTACACACCCGGC</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>CTATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;36)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;13</entry></row><row><entry/><entry>13N-f</entry><entry>nnnnnnnnTTGAGCTAACCGGTACTA</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>ATGAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;37)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;13</entry></row><row><entry/><entry>13N-r</entry><entry>CnnnnnnnnnnnnnCTTACACACCCGG</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>CCTATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;38)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;14</entry></row><row><entry/><entry>14N-f</entry><entry>nnnnnnnnTTGAGCTAACCGGTACTA</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>ATGAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;39)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;14</entry></row><row><entry/><entry>14N-r</entry><entry>CnnnnnnnnnnnnnCTTACACACCCGG</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>CCTATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;40)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;15</entry></row><row><entry/><entry>15N-f</entry><entry>nnnnnnnnnnTTGAGCTAACCGGTACT</entry><entry>degenerate&#x2003;nucleotides&#x2003;inTl&#x2003;region,</entry></row><row><entry/><entry/><entry>AATGAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;41)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry/><entry>RTv3_BroadSample_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;used&#x2003;to&#x2003;install&#x2003;15</entry></row><row><entry/><entry>15N-r</entry><entry>CnnnnnnnnnnnnnCTTACACACCCGG</entry><entry>degenerate&#x2003;nucleotides&#x2003;in&#x2003;T2&#x2003;region,</entry></row><row><entry/><entry/><entry>CCTATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;42)</entry><entry>Broad&#x2003;Sampling&#x2003;Library</entry></row><row><entry> </entry></row><row><entry>Tether-H101</entry><entry>d1_RTv2-f</entry><entry>GAAGTAGGTAGCTTAACCcaatgaacaa</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;1&#x2003;residue</entry></row><row><entry>Junction</entry><entry/><entry>ttggaGCGTTGAGCTAACCGGTACTA</entry><entry>deletion&#x2003;in&#x2003;Tether-H101&#x2003;junction</entry></row><row><entry>Library</entry><entry/><entry>ATGAAC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;43)</entry><entry/></row><row><entry>construction,</entry><entry>d1_RTv2-r</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;1&#x2003;residue</entry></row><row><entry>insert</entry><entry/><entry>CactagttatcGCGCTTACACACCCGGC</entry><entry>deletion&#x2003;in&#x2003;Tether-H10&#x2003;junction</entry></row><row><entry/><entry/><entry>CTATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;44)</entry><entry/></row><row><entry/><entry>d2_RTv2-f</entry><entry>GAAGTAGGTAGCTTAACCcaatgaacaa</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;2&#x2003;residue</entry></row><row><entry/><entry/><entry>ttggaCGTTGAGCTAACCGGTACTAA</entry><entry>deletion&#x2003;in&#x2003;Tether-H101&#x2003;junction</entry></row><row><entry/><entry/><entry>TGAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;45)</entry><entry/></row><row><entry/><entry>d2_RTv2-r</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;2&#x2003;residue</entry></row><row><entry/><entry/><entry>CactagttatcCGCTTACACACCCGGCC</entry><entry>deletion&#x2003;in&#x2003;Tether-H101&#x2003;junction</entry></row><row><entry/><entry/><entry>TATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;46)</entry><entry/></row><row><entry/><entry>d3_RTv2-f</entry><entry>GAAGTAGGTAGCTTAACCcaatgaacaa</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;3&#x2003;residue</entry></row><row><entry/><entry/><entry>ttggaGTTGAGCTAACCGGTACTAAT</entry><entry>deletion&#x2003;in&#x2003;Tether-H101&#x2003;junction</entry></row><row><entry/><entry/><entry>GAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;47)</entry><entry/></row><row><entry/><entry>d3_RTv2-f</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;3&#x2003;residue</entry></row><row><entry/><entry/><entry>CactagttatcGCTTACACACCCGGCCT</entry><entry>deletion&#x2003;in&#x2003;Tether-H101&#x2003;junction</entry></row><row><entry/><entry/><entry>ATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;48)</entry><entry/></row><row><entry/><entry>d4_RTv2-f</entry><entry>AAGAAGTAGGTAGCTTAACCcaatga</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;4&#x2003;residue</entry></row><row><entry/><entry/><entry>acaattggaTTGAGCTAACCGGTACTAA</entry><entry>deletion&#x2003;in&#x2003;Tether-H101&#x2003;junction</entry></row><row><entry/><entry/><entry>TGAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;49)</entry><entry/></row><row><entry/><entry>d4_RTv2-r</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;4&#x2003;residue</entry></row><row><entry/><entry/><entry>CactagttatcCTTACACACCCGGCCTA</entry><entry>deletion&#x2003;in&#x2003;Tether-H101&#x2003;junction</entry></row><row><entry/><entry/><entry>TCA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;50)</entry><entry/></row><row><entry/><entry>d5_RTv2-f</entry><entry>AAGAAGTAGGTAGCTTAACCcaatga</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;5&#x2003;residue</entry></row><row><entry/><entry/><entry>acaattggaTGAGCTAACCGGTACTAAT</entry><entry>deletion&#x2003;in&#x2003;Tether-H101&#x2003;junction</entry></row><row><entry/><entry/><entry>GAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;51)</entry><entry/></row><row><entry/><entry>d5_RTv2-r</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;5&#x2003;residue</entry></row><row><entry/><entry/><entry>CactagttatcTTACACACCCGGCCTAT</entry><entry>deletion&#x2003;in&#x2003;Tether-H101&#x2003;junction</entry></row><row><entry/><entry/><entry>CAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;52)</entry><entry/></row><row><entry> </entry></row><row><entry>Designed</entry><entry>RTv3_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry>Junction</entry><entry>DesignedJunc_</entry><entry>CnnnnnGCCTTACACACCCGGCCTAT</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry>Library</entry><entry>5N-r</entry><entry>CAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;53)</entry><entry>Library</entry></row><row><entry> </entry></row><row><entry>construction,</entry><entry>RTv3_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry>insert</entry><entry>DesignedJunc_</entry><entry>CnnnnnGTCCTTACACACCCGGCCTA</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry/><entry>5N-r</entry><entry>TCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;54)</entry><entry>Library</entry></row><row><entry/><entry>RTv3_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry/><entry>DesignedJunc_</entry><entry>nGCTTGAGCTAACCGGTACTAATG</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry/><entry>6N-f</entry><entry>AACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;55)</entry><entry>Library</entry></row><row><entry/><entry>RTv3_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry/><entry>DesignedJunc_</entry><entry>CnnnnnnGCCTTACACACCCGGCCTA</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry/><entry>6N-r</entry><entry>TCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;56)</entry><entry>Library</entry></row><row><entry/><entry>RTv3_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry/><entry>DesignedJunc_</entry><entry>nnGCTTGAGCTAACCGGTACTAATG</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry/><entry>7N-f</entry><entry>AACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;57)</entry><entry>Library</entry></row><row><entry/><entry>RTv3_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry/><entry>DesignedJunc_</entry><entry>CnnnnnnnGCCTTACACACCCGGCCT</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry/><entry>7N-r</entry><entry>ATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;58)</entry><entry>Library</entry></row><row><entry/><entry>RTv3_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry/><entry>DesignedJunc_</entry><entry>nnnGCTTGAGCTAACCGGTACTAAT</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry/><entry>8N-f</entry><entry>GAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;59)</entry><entry>Library</entry></row><row><entry/><entry>RTv3_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry/><entry>DesignedJunc_</entry><entry>CnnnnnnnnGCCTTACACACCCGGCC</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry/><entry>8N-r</entry><entry>TATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;60)</entry><entry>Library</entry></row><row><entry/><entry>RTv3_</entry><entry>AAGAAGTAGGTAGCTTAACCnnnnn</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry/><entry>DesignedJunc_</entry><entry>nnnnGCTTGAGCTAACCGGTACTAA</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry/><entry>9N-f</entry><entry>TGAACC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;61)</entry><entry>Library</entry></row><row><entry/><entry>RTv3_</entry><entry>AATCACAAAGTGGTAAGCGCCCTC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;5&#x2003;degenerate</entry></row><row><entry/><entry>DesignedJunc_</entry><entry>CnnnnnnnnGCCTTACACACCCGGCC</entry><entry>residues&#x2003;for&#x2003;Designed&#x2003;Junction</entry></row><row><entry/><entry>N-r</entry><entry>TATCAA&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;62)</entry><entry>Library</entry></row><row><entry> </entry></row><row><entry>Backbone</entry><entry>Ribo-T_lib_bb-f</entry><entry>GGAGGGCGCTTACCACTTTGTGAT</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;amplification&#x2003;of</entry></row><row><entry>for&#x2003;Ribo-T&#x2003;v3</entry><entry/><entry>T&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;63)</entry><entry>backbone&#x2003;with&#x2003;library&#x2003;inserts,</entry></row><row><entry>library</entry><entry/><entry/><entry>assemble&#x2003;by&#x2003;isothermal&#x2003;assembly</entry></row><row><entry>construction</entry><entry>Ribo-T_lib_bb-r</entry><entry>GGTTAAGCTACCTACTTCTTTTGCA</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;amplification&#x2003;of</entry></row><row><entry>amplification</entry><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;64)</entry><entry>backbone&#x2003;with&#x2003;library&#x2003;inserts,</entry></row><row><entry/><entry/><entry/><entry>assemble&#x2003;by&#x2003;isothermal&#x2003;assembly</entry></row><row><entry> </entry></row><row><entry>Testing&#x2003;PCR1</entry><entry>T1-T2_PCR1_GA_-f</entry><entry>GGAACGTTGAAGACGACGACGTTG</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;PCR1,&#x2003;compatible</entry></row><row><entry>compati-</entry><entry/><entry>ATAGG&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;65)</entry><entry>for&#x2003;isothermal&#x2003;assembly</entry></row><row><entry>bility&#x2003;with</entry><entry>T1-T2_PCR1_GA-r</entry><entry>CCTATCAACGTCGTCGTCTTCAACG</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;PCR1,&#x2003;compatible</entry></row><row><entry>different</entry><entry/><entry>TTCCACGGTTCATTAGTACCGGTTA</entry><entry>for&#x2003;isothermal&#x2003;assembly</entry></row><row><entry>ligation</entry><entry/><entry>GC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;66)</entry><entry/></row><row><entry>methods</entry><entry>\Phos\T1-</entry><entry>GGAACGTTGAAGACGACGACGTTG</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;PCR1,&#x2003;compatible</entry></row><row><entry/><entry>T2_PCR1_blunt-f</entry><entry>ATAGG&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;67)</entry><entry>for&#x2003;blunt&#x2003;end&#x2003;ligation</entry></row><row><entry/><entry/><entry/><entry>(phosphorylated&#x2003;prior&#x2003;to&#x2003;PCR)</entry></row><row><entry/><entry>\Phos\T1-</entry><entry>CACGGTTCATTAGTACCGGTTAGC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;PCR1,&#x2003;compatible</entry></row><row><entry/><entry>T2_PCR1_blunt-r</entry><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;68)</entry><entry>for&#x2003;blunt&#x2003;end&#x2003;ligation</entry></row><row><entry/><entry/><entry/><entry>(phosphorylated&#x2003;prior&#x2003;to&#x2003;PCR)</entry></row><row><entry/><entry>T1-</entry><entry>agatggatccGGAACGTTGAAGACGAC</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;PCR1,&#x2003;compatible</entry></row><row><entry/><entry>T2&#x2003;PCR1_BamHI-</entry><entry>GACGTTGATAGG&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;69)</entry><entry>for&#x2003;digestion&#x2003;with&#x2003;BamHI&#x2003;prior&#x2003;to</entry></row><row><entry/><entry>for</entry><entry/><entry>ligation</entry></row><row><entry/><entry>T1-</entry><entry>ggatccatctCACGGTTCATTAGTACCG</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;PCR1,&#x2003;compatible</entry></row><row><entry/><entry>T2_PCR1_BamHI-</entry><entry>GTTAGC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;70)</entry><entry>for&#x2003;digestion&#x2003;with&#x2003;BamHI&#x2003;prior&#x2003;to</entry></row><row><entry/><entry>rev</entry><entry/><entry>ligation</entry></row><row><entry/><entry>T1-T2_PCR1_SapI-</entry><entry>gctcttcagcgGGAACGTTGAAGACGAC</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;PCR1,&#x2003;compatible</entry></row><row><entry/><entry>for</entry><entry>GACGTTGATAGG&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;71)</entry><entry>for&#x2003;digestion&#x2003;with&#x2003;SapI&#x2003;prior&#x2003;to</entry></row><row><entry/><entry/><entry/><entry>ligation</entry></row><row><entry/><entry>T1-T2_PCR1_SapI-</entry><entry>ggctcttcacgcCACGGTTCATTAGTACC</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;PCR1,&#x2003;compatible</entry></row><row><entry/><entry>rev</entry><entry>GGTTAGC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;72)</entry><entry>for&#x2003;digestion&#x2003;with&#x2003;SapI&#x2003;prior&#x2003;to</entry></row><row><entry/><entry/><entry/><entry>ligation</entry></row><row><entry> </entry></row><row><entry>PCR2</entry><entry>T1-T2-PCR2-for</entry><entry>AGTGGGTTGCAAAAGAAGTAGGTA</entry><entry>Forward&#x2003;primer&#x2003;for&#x2003;PCR2</entry></row><row><entry/><entry/><entry>GC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;73)</entry><entry/></row><row><entry/><entry>T1-T2-PCR2-rev</entry><entry>CCAGTCATGAATCACAAAGTGGTA</entry><entry>Reverse&#x2003;primer&#x2003;for&#x2003;PCR2</entry></row><row><entry/><entry/><entry>AGC&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;74)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0206" num="0198">Comparisons of orthogonal sfGFP production by multiple Ribo-T v3 candidates (<figref idref="DRAWINGS">FIG. <b>5</b>C</figref>) compared to Ribo-T v2. One-sided Welch's t-test performed to compare Ribo-T v3 candidates to Ribo-T v2. T1 and T2 sequences are shown 5&#x2032; to 3&#x2032;. Data shown representative of three independent experiments, and within each experiment, data from three replicates per T1 and T2 sequence genotype used to calculate standard deviation and perform t-test. Experiment and analysis were performed to analyze which Ribo-T v3 candidates had greater orthogonal sfGFP synthesis ability. * marks sequence chosen as Ribo-T v3.</p><p id="p-0207" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><colspec colname="3" colwidth="84pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><colspec colname="5" colwidth="35pt" align="left"/><thead><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Normalized&#x2003;sfGFP</entry><entry/><entry/></row><row><entry/><entry/><entry>expression</entry><entry>Standard</entry><entry>P-</entry></row><row><entry>T1&#x2003;sequence</entry><entry>T2&#x2003;sequence</entry><entry>(fluorescence/A<sub>600</sub>)</entry><entry>Deviation</entry><entry>value</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>GUUAUA</entry><entry>AUCCCAGG</entry><entry>13457</entry><entry>&#x2003;103</entry><entry>0.000145</entry></row><row><entry> </entry></row><row><entry>GUUAUA</entry><entry>UCACAAC</entry><entry>15196</entry><entry>&#x2003;871</entry><entry>0.000362</entry></row><row><entry> </entry></row><row><entry>GUUAUA</entry><entry>GACCUUCG</entry><entry>12628</entry><entry>&#x2003;733</entry><entry>0.002386</entry></row><row><entry> </entry></row><row><entry>GUUAUA</entry><entry>ACAUAAUG</entry><entry>&#x2003;6998</entry><entry>&#x2003;233</entry><entry>0.000793</entry></row><row><entry> </entry></row><row><entry>AGUCAAUAA</entry><entry>AUCCCAGG</entry><entry>12997</entry><entry>&#x2003;222</entry><entry>0.000300</entry></row><row><entry> </entry></row><row><entry>AGUCAAUAA</entry><entry>UCACAAC</entry><entry>13597</entry><entry>&#x2003;834</entry><entry>0.001172</entry></row><row><entry> </entry></row><row><entry>AGUCAAUAA*</entry><entry>GACCUUCG*</entry><entry>15097</entry><entry>&#x2003;682</entry><entry>0.000207</entry></row><row><entry> </entry></row><row><entry>AGUCAAUAA</entry><entry>ACAUAAUG</entry><entry>12327</entry><entry>&#x2003;543</entry><entry>0.001885</entry></row><row><entry> </entry></row><row><entry>CAUCAUGG</entry><entry>AUCCCAGG</entry><entry>10482</entry><entry>&#x2003;525</entry><entry>0.061960</entry></row><row><entry> </entry></row><row><entry>CAUCAUGG</entry><entry>UCACAAC</entry><entry>12729</entry><entry>1559</entry><entry>0.015705</entry></row><row><entry> </entry></row><row><entry>CAUCAUGG</entry><entry>GACCUUCG</entry><entry>10866</entry><entry>1221</entry><entry>0.092446</entry></row><row><entry> </entry></row><row><entry>CAUCAUGG</entry><entry>ACAUAAUG</entry><entry>13455</entry><entry>&#x2003;979</entry><entry>0.002063</entry></row><row><entry> </entry></row><row><entry>AUAUAAU</entry><entry>AUCCCAGG</entry><entry>14094</entry><entry>&#x2003;483</entry><entry>0.000227</entry></row><row><entry> </entry></row><row><entry>AUAUAAU</entry><entry>UCACAAC</entry><entry>13501</entry><entry>1135</entry><entry>0.003005</entry></row><row><entry> </entry></row><row><entry>AUAUAAU</entry><entry>GACCUUCG</entry><entry>13572</entry><entry>1896</entry><entry>0.012928</entry></row><row><entry> </entry></row><row><entry>AUAUAAU</entry><entry>ACAUAAUG</entry><entry>&#x2003;6057</entry><entry>&#x2003;428</entry><entry>0.000444</entry></row><row><entry> </entry></row><row><entry>RTv2</entry><entry>RTv2</entry><entry>&#x2003;9629</entry><entry>&#x2003;550</entry><entry>1</entry></row><row><entry>(CAAUGAACAAUUGGA)</entry><entry>(GAUAACUAGU)</entry><entry/><entry/><entry/></row><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;75)</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>WT&#x2003;(no&#x2003;tether)</entry><entry>WT&#x2003;(no&#x2003;tether)</entry><entry>&#x2003;&#x2003;&#x2003;673</entry><entry>&#x2003;&#x2003;44</entry><entry>&#x2014;</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0208" num="0199">Code Availability</p><p id="p-0209" num="0200">All inputs and command files used in setting up computational modeling are available at github.com/everyday847/ribotv3_simulations.</p><heading id="h-0014" level="1">REFERENCES</heading><p id="p-0210" num="0000"><ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0201">1 Dedkova, L. M., Fahmi, N. E., Golovine, S. Y. &#x26; Hecht, S. M. Enhanced D-amino acid incorporation into protein by modified ribosomes. <i>Journal of the American Chemical Society </i>125, 6616-6617 (2003).</li>    <li id="ul0001-0002" num="0202">2 Dedkova, L. M., Fahmi, N. E., Golovine, S. Y. &#x26; Hecht, S. M. Construction of modified ribosomes for incorporation of D-amino acids into proteins. <i>Biochemistry </i>45, 15541-15551 (2006).</li>    <li id="ul0001-0003" num="0203">3 Dedkova, L. M. et al. &#x3b2;-Puromycin selection of modified ribosomes for in vitro incorporation of &#x3b2;-amino acids. <i>Biochemistry </i>51, 401-415 (2012).</li>    <li id="ul0001-0004" num="0204">4 Dedkova, L. M. &#x26; Hecht, S. M. Expanding the scope of protein synthesis using modified ribosomes. <i>Journal of the American Chemical Society </i>141, 6430-6447 (2019).</li>    <li id="ul0001-0005" num="0205">5 Des Soye, B. J., Patel, J. R., Isaacs, F. J. &#x26; Jewett, M. C. Repurposing the translation apparatus for synthetic biology. <i>Current opinion in chemical biology </i>28, 83-90 (2015).</li>    <li id="ul0001-0006" num="0206">6 Ellefson, J. W. et al. Synthetic evolutionary origin of a proofreading reverse transcriptase. <i>Science </i>352, 1590-1593 (2016).</li>    <li id="ul0001-0007" num="0207">7 Hammerling, M. J., Fritz, B. R., Yoesep, D. J., Carlson, E. D. &#x26; Jewett, M. C. In vitro ribosome synthesis and evolution through ribosome display. <i>Nature communications </i>11, 1-10 (2020).</li>    <li id="ul0001-0008" num="0208">8 Maini, R. et al. Protein synthesis with ribosomes selected for the incorporation of j-amino acids. <i>Biochemistry </i>54, 3694-3706 (2015).</li>    <li id="ul0001-0009" num="0209">9 Carlson, E. D. et al. Engineered ribosomes with tethered subunits for expanding biological function. <i>Nature communications </i>10, 1-13 (2019).</li>    <li id="ul0001-0010" num="0210">10 Sailer, Z. R. &#x26; Harms, M. J. Molecular ensembles make evolution unpredictable. <i>Proceedings of the National Academy of Sciences </i>114, 11938-11943 (2017).</li>    <li id="ul0001-0011" num="0211">11 Romero, P. A. &#x26; Arnold, F. H. Exploring protein fitness landscapes by directed evolution. <i>Nature reviews Molecular cell biology </i>10, 866-876 (2009).</li>    <li id="ul0001-0012" num="0212">12 Sarkisyan, K. S. et al. Local fitness landscape of the green fluorescent protein. <i>Nature </i>533, 397-401 (2016).</li>    <li id="ul0001-0013" num="0213">13 Ramakrishnan, V. Ribosome structure and the mechanism of translation. Cell 108, 557-572 (2002).</li>    <li id="ul0001-0014" num="0214">14 Schmied, W. H. et al. Controlling orthogonal ribosome subunit interactions enables evolution of new function. <i>Nature </i>564, 444-448 (2018).</li>    <li id="ul0001-0015" num="0215">15 Fried, S. D., Schmied, W. H., Uttamapinant, C. &#x26; Chin, J. W. Ribosome subunit stapling for orthogonal translation in <i>E. coli. Angewandte Chemie </i>127, 12982-12985 (2015).</li>    <li id="ul0001-0016" num="0216">16 Liu, C. C., Jewett, M. C., Chin, J. W. &#x26; Voigt, C. A. Toward an orthogonal central dogma. <i>Nature chemical biology </i>14, 103-106 (2018).</li>    <li id="ul0001-0017" num="0217">17 Liu, Y., Kim, D. S. &#x26; Jewett, M. C. Repurposing ribosomes for synthetic biology. <i>Current opinion in chemical biology </i>40, 87-94 (2017).</li>    <li id="ul0001-0018" num="0218">18 Orelle, C. et al. Protein synthesis by ribosomes with tethered subunits. <i>Nature </i>524, 119-124 (2015).</li>    <li id="ul0001-0019" num="0219">19 Rackham, O. &#x26; Chin, J. W. A network of orthogonal ribosome mRNA pairs. <i>Nature chemical biology </i>1, 159-166 (2005).</li>    <li id="ul0001-0020" num="0220">20 Neumann, H., Wang, K., Davis, L., Garcia-Alai, M. &#x26; Chin, J. W. Encoding multiple unnatural amino acids via evolution of a quadruplet-decoding ribosome. <i>Nature </i>464, 441-444 (2010).</li>    <li id="ul0001-0021" num="0221">21 Wang, K., Neumann, H., Peak-Chew, S. Y. &#x26; Chin, J. W. Evolved orthogonal ribosomes enhance the efficiency of synthetic genetic code expansion. <i>Nature biotechnology </i>25, 770-777 (2007).</li>    <li id="ul0001-0022" num="0222">22 Goto, Y., Katoh, T. &#x26; Suga, H. Flexizymes for genetic code reprogramming. <i>Nature protocols </i>6, 779-790 (2011).</li>    <li id="ul0001-0023" num="0223">23 Melo Czekster, C., Robertson, W. E., Walker, A. S., S&#xf6;ll, D. &#x26; Schepartz, A. In vivo biosynthesis of a &#x3b2;-amino acid-containing protein. <i>Journal of the American Chemical Society </i>138, 5194-5197 (2016).<br/>24 Chin, J. W. Expanding and reprogramming the genetic code. <i>Nature </i>550, 53-60 (2017).</li>    <li id="ul0001-0024" num="0224">25 Jewett, M. C., Fritz, B. R., Timmerman, L. E. &#x26; Church, G. M. In vitro integration of ribosomal RNA synthesis, ribosome assembly, and translation. <i>Molecular systems biology </i>9, 678 (2013).</li>    <li id="ul0001-0025" num="0225">26 Hui, A. &#x26; de Boer, H. A. Specialized ribosome system: preferential translation of a single mRNA species by a subpopulation of mutated ribosomes in <i>Escherichia coli. Proc Natl Acad Sci USA </i>84, 4762-4766, doi:10.1073/pnas.84.14.4762 (1987).</li>    <li id="ul0001-0026" num="0226">27 Rackham, O. &#x26; Chin, J. W. Cellular logic with orthogonal ribosomes. <i>Journal of the American Chemical Society </i>127, 17584-17585 (2005).</li>    <li id="ul0001-0027" num="0227">28 Cho, N. et al. De novo assembly and next-generation sequencing to analyse full-length gene variants from codon-barcoded libraries. <i>Nature communications </i>6, 1-9 (2015).</li>    <li id="ul0001-0028" num="0228">29 Yoo, J. I., Daugherty, P. S. &#x26; O'Malley, M. A. Bridging non-overlapping reads illuminates high-order epistasis between distal protein sites in a GPCR. <i>Nature communications </i>11, 1-12 (2020).</li>    <li id="ul0001-0029" num="0229">30 Borgstr&#xf6;m, E. et al. Phasing of single DNA molecules by massively parallel barcoding. <i>Nature communications </i>6, 7173 (2015).</li>    <li id="ul0001-0030" num="0230">31 Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. <i>Nature methods </i>6, 343-345 (2009).</li>    <li id="ul0001-0031" num="0231">32 Carlson, E. D. et al. Engineered ribosomes with tethered subunits for expanding biological function. <i>Nature communications </i>10, 1-13 (2019).</li>    <li id="ul0001-0032" num="0232">33 Asai, T., Zaporojets, D., Squires, C. &#x26; Squires, C. L. An <i>Escherichia coli </i>strain with all chromosomal rRNA operons inactivated: complete exchange of rRNA genes between bacteria. <i>Proceedings of the National Academy of Sciences </i>96, 1971-1976 (1999).</li>    <li id="ul0001-0033" num="0233">34 Lorenz, R. et al. ViennaRNA Package 2.0<i>. Algorithms for molecular biology </i>6, 26 (2011).</li>    <li id="ul0001-0034" num="0234">35 Watkins, A. M., Rangan, R. &#x26; Das, R. FARFAR2: Improved de novo Rosetta prediction of complex global RNA folds. <i>Structure </i>(2020).</li>    <li id="ul0001-0035" num="0235">36 Noeske, J. et al. High-resolution structure of the <i>Escherichia coli </i>ribosome. <i>Nature structural </i>&#x26; <i>molecular biology </i>22, 336-341 (2015).</li>    <li id="ul0001-0036" num="0236">37 Lee, J., Schwarz, K. J., Kim, D. S., Moore, J. S. &#x26; Jewett, M. C. Ribosome-mediated polymerization of long chain carbon and cyclic amino acids into peptides in vitro. <i>Nature Communications </i>11, 4304, doi:10.1038/s41467-020-18001-x (2020).</li>    <li id="ul0001-0037" num="0237">38 Lee, J. et al. Expanding the limits of the second genetic code with ribozymes. <i>Nature communications </i>10, 1-12 (2019).</li>    <li id="ul0001-0038" num="0238">39 Lee, J. et al. Ribosomal incorporation of cyclic &#x3b2;-amino acids into peptides using in vitro translation. <i>Chemical Communications </i>56, 5597-5600 (2020).</li>    <li id="ul0001-0039" num="0239">40 Aleksashin, N. A. et al. A fully orthogonal system for protein synthesis in bacterial cells. <i>Nature communications </i>11, 1-11 (2020).</li></ul></p><p id="p-0211" num="0240">Full Sequences of modified ribosome RNA including tether pairs 1-16 of <figref idref="DRAWINGS">FIG. <b>23</b></figref> are provided below. Disclosed herein are engineered ribosomes comprising the full sequences of any one of Pair 1-16 full sequence, as shown below.</p><p id="p-0212" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="280pt" align="left"/><thead><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>Pair&#x2003;1:&#x2003;Full&#x2003;Sequence&#x2003;[SEQ&#x2003;ID&#x2003;NO:&#x2003;1]</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>GUUAUAGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGACU</entry></row><row><entry>AAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUAAG</entry></row><row><entry>CGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUGUU</entry></row><row><entry>UCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACAUC</entry></row><row><entry>UAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGAGC</entry></row><row><entry>AGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAGGG</entry></row><row><entry>UGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUGGU</entry></row><row><entry>AUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGUGA</entry></row><row><entry>ACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAAAC</entry></row><row><entry>CGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUGGG</entry></row><row><entry>UCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUCUU</entry></row><row><entry>AACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUUGA</entry></row><row><entry>AGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACUUG</entry></row><row><entry>UGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUAGG</entry></row><row><entry>UAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGACU</entry></row><row><entry>UACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGUGC</entry></row><row><entry>UAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGUUA</entry></row><row><entry>AGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAUUU</entry></row><row><entry>AAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAACC</entry></row><row><entry>AUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGCCU</entry></row><row><entry>GCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAACGA</entry></row><row><entry>UAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGGGC</entry></row><row><entry>AGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAUUC</entry></row><row><entry>CUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUGUC</entry></row><row><entry>CCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGAUG</entry></row><row><entry>ACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUCAG</entry></row><row><entry>GUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUUGA</entry></row><row><entry>GAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGAUA</entry></row><row><entry>UGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAACUG</entry></row><row><entry>UUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCCCG</entry></row><row><entry>GUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAAAC</entry></row><row><entry>GGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCUGC</entry></row><row><entry>ACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCUGU</entry></row><row><entry>GAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGACAC</entry></row><row><entry>UGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUGCA</entry></row><row><entry>UGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCGGUAAUCCGG</entry></row><row><entry>GUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGAGG</entry></row><row><entry>AGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAGCU</entry></row><row><entry>UGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCUGA</entry></row><row><entry>AUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCCAA</entry></row><row><entry>GAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGAAG</entry></row><row><entry>UAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGUCG</entry></row><row><entry>UGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGUAC</entry></row><row><entry>GAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGGUA</entry></row><row><entry>GCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAGUU</entry></row><row><entry>CUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGUGU</entry></row><row><entry>GUAAGGACUCACAACGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGUAAC</entry></row><row><entry>AAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;2:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>AGUCAAUAAGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCG</entry></row><row><entry>ACUAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAU</entry></row><row><entry>AAGCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGU</entry></row><row><entry>GUUUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAAC</entry></row><row><entry>AUCUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGG</entry></row><row><entry>AGCAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACA</entry></row><row><entry>GGGUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGU</entry></row><row><entry>GGUAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAG</entry></row><row><entry>UGAACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGA</entry></row><row><entry>AACCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAU</entry></row><row><entry>GGGUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGU</entry></row><row><entry>CUUAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGU</entry></row><row><entry>UGAAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGAC</entry></row><row><entry>UUGUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUU</entry></row><row><entry>AGGUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCG</entry></row><row><entry>ACUUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGG</entry></row><row><entry>UGCUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGG</entry></row><row><entry>UUAAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCA</entry></row><row><entry>UUUAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAA</entry></row><row><entry>ACCAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAG</entry></row><row><entry>CCUGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAA</entry></row><row><entry>CGAUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGG</entry></row><row><entry>GGCAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUA</entry></row><row><entry>UUCCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUU</entry></row><row><entry>GUCCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUG</entry></row><row><entry>AUGACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAU</entry></row><row><entry>CAGGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCU</entry></row><row><entry>UGAGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUG</entry></row><row><entry>AUAUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAA</entry></row><row><entry>CUGUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGC</entry></row><row><entry>CCGGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUA</entry></row><row><entry>AACGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACC</entry></row><row><entry>UGCACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGC</entry></row><row><entry>UGUGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGA</entry></row><row><entry>CACUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCU</entry></row><row><entry>GCAUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCCGUAAUC</entry></row><row><entry>CGGGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGG</entry></row><row><entry>AGGAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCA</entry></row><row><entry>GCUUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUC</entry></row><row><entry>UGAAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCC</entry></row><row><entry>CAAGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUG</entry></row><row><entry>AAGUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACG</entry></row><row><entry>UCGUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAG</entry></row><row><entry>UACGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCG</entry></row><row><entry>GUAGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGA</entry></row><row><entry>GUUCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGG</entry></row><row><entry>UGUGUAAGGACGACCUUCGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCG</entry></row><row><entry>UAACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;3:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;3)</entry></row><row><entry>c</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;4:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;4)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>AGUCAAUAAGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCG</entry></row><row><entry>ACUAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAU</entry></row><row><entry>AAGCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGU</entry></row><row><entry>GUUUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAAC</entry></row><row><entry>AUCUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGG</entry></row><row><entry>AGCAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACA</entry></row><row><entry>GGGUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGU</entry></row><row><entry>GGUAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAG</entry></row><row><entry>UGAACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGA</entry></row><row><entry>AACCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAU</entry></row><row><entry>GGGUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGU</entry></row><row><entry>CUUAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGU</entry></row><row><entry>UGAAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGAC</entry></row><row><entry>UUGUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUU</entry></row><row><entry>AGGUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCG</entry></row><row><entry>ACUUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGG</entry></row><row><entry>UGCUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGG</entry></row><row><entry>UUAAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCA</entry></row><row><entry>UUUAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAA</entry></row><row><entry>ACCAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAG</entry></row><row><entry>CCUGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAA</entry></row><row><entry>CGAUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGG</entry></row><row><entry>GGCAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUA</entry></row><row><entry>UUCCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUU</entry></row><row><entry>GUCCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUG</entry></row><row><entry>AUGACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAU</entry></row><row><entry>CAGGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCU</entry></row><row><entry>UGAGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUG</entry></row><row><entry>AUAUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAA</entry></row><row><entry>CUGUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGC</entry></row><row><entry>CCGGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUA</entry></row><row><entry>AACGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACC</entry></row><row><entry>UGCACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGC</entry></row><row><entry>UGUGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGA</entry></row><row><entry>CACUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCU</entry></row><row><entry>GCAUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCCGUAAUC</entry></row><row><entry>CGGGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGG</entry></row><row><entry>AGGAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCA</entry></row><row><entry>GCUUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUC</entry></row><row><entry>UGAAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCC</entry></row><row><entry>CAAGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUG</entry></row><row><entry>AAGUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACG</entry></row><row><entry>UCGUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAG</entry></row><row><entry>UACGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCG</entry></row><row><entry>GUAGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGA</entry></row><row><entry>GUUCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGG</entry></row><row><entry>UGUGUAAGGACUCACAACGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGU</entry></row><row><entry>AACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;5:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;5)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>AUAUAAUGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGAC</entry></row><row><entry>UAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUAA</entry></row><row><entry>GCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUGU</entry></row><row><entry>UUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACAU</entry></row><row><entry>CUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGAG</entry></row><row><entry>CAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAGG</entry></row><row><entry>GUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUGG</entry></row><row><entry>UAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGUG</entry></row><row><entry>AACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAAA</entry></row><row><entry>CCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUGG</entry></row><row><entry>GUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUCU</entry></row><row><entry>UAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUUG</entry></row><row><entry>AAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACUU</entry></row><row><entry>GUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUAG</entry></row><row><entry>GUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGAC</entry></row><row><entry>UUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGUG</entry></row><row><entry>CUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGUU</entry></row><row><entry>AAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAUU</entry></row><row><entry>UAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAAC</entry></row><row><entry>CAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGCC</entry></row><row><entry>UGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAACG</entry></row><row><entry>AUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGGG</entry></row><row><entry>CAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAUU</entry></row><row><entry>CCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUGU</entry></row><row><entry>CCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGAU</entry></row><row><entry>GACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUCA</entry></row><row><entry>GGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUUG</entry></row><row><entry>AGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGAU</entry></row><row><entry>AUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAACU</entry></row><row><entry>GUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCCC</entry></row><row><entry>GGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAAA</entry></row><row><entry>CGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCUG</entry></row><row><entry>CACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCUG</entry></row><row><entry>UGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGACA</entry></row><row><entry>CUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUGC</entry></row><row><entry>AUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCCGUAAUCCG</entry></row><row><entry>GGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGAG</entry></row><row><entry>GAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAGC</entry></row><row><entry>UUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCUG</entry></row><row><entry>AAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCCA</entry></row><row><entry>AGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGAA</entry></row><row><entry>GUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGUC</entry></row><row><entry>GUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGUA</entry></row><row><entry>CGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGGU</entry></row><row><entry>AGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAGU</entry></row><row><entry>UCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGUG</entry></row><row><entry>UGUAAGGACGACCUUCGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGUA</entry></row><row><entry>ACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;6:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;6)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>AUAUAAUGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGAC</entry></row><row><entry>UAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUAA</entry></row><row><entry>GCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUGU</entry></row><row><entry>UUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACAU</entry></row><row><entry>CUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGAG</entry></row><row><entry>CAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAGG</entry></row><row><entry>GUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUGG</entry></row><row><entry>UAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGUG</entry></row><row><entry>AACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAAA</entry></row><row><entry>CCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUGG</entry></row><row><entry>GUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUCU</entry></row><row><entry>UAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUUG</entry></row><row><entry>AAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACUU</entry></row><row><entry>GUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUAG</entry></row><row><entry>GUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGAC</entry></row><row><entry>UUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGUG</entry></row><row><entry>CUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGUU</entry></row><row><entry>AAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAUU</entry></row><row><entry>UAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAAC</entry></row><row><entry>CAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGCC</entry></row><row><entry>UGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAACG</entry></row><row><entry>AUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGGG</entry></row><row><entry>CAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAUU</entry></row><row><entry>CCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUGU</entry></row><row><entry>CCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGAU</entry></row><row><entry>GACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUCA</entry></row><row><entry>GGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUUG</entry></row><row><entry>AGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGAU</entry></row><row><entry>AUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAACU</entry></row><row><entry>GUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCCC</entry></row><row><entry>GGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAAA</entry></row><row><entry>CGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCUG</entry></row><row><entry>CACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCUG</entry></row><row><entry>UGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGACA</entry></row><row><entry>CUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUGC</entry></row><row><entry>AUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCCGUAAUCCG</entry></row><row><entry>GGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGAG</entry></row><row><entry>GAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAGC</entry></row><row><entry>UUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCUG</entry></row><row><entry>AAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCCA</entry></row><row><entry>AGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGAA</entry></row><row><entry>GUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGUC</entry></row><row><entry>GUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGUA</entry></row><row><entry>CGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGGU</entry></row><row><entry>AGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAGU</entry></row><row><entry>UCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGUG</entry></row><row><entry>UGUAAGGACUCACAACGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGUAA</entry></row><row><entry>CAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;7:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;7)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>GUUAUAGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGACU</entry></row><row><entry>AAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUAAG</entry></row><row><entry>CGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUGUU</entry></row><row><entry>UCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACAUC</entry></row><row><entry>UAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGAGC</entry></row><row><entry>AGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAGGG</entry></row><row><entry>UGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUGGU</entry></row><row><entry>AUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGUGA</entry></row><row><entry>ACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAAAC</entry></row><row><entry>CGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUGGG</entry></row><row><entry>UCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUCUU</entry></row><row><entry>AACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUUGA</entry></row><row><entry>AGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACUUG</entry></row><row><entry>UGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUAGG</entry></row><row><entry>UAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGACU</entry></row><row><entry>UACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGUGC</entry></row><row><entry>UAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGUUA</entry></row><row><entry>AGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAUUU</entry></row><row><entry>AAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAACC</entry></row><row><entry>AUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGCCU</entry></row><row><entry>GCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAACGA</entry></row><row><entry>UAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGGGC</entry></row><row><entry>AGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAUUC</entry></row><row><entry>CUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUGUC</entry></row><row><entry>CCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGAUG</entry></row><row><entry>ACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUCAG</entry></row><row><entry>GUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUUGA</entry></row><row><entry>GAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGAUA</entry></row><row><entry>UGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAACUG</entry></row><row><entry>UUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCCCG</entry></row><row><entry>GUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAAAC</entry></row><row><entry>GGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCUGC</entry></row><row><entry>ACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCUGU</entry></row><row><entry>GAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGACAC</entry></row><row><entry>UGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUGCA</entry></row><row><entry>UGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCGGUAAUCCGG</entry></row><row><entry>GUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGAGG</entry></row><row><entry>AGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAGCU</entry></row><row><entry>UGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCUGA</entry></row><row><entry>AUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCCAA</entry></row><row><entry>GAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGAAG</entry></row><row><entry>UAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGUCG</entry></row><row><entry>UGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGUAC</entry></row><row><entry>GAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGGUA</entry></row><row><entry>GCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAGUU</entry></row><row><entry>CUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGUGU</entry></row><row><entry>GUAAGGACAUCCCAGGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGUAA</entry></row><row><entry>CAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;8:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;8)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>CAUCAUGGGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGA</entry></row><row><entry>CUAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUA</entry></row><row><entry>AGCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUG</entry></row><row><entry>UUUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACA</entry></row><row><entry>UCUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGA</entry></row><row><entry>GCAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAG</entry></row><row><entry>GGUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUG</entry></row><row><entry>GUAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGU</entry></row><row><entry>GAACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAA</entry></row><row><entry>ACCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUG</entry></row><row><entry>GGUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUC</entry></row><row><entry>UUAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUU</entry></row><row><entry>GAAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACU</entry></row><row><entry>UGUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUA</entry></row><row><entry>GGUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGA</entry></row><row><entry>CUUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGU</entry></row><row><entry>GCUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGU</entry></row><row><entry>UAAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAU</entry></row><row><entry>UUAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAA</entry></row><row><entry>CCAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGC</entry></row><row><entry>CUGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAAC</entry></row><row><entry>GAUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGG</entry></row><row><entry>GCAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAU</entry></row><row><entry>UCCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUG</entry></row><row><entry>UCCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGA</entry></row><row><entry>UGACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUC</entry></row><row><entry>AGGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUU</entry></row><row><entry>GAGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGA</entry></row><row><entry>UAUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAAC</entry></row><row><entry>UGUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCC</entry></row><row><entry>CGGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAA</entry></row><row><entry>ACGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCU</entry></row><row><entry>GCACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCU</entry></row><row><entry>GUGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGAC</entry></row><row><entry>ACUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUG</entry></row><row><entry>CAUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCGGUAAUCC</entry></row><row><entry>GGGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGA</entry></row><row><entry>GGAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAG</entry></row><row><entry>CUUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCU</entry></row><row><entry>GAAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCC</entry></row><row><entry>AAGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGA</entry></row><row><entry>AGUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGU</entry></row><row><entry>CGUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGU</entry></row><row><entry>ACGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGG</entry></row><row><entry>UAGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAG</entry></row><row><entry>UUCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGU</entry></row><row><entry>GUGUAAGGACACAUAAUGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGU</entry></row><row><entry>AACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;9:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;9)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>AGUCAAUAAGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCG</entry></row><row><entry>ACUAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAU</entry></row><row><entry>AAGCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGU</entry></row><row><entry>GUUUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAAC</entry></row><row><entry>AUCUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGG</entry></row><row><entry>AGCAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACA</entry></row><row><entry>GGGUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGU</entry></row><row><entry>GGUAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAG</entry></row><row><entry>UGAACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGA</entry></row><row><entry>AACCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAU</entry></row><row><entry>GGGUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGU</entry></row><row><entry>CUUAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGU</entry></row><row><entry>UGAAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGAC</entry></row><row><entry>UUGUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUU</entry></row><row><entry>AGGUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCG</entry></row><row><entry>ACUUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGG</entry></row><row><entry>UGCUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGG</entry></row><row><entry>UUAAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCA</entry></row><row><entry>UUUAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAA</entry></row><row><entry>ACCAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAG</entry></row><row><entry>CCUGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAA</entry></row><row><entry>CGAUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGG</entry></row><row><entry>GGCAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUA</entry></row><row><entry>UUCCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUU</entry></row><row><entry>GUCCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUG</entry></row><row><entry>AUGACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAU</entry></row><row><entry>CAGGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCU</entry></row><row><entry>UGAGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUG</entry></row><row><entry>AUAUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAA</entry></row><row><entry>CUGUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGC</entry></row><row><entry>CCGGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUA</entry></row><row><entry>AACGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACC</entry></row><row><entry>UGCACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGC</entry></row><row><entry>UGUGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGA</entry></row><row><entry>CACUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCU</entry></row><row><entry>GCAUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCCGUAAUC</entry></row><row><entry>CGGGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGG</entry></row><row><entry>AGGAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCA</entry></row><row><entry>GCUUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUC</entry></row><row><entry>UGAAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCC</entry></row><row><entry>CAAGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUG</entry></row><row><entry>AAGUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACG</entry></row><row><entry>UCGUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAG</entry></row><row><entry>UACGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCG</entry></row><row><entry>GUAGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGA</entry></row><row><entry>GUUCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGG</entry></row><row><entry>UGUGUAAGGACAUCCCAGGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCG</entry></row><row><entry>UAACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;10:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;10)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>CAUCAUGGGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGA</entry></row><row><entry>CUAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUA</entry></row><row><entry>AGCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUG</entry></row><row><entry>UUUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACA</entry></row><row><entry>UCUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGA</entry></row><row><entry>GCAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAG</entry></row><row><entry>GGUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUG</entry></row><row><entry>GUAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGU</entry></row><row><entry>GAACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAA</entry></row><row><entry>ACCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUG</entry></row><row><entry>GGUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUC</entry></row><row><entry>UUAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUU</entry></row><row><entry>GAAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACU</entry></row><row><entry>UGUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUA</entry></row><row><entry>GGUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGA</entry></row><row><entry>CUUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGU</entry></row><row><entry>GCUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGU</entry></row><row><entry>UAAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAU</entry></row><row><entry>UUAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAA</entry></row><row><entry>CCAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGC</entry></row><row><entry>CUGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAAC</entry></row><row><entry>GAUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGG</entry></row><row><entry>GCAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAU</entry></row><row><entry>UCCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUG</entry></row><row><entry>UCCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGA</entry></row><row><entry>UGACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUC</entry></row><row><entry>AGGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUU</entry></row><row><entry>GAGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGA</entry></row><row><entry>UAUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAAC</entry></row><row><entry>UGUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCC</entry></row><row><entry>CGGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAA</entry></row><row><entry>ACGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCU</entry></row><row><entry>GCACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCU</entry></row><row><entry>GUGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGAC</entry></row><row><entry>ACUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUG</entry></row><row><entry>CAUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCGGUAAUCC</entry></row><row><entry>GGGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGA</entry></row><row><entry>GGAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAG</entry></row><row><entry>CUUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCU</entry></row><row><entry>GAAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCC</entry></row><row><entry>AAGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGA</entry></row><row><entry>AGUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGU</entry></row><row><entry>CGUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGU</entry></row><row><entry>ACGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGG</entry></row><row><entry>UAGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAG</entry></row><row><entry>UUCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGU</entry></row><row><entry>GUGUAAGGACUCACAACGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGUA</entry></row><row><entry>ACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;11:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;11)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>GUUAUAGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGACU</entry></row><row><entry>AAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUAAG</entry></row><row><entry>CGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUGUU</entry></row><row><entry>UCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACAUC</entry></row><row><entry>UAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGAGC</entry></row><row><entry>AGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAGGG</entry></row><row><entry>UGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUGGU</entry></row><row><entry>AUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGUGA</entry></row><row><entry>ACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAAAC</entry></row><row><entry>CGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUGGG</entry></row><row><entry>UCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUCUU</entry></row><row><entry>AACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUUGA</entry></row><row><entry>AGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACUUG</entry></row><row><entry>UGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUAGG</entry></row><row><entry>UAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGACU</entry></row><row><entry>UACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGUGC</entry></row><row><entry>UAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGUUA</entry></row><row><entry>AGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAUUU</entry></row><row><entry>AAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAACC</entry></row><row><entry>AUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGCCU</entry></row><row><entry>GCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAACGA</entry></row><row><entry>UAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGGGC</entry></row><row><entry>AGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAUUC</entry></row><row><entry>CUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUGUC</entry></row><row><entry>CCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGAUG</entry></row><row><entry>ACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUCAG</entry></row><row><entry>GUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUUGA</entry></row><row><entry>GAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGAUA</entry></row><row><entry>UGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAACUG</entry></row><row><entry>UUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCCCG</entry></row><row><entry>GUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAAAC</entry></row><row><entry>GGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCUGC</entry></row><row><entry>ACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCUGU</entry></row><row><entry>GAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGACAC</entry></row><row><entry>UGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUGCA</entry></row><row><entry>UGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCGGUAAUCCGG</entry></row><row><entry>GUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGAGG</entry></row><row><entry>AGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAGCU</entry></row><row><entry>UGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCUGA</entry></row><row><entry>AUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCCAA</entry></row><row><entry>GAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGAAG</entry></row><row><entry>UAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGUCG</entry></row><row><entry>UGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGUAC</entry></row><row><entry>GAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGGUA</entry></row><row><entry>GCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAGUU</entry></row><row><entry>CUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGUGU</entry></row><row><entry>GUAAGGACGACCUUCGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGUAA</entry></row><row><entry>CAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;12:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;12)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>AGUCAAUAAGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCG</entry></row><row><entry>ACUAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAU</entry></row><row><entry>AAGCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGU</entry></row><row><entry>GUUUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAAC</entry></row><row><entry>AUCUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGG</entry></row><row><entry>AGCAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACA</entry></row><row><entry>GGGUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGU</entry></row><row><entry>GGUAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAG</entry></row><row><entry>UGAACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGA</entry></row><row><entry>AACCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAU</entry></row><row><entry>GGGUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGU</entry></row><row><entry>CUUAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGU</entry></row><row><entry>UGAAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGAC</entry></row><row><entry>UUGUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUU</entry></row><row><entry>AGGUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCG</entry></row><row><entry>ACUUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGG</entry></row><row><entry>UGCUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGG</entry></row><row><entry>UUAAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCA</entry></row><row><entry>UUUAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAA</entry></row><row><entry>ACCAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAG</entry></row><row><entry>CCUGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAA</entry></row><row><entry>CGAUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGG</entry></row><row><entry>GGCAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUA</entry></row><row><entry>UUCCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUU</entry></row><row><entry>GUCCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUG</entry></row><row><entry>AUGACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAU</entry></row><row><entry>CAGGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCU</entry></row><row><entry>UGAGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUG</entry></row><row><entry>AUAUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAA</entry></row><row><entry>CUGUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGC</entry></row><row><entry>CCGGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUA</entry></row><row><entry>AACGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACC</entry></row><row><entry>UGCACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGC</entry></row><row><entry>UGUGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGA</entry></row><row><entry>CACUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCU</entry></row><row><entry>GCAUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCCGUAAUC</entry></row><row><entry>CGGGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGG</entry></row><row><entry>AGGAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCA</entry></row><row><entry>GCUUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUC</entry></row><row><entry>UGAAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCC</entry></row><row><entry>CAAGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUG</entry></row><row><entry>AAGUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACG</entry></row><row><entry>UCGUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAG</entry></row><row><entry>UACGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCG</entry></row><row><entry>GUAGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGA</entry></row><row><entry>GUUCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGG</entry></row><row><entry>UGUGUAAGGACACAUAAUGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCG</entry></row><row><entry>UAACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;13:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;13)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>CAUCAUGGGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGA</entry></row><row><entry>CUAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUA</entry></row><row><entry>AGCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUG</entry></row><row><entry>UUUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACA</entry></row><row><entry>UCUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGA</entry></row><row><entry>GCAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAG</entry></row><row><entry>GGUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUG</entry></row><row><entry>GUAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGU</entry></row><row><entry>GAACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAA</entry></row><row><entry>ACCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUG</entry></row><row><entry>GGUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUC</entry></row><row><entry>UUAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUU</entry></row><row><entry>GAAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACU</entry></row><row><entry>UGUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUA</entry></row><row><entry>GGUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGA</entry></row><row><entry>CUUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGU</entry></row><row><entry>GCUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGU</entry></row><row><entry>UAAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAU</entry></row><row><entry>UUAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAA</entry></row><row><entry>CCAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGC</entry></row><row><entry>CUGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAAC</entry></row><row><entry>GAUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGG</entry></row><row><entry>GCAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAU</entry></row><row><entry>UCCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUG</entry></row><row><entry>UCCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGA</entry></row><row><entry>UGACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUC</entry></row><row><entry>AGGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUU</entry></row><row><entry>GAGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGA</entry></row><row><entry>UAUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAAC</entry></row><row><entry>UGUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCC</entry></row><row><entry>CGGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAA</entry></row><row><entry>ACGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCU</entry></row><row><entry>GCACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCU</entry></row><row><entry>GUGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGAC</entry></row><row><entry>ACUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUG</entry></row><row><entry>CAUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCGGUAAUCC</entry></row><row><entry>GGGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGA</entry></row><row><entry>GGAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAG</entry></row><row><entry>CUUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCU</entry></row><row><entry>GAAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCC</entry></row><row><entry>AAGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGA</entry></row><row><entry>AGUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGU</entry></row><row><entry>CGUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGU</entry></row><row><entry>ACGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGG</entry></row><row><entry>UAGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAG</entry></row><row><entry>UUCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGU</entry></row><row><entry>GUGUAAGGACGACCUUCGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGU</entry></row><row><entry>AACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;14:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;14)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>CAUCAUGGGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGA</entry></row><row><entry>CUAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUA</entry></row><row><entry>AGCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUG</entry></row><row><entry>UUUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACA</entry></row><row><entry>UCUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGA</entry></row><row><entry>GCAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAG</entry></row><row><entry>GGUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUG</entry></row><row><entry>GUAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGU</entry></row><row><entry>GAACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAA</entry></row><row><entry>ACCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUG</entry></row><row><entry>GGUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUC</entry></row><row><entry>UUAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUU</entry></row><row><entry>GAAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACU</entry></row><row><entry>UGUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUA</entry></row><row><entry>GGUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGA</entry></row><row><entry>CUUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGU</entry></row><row><entry>GCUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGU</entry></row><row><entry>UAAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAU</entry></row><row><entry>UUAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAA</entry></row><row><entry>CCAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGC</entry></row><row><entry>CUGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAAC</entry></row><row><entry>GAUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGG</entry></row><row><entry>GCAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAU</entry></row><row><entry>UCCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUG</entry></row><row><entry>UCCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGA</entry></row><row><entry>UGACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUC</entry></row><row><entry>AGGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUU</entry></row><row><entry>GAGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGA</entry></row><row><entry>UAUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAAC</entry></row><row><entry>UGUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCC</entry></row><row><entry>CGGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAA</entry></row><row><entry>ACGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCU</entry></row><row><entry>GCACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCU</entry></row><row><entry>GUGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGAC</entry></row><row><entry>ACUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUG</entry></row><row><entry>CAUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCGGUAAUCC</entry></row><row><entry>GGGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGA</entry></row><row><entry>GGAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAG</entry></row><row><entry>CUUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCU</entry></row><row><entry>GAAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCC</entry></row><row><entry>AAGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGA</entry></row><row><entry>AGUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGU</entry></row><row><entry>CGUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGU</entry></row><row><entry>ACGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGG</entry></row><row><entry>UAGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAG</entry></row><row><entry>UUCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGU</entry></row><row><entry>GUGUAAGGACAUCCCAGGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGU</entry></row><row><entry>AACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;15:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;15)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>GUUAUAGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGACU</entry></row><row><entry>AAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUAAG</entry></row><row><entry>CGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUGUU</entry></row><row><entry>UCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACAUC</entry></row><row><entry>UAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGAGC</entry></row><row><entry>AGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAGGG</entry></row><row><entry>UGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUGGU</entry></row><row><entry>AUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGUGA</entry></row><row><entry>ACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAAAC</entry></row><row><entry>CGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUGGG</entry></row><row><entry>UCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUCUU</entry></row><row><entry>AACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUUGA</entry></row><row><entry>AGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACUUG</entry></row><row><entry>UGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUAGG</entry></row><row><entry>UAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGACU</entry></row><row><entry>UACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGUGC</entry></row><row><entry>UAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGUUA</entry></row><row><entry>AGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAUUU</entry></row><row><entry>AAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAACC</entry></row><row><entry>AUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGCCU</entry></row><row><entry>GCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAACGA</entry></row><row><entry>UAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGGGC</entry></row><row><entry>AGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAUUC</entry></row><row><entry>CUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUGUC</entry></row><row><entry>CCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGAUG</entry></row><row><entry>ACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUCAG</entry></row><row><entry>GUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUUGA</entry></row><row><entry>GAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGAUA</entry></row><row><entry>UGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAACUG</entry></row><row><entry>UUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCCCG</entry></row><row><entry>GUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAAAC</entry></row><row><entry>GGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCUGC</entry></row><row><entry>ACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCUGU</entry></row><row><entry>GAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGACAC</entry></row><row><entry>UGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUGCA</entry></row><row><entry>UGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCGGUAAUCCGG</entry></row><row><entry>GUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGAGG</entry></row><row><entry>AGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAGCU</entry></row><row><entry>UGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCUGA</entry></row><row><entry>AUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCCAA</entry></row><row><entry>GAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGAAG</entry></row><row><entry>UAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGUCG</entry></row><row><entry>UGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGUAC</entry></row><row><entry>GAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGGUA</entry></row><row><entry>GCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAGUU</entry></row><row><entry>CUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGUGU</entry></row><row><entry>GUAAGGACACAUAAUGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGUAA</entry></row><row><entry>CAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry> </entry></row><row><entry>Pair&#x2003;16:&#x2003;Full&#x2003;Sequence&#x2003;(SEQ&#x2003;ID&#x2003;NO:&#x2003;16)</entry></row><row><entry>AAAUUGAAGAGUUUGAUCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUC</entry></row><row><entry>GAACGGUAACAGGAAGAAGCUUGCUUCUUUGCUGACGAGUGGCGGACGGGUGAGUAAUGUCUG</entry></row><row><entry>GGAAACUGCCUGAUGGAGGGGGAUAACUACUGGAAACGGUAGCUAAUACCGCAUAACGUCGCA</entry></row><row><entry>AGACCAAAGAGGGGGACCUUCGGGCCUCUUGCCAUCGGAUGUGCCCAGAUGGGAUUAGCUAGU</entry></row><row><entry>AGGUGGGGUAACGGCUCACCUAGGCGACGAUCCCUAGCUGGUCUGAGAGGAUGACCAGCCACA</entry></row><row><entry>CUGGAACUGAGACACGGUCCAGACUCCUACGGGAGGCAGCAGUGGGGAAUAUUGCACAAUGGG</entry></row><row><entry>CGCAAGCCUGAUGCAGCCAUGCCGCGUGUAUGAAGAAGGCCUUCGGGUUGUAAAGUACUUUCA</entry></row><row><entry>GCGGGGAGGAAGGGAGUAAAGUUAAUACCUUUGCUCAUUGACGUUACCCGCAGAAGAAGCACC</entry></row><row><entry>GGCUAACUCCGUGCCAGCAGCCGCGGUAAUACGGAGGGUGCAAGCGUUAAUCGGAAUUACUGG</entry></row><row><entry>GCGUAAAGCGCACGCAGGCGGUUUGUUAAGUCAGAUGUGAAAUCCCCGGGCUCAACCUGGGAA</entry></row><row><entry>CUGCAUCUGAUACUGGCAAGCUUGAGUCUCGUAGAGGGGGGUAGAAUUCCAGGUGUAGCGGUG</entry></row><row><entry>AAAUGCGUAGAGAUCUGGAGGAAUACCGGUGGCGAAGGCGGCCCCCUGGACGAAGACUGACGC</entry></row><row><entry>UCAGGUGCGAAAGCGUGGGGAGCAAACAGGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGA</entry></row><row><entry>UGUCGACUUGGAGGUUGUGCCCUUGAGGCGUGGCUUCCGGAGCUAACGCGUUAAGUCGACCGC</entry></row><row><entry>CUGGGGAGUACGGCCGCAAGGUUAAAACUCAAAUGAAUUGACGGGGGCCCGCACAAGCGGUGG</entry></row><row><entry>AGCAUGUGGUUUAAUUCGAUGCAACGCGAAGAACCUUACCUGGUCUUGACAUCCACGGAAGUU</entry></row><row><entry>UUCAGAGAUGAGAAUGUGCCUUCGGGAACCGUGAGACAGGUGCUGCAUGGCUGUCGUCAGCUC</entry></row><row><entry>GUGUUGUGAAAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCCUUUGUUGCCAGCGG</entry></row><row><entry>UCCGGCCGGGAACUCAAAGGAGACUGCCAGUGAUAAACUGGAGGAAGGUGGGGAUGACGUCAA</entry></row><row><entry>GUCAUCAUGGCCCUUACGACCAGGGCUACACACGUGCUACAAUGGCGCAUACAAAGAGAAGCG</entry></row><row><entry>ACCUCGCGAGAGCAAGCGGACCUCAUAAAGUGCGUCGUAGUCCGGAUUGGAGUCUGCAACUCG</entry></row><row><entry>ACUCCAUGAAGUCGGAAUCGCUAGUAAUCGUGGAUCAGAAUGCCACGGUGAAUACGUUCCCGG</entry></row><row><entry>GCCUUGUACACACCGCCCGUCACACCAUGGGAGUGGGUUGCAAAAGAAGUAGGUAGCUUAACC</entry></row><row><entry>AUAUAAUGUCUUGAGCUAACCGGUACUAAUGAACCGUGAGGCUUAACCGAGAGGUUAAGCGAC</entry></row><row><entry>UAAGCGUACACGGUGGAUGCCCUGGCAGUCAGAGGCGAUGAAGGACGUGCUAAUCUGCGAUAA</entry></row><row><entry>GCGUCGGUAAGGUGAUAUGAACCGUUAUAACCGGCGAUUUCCGAAUGGGGAAACCCAGUGUGU</entry></row><row><entry>UUCGACACACUAUCAUUAACUGAAUCCAUAGGUUAAUGAGGCGAACCGGGGGAACUGAAACAU</entry></row><row><entry>CUAAGUACCCCGAGGAAAAGAAAUCAACCGAGAUUCCCCCAGUAGCGGCGAGCGAACGGGGAG</entry></row><row><entry>CAGCCCAGAGCCUGAAUCAGUGUGUGUGUUAGUGGAAGCGUCUGGAAAGGCGCGCGAUACAGG</entry></row><row><entry>GUGACAGCCCCGUACACAAAAAUGCACAUGCUGUGAGCUCGAUGAGUAGGGCGGGACACGUGG</entry></row><row><entry>UAUCCUGUCUGAAUAUGGGGGGACCAUCCUCCAAGGCUAAAUACUCCUGACUGACCGAUAGUG</entry></row><row><entry>AACCAGUACCGUGAGGGAAAGGCGAAAAGAACCCCGGCGAGGGGAGUGAAAAAGAACCUGAAA</entry></row><row><entry>CCGUGUACGUACAAGCAGUGGGAGCACGCUUAGGCGUGUGACUGCGUACCUUUUGUAUAAUGG</entry></row><row><entry>GUCAGCGACUUAUAUUCUGUAGCAAGGUUAACCGAAUAGGGGAGCCGAAGGGAAACCGAGUCU</entry></row><row><entry>UAACUGGGCGUUAAGUUGCAGGGUAUAGACCCGAAACCCGGUGAUCUAGCCAUGGGCAGGUUG</entry></row><row><entry>AAGGUUGGGUAACACUAACUGGAGGACCGAACCGACUAAUGUUGAAAAAUUAGCGGAUGACUU</entry></row><row><entry>GUGGCUGGGGGUGAAAGGCCAAUCAAACCGGGAGAUAGCUGGUUCUCCCCGAAAGCUAUUUAG</entry></row><row><entry>GUAGCGCCUCGUGAAUUCAUCUCCGGGGGUAGAGCACUGUUUCGGCAAGGGGGUCAUCCCGAC</entry></row><row><entry>UUACCAACCCGAUGCAAACUGCGAAUACCGGAGAAUGUUAUCACGGGAGACACACGGCGGGUG</entry></row><row><entry>CUAACGUCCGUCGUGAAGAGGGAAACAACCCAGACCGCCAGCUAAGGUCCCAAAGUCAUGGUU</entry></row><row><entry>AAGUGGGAAACGAUGUGGGAAGGCCCAGACAGCCAGGAUGUUGGCUUAGAAGCAGCCAUCAUU</entry></row><row><entry>UAAAGAAAGCGUAAUAGCUCACUGGUCGAGUCGGCCUGCGCGGAAGAUGUAACGGGGCUAAAC</entry></row><row><entry>CAUGCACCGAAGCUGCGGCAGCGACGCUUAUGCGUUGUUGGGUAGGGGAGCGUUCUGUAAGCC</entry></row><row><entry>UGCGAAGGUGUGCUGUGAGGCAUGCUGGAGGUAUCAGAAGUGCGAAUGCUGACAUAAGUAACG</entry></row><row><entry>AUAAAGCGGGUGAAAAGCCCGCUCGCCGGAAGACCAAGGGUUCCUGUCCAACGUUAAUCGGGG</entry></row><row><entry>CAGGGUGAGUCGACCCCUAAGGCGAGGCCGAAAGGCGUAGUCGAUGGGAAACAGGUUAAUAUU</entry></row><row><entry>CCUGUACUUGGUGUUACUGCGAAGGGGGGACGGAGAAGGCUAUGUUGGCCGGGCGACGGUUGU</entry></row><row><entry>CCCGGUUUAAGCGUGUAGGCUGGUUUUCCAGGCAAAUCCGGAAAAUCAAGGCUGAGGCGUGAU</entry></row><row><entry>GACGAGGCACUACGGUGCUGAAGCAACAAAUGCCCUGCUUCCAGGAAAAGCCUCUAAGCAUCA</entry></row><row><entry>GGUAACAUCAAAUCGUACCCCAAACCGACACAGGUGGUCAGGUAGAGAAUACCAAGGCGCUUG</entry></row><row><entry>AGAGAACUCGGGUGAAGGAACUAGGCAAAAUGGUGCCGUAACUUCGGGAGAAGGCACGCUGAU</entry></row><row><entry>AUGUAGGUGAGGUCCCUCGCGGAUGGAGCUGAAAUCAGUCGAAGAUACCAGCUGGCUGCAACU</entry></row><row><entry>GUUUAUUAAAAACACAGCACUGUGCAAACACGAAAGUGGACGUAUACGGUGUGACGCCUGCCC</entry></row><row><entry>GGUGCCGGAAGGUUAAUUGAUGGGGUUAGCGCAAGCGAAGCUCUUGAUCGAAGCCCCGGUAAA</entry></row><row><entry>CGGCGGCCGUAACUAUAACGGUCCUAAGGUAGCGAAAUUCCUUGUCGGGUAAGUUCCGACCUG</entry></row><row><entry>CACGAAUGGCGUAAUGAUGGCCAGGCUGUCUCCACCCGAGACUCAGUGAAAUUGAACUCGCUG</entry></row><row><entry>UGAAGAUGCAGUGUACCCGCGGCAAGACGGAAAGACCCCGUGAACCUUUACUAUAGCUUGACA</entry></row><row><entry>CUGAACAUUGAGCCUUGAUGUGUAGGAUAGGUGGGAGGCUUUGAAGUGUGGACGCCAGUCUGC</entry></row><row><entry>AUGGAGCCGAGCUUGAAAUACCACCCUUUAAUGUUUGAUGUUCUAACGUUGACCCGUAAUCCG</entry></row><row><entry>GGUUGCGGACAGUGUCUGGUGGGUAGUUUGACUGGGGCGGUCUCCUCCUAAAGAGUAACGGAG</entry></row><row><entry>GAGCACGAAGGUUGGCUAAUCCUGGUCGGACAUCAGGAGGUUAGUGCAAUGGCAUAAGCCAGC</entry></row><row><entry>UUGACUGCGAGCGUGACGGCGCGAGCAGGUGCGAAAGCAGGUCAUAGUGAUCCGGUGGUUCUG</entry></row><row><entry>AAUGGAAGGGCCAUCGCUCAACGGAUAAAAGGUACUCCGGGGAUAACAGGCUGAUACCGCCCA</entry></row><row><entry>AGAGUUCAUAUCGACGGCGGUGUUUGGCACCUCGAUGUCGGCUCAUCACAUCCUGGGGCUGAA</entry></row><row><entry>GUAGGUCCCAAGGGUAUGGCUGUUCGCCAUUUAAAGUGGUACGCGAGCUGGGUUUAGAACGUC</entry></row><row><entry>GUGAGACAGUUCGGUCCCUAUCUGCCGUGGGCGCUGGAGAACUGAGGGGGGCUGCUCCUAGUA</entry></row><row><entry>CGAGAGGACCGGAGUGGACGCAUCACUGGUGUUCGGGUUGUCAUGCCAAUGGCACUGCCCGGU</entry></row><row><entry>AGCUAAAUGCGGAAGAGAUAAGUGCUGAAAGCAUCUAAGCACGAAACUUGCCCCGAGAUGAGU</entry></row><row><entry>UCUCCCUGACCCUUUAAGGGUCCUGAAGGAACGUUGAAGACGACGACGUUGAUAGGCCGGGUG</entry></row><row><entry>UGUAAGGACACAUAAUGGGAGGGCGCUUACCACUUUGUGAUUCAUGACUGGGGUGAAGUCGUA</entry></row><row><entry>ACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACUGUGGUA</entry></row><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0213" num="0241">It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been illustrated by specific embodiments and optional features, modification and/or variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.</p><p id="p-0214" num="0242">Citations to a number of patent and non-patent references may be made herein. Any cited references are incorporated by reference herein in their entireties. In the event that there is an inconsistency between a definition of a term in the specification as compared to a definition of the term in a cited reference, the term should be interpreted based on the definition in the specification.</p><p id="p-0215" num="0000">2. The engineered ribosome of claim <b>1</b>, wherein the T1 polynucleotide domain comprises 5&#x2032;-GUUAUA-3&#x2032; and the T2 polynucleotide domain comprises 5&#x2032;-UCACAAG-3&#x2032; (Pair 1).<br/>3. The engineered ribosome of claim <b>1</b>, wherein the T1 polynucleotide domain comprises 5&#x2032;-AGUCAAUAA-3&#x2032; and T2 polynucleotide comprises 5&#x2032;-GACCUUCG-3&#x2032; (Pair 2).<br/>4. The engineered ribosome of claim <b>1</b> comprising SEQ ID NO: 1, or any one SEQ ID NOs 1-16.<br/>5. A polynucleotide, the polynucleotide encoding the rRNA of the engineered ribosome of claim <b>1</b>.<br/>6. The polynucleotide of claim <b>5</b>, wherein the polynucleotide is in a vector.<br/>7. The polynucleotide of claim <b>6</b>, wherein the polynucleotide further comprises a gene to be expressed by the engineered ribosome.<br/>8. The polynucleotide of claim <b>7</b>, wherein the engineered ribosome comprises a modified anti-Shine-Dalgarno sequence and the gene comprises a complementary Shine-Dalgarno sequence to the engineered ribosome.<br/>9. The polynucleotide of claim <b>8</b> wherein the gene comprises one or more codons, wherein at least one of the one or more codons comprises a non-canonical codon or an unnatural codon.<br/>10. The polynucleotide of claim <b>9</b>, wherein the non-canonical codon or the unnatural codon codes for a non-canonical amino acid, or a non-amino acid monomer.<br/>11. A method for preparing an engineered ribosome, the method comprising expressing the polynucleotide of claim <b>5</b>.<br/>12. A cell, the cell comprising (i) the polynucleotide of claim <b>5</b>, (ii) the engineered ribosome of claim <b>1</b>, or both (i) and (ii).<br/>13. A cell, the cell comprising a first protein translation mechanism and a second protein translation mechanism;</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002758A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-chemistry idref="CHEM-US-00001" cdx-file="US20230002758A1-20230105-C00001.CDX" mol-file="US20230002758A1-20230105-C00001.MOL"/><us-math idrefs="MATH-US-00001" nb-file="US20230002758A1-20230105-M00001.NB"><img id="EMI-M00001" he="8.13mm" wi="76.20mm" file="US20230002758A1-20230105-M00001.TIF" alt="embedded image " img-content="math" img-format="tif"/></us-math><us-math idrefs="MATH-US-00002" nb-file="US20230002758A1-20230105-M00002.NB"><img id="EMI-M00002" he="6.01mm" wi="76.20mm" file="US20230002758A1-20230105-M00002.TIF" alt="embedded image " img-content="math" img-format="tif"/></us-math><us-claim-statement>What is claimed:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An engineered ribosome, the engineered ribosome comprising:<claim-text>a) a small subunit comprising a 16S rRNA polynucleotide sequence or variant thereof,</claim-text><claim-text>b) a large subunit comprising a 23S rRNA polynucleotide sequence or variant thereof, and</claim-text><claim-text>c) a linking moiety comprising<claim-text>a T1 polynucleotide domain and a T2 polynucleotide domain, wherein the linking moiety links the 16S RNA and the 23S rRNA, thereby linking the large and small ribosomal subunits;</claim-text><claim-text>wherein the linking moiety covalently bonds helix 101 of the 23S rRNA large subunit to helix 44 of the 16s rRNA of the small subunit; and</claim-text><claim-text>wherein the T1 domain and the T2 domain are paired, and the T1 and T2 domains comprise one of Pairs 1-16 as shown in the table below:</claim-text></claim-text></claim-text><claim-text><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="70pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>PAIR</entry><entry>T1&#x2003;(5&#x2032;-3&#x2032;)</entry><entry>T2&#x2003;(5&#x2032;-3&#x2032;)</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>&#x2003;1</entry><entry>GUUAUA</entry><entry>UCACAAC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>&#x2003;2</entry><entry>AGUCAAUAA</entry><entry>GACCUUCG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>&#x2003;3</entry><entry>AUAUAAU</entry><entry>AUCCCAGG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>&#x2003;4</entry><entry>AGUCAAUAA</entry><entry>UCACAAC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>&#x2003;5</entry><entry>AUAUAAU</entry><entry>GACCUUCG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>&#x2003;6</entry><entry>AUAUAAU</entry><entry>UCACAAC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>&#x2003;7</entry><entry>GUUAUA</entry><entry>AUCCCAGG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>&#x2003;8</entry><entry>CAUCAUGG</entry><entry>ACAUAAUG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>&#x2003;9</entry><entry>AGUCAAUAA</entry><entry>AUCCCAGG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>10</entry><entry>CAUCAUGG</entry><entry>UCACAAC</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>11</entry><entry>GUUAUA</entry><entry>GACCUUCG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>12</entry><entry>AGUCAAUAA</entry><entry>ACAUAAUG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>13</entry><entry>CAUCAUGG</entry><entry>GACCUUCG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>14</entry><entry>CAUCAUGG</entry><entry>AUCCCAGG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>15</entry><entry>GUUAUA</entry><entry>ACAUAAUG</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>16</entry><entry>AUAUAAU</entry><entry>ACAUAAUG</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><claim-text>wherein the first protein translation mechanism comprises a ribosome, wherein the ribosome lacks a linking moiety between the large subunit and the small subunit; and</claim-text><claim-text>wherein the second protein translation mechanism comprises the engineered ribosome of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The cell of claim <b>13</b>, wherein the cell comprises a bacterial cell.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The cell of <claim-ref idref="CLM-00014">claim 14</claim-ref>, wherein the bacterial cell comprises an <i>Escherichia coli </i>cell.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. A method for preparing a sequence-defined polymer, the method comprising:<claim-text>(a) providing the engineered ribosome of <claim-ref idref="CLM-00001">claim 1</claim-ref>; and</claim-text><claim-text>(b) providing an mRNA or DNA template encoding the sequence-defined polymer.</claim-text></claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The method of <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the sequence-defined polymer is prepared in vitro.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The method of <claim-ref idref="CLM-00017">claim 17</claim-ref>, the method further comprising providing a ribosome-depleted cellular extract or purified translation system.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The method of <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the sequence defined polymer is prepared in vivo.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The method of <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the sequence defined polymer is prepared in the cell of claim <b>13</b>.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The method of <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the mRNA or DNA encodes a modified Shine-Dalgarno sequence and the engineered ribosome comprises an anti-Shine-Dalgarno sequence complementary to the modified Shine-Dalgarno sequence.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The method of <claim-ref idref="CLM-00016">claim 16</claim-ref>, comprising flexizymes, wherein the mRNA or DNA template encoding the sequence defined polymer comprises one or more codons, wherein at least one of the one or more codons encodes a non-canonical amino acid, or a non-amino acid monomer.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. A method for the directed evolution of a target nucleic acid sequence,<claim-text>wherein the target nucleic acid sequence comprises at least two regions of interest, wherein the regions of interest are separated by an intervening sequence of at least 300 nucleotides in length, the method comprising:</claim-text><claim-text>(a) generating a library of test nucleic acid sequences, wherein each test nucleic acid sequence has a different nucleotide sequence for at least one of the regions of interest;</claim-text><claim-text>(b) screening the library for functional test nucleic acid sequences;</claim-text><claim-text>(c) sequencing the functional test nucleic acid sequences, wherein sequencing comprises:<claim-text>(i) performing a first polymerase chain reaction (PCR), wherein the first PCR provides a first PCR product comprising the at least two regions of interest but does not include at least a portion of the intervening sequence;</claim-text><claim-text>(ii) performing a ligation reaction, wherein the ligation reaction provides a first ligation product comprising the two regions of interest, wherein after the ligation reaction, the two regions of interest are positioned less than 300 nucleotides apart;</claim-text><claim-text>(iii) performing a second PCR, wherein the second PCR provides a second PCR product comprising the two regions of interest;</claim-text><claim-text>(iv) sequencing the second PCR product comprising the two regions of interest.</claim-text></claim-text></claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. The method of <claim-ref idref="CLM-00023">claim 23</claim-ref>, wherein the sequencing comprises next generation sequencing.</claim-text></claim></claims></us-patent-application>